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ABSTRACT 
RNA interference (RNAi) is being widely explored as a means of tumour therapy 
due to the specific and potent silencing of targeted genes. However, in vivo 
delivery of RNAi effectors, such as small interfering RNA (siRNA) and detection 
of delivery is fraught with problems. In this thesis a novel theranostic PEGylated 
siRNA nanoparticle, termed liposome encapsulated siRNA (LEsiRNA) was 
developed and tested in vitro and in vivo.  
 
The LEsiRNA nanoparticles were formulated to be MR sensitive and contain 
labels for fluorescence microscopy/histology. The nanoparticles were shown to 
be an ideal size for in vivo delivery, under 100 nm, stable over 4 days and have 
a MR relaxivity better than the clinically used contrast agent Dotarem. The 
LEsiRNA nanoparticles were tested in vitro to assess their suitability for use in 
vivo. It was found that incubation of the particles with cells led to a decrease in 
protein level of the targeted cancer gene, Survivin, an inhibitor of apoptosis.    
 
In vivo assessment of the LEsiRNA nanoparticles demonstrated their potential 
as a theranostic agent, delivering therapy, while simultaneously allowing 
monitoring of tumour delivery. The LEsiRNA nanoparticles, administered by 
intravenous injection, were shown to accumulate in xenograft tumours by MRI 
at 16 and 24 hours post administration. Fluorescence microscopy of ex vivo 
tumour samples was used to corroborate the MR results and simultaneously 
demonstrate co-localisation of nanoparticles and siRNA within the tumours. The 
LEsiRNA nanoparticle-mediated delivery of the anti-cancer Survivin siRNA 
caused a significant reduction in both Survivin expression and tumour growth 
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when compared to controls. These results suggest that LEsiRNA nanoparticles 
can be valuable as an in vivo delivery agent for siRNA therapy to tumours. 
 
As a way to non-invasively assess the tumour therapy effect caused by the 
Survivin LEsiRNA nanoparticles, an MR contrast agent targeted to apoptotic 
cells was investigated. This agent was tested in vitro and found, by MRI, to 
selectively bind to apoptotic cells. This suggests that the agent could be used in 
vivo to give an early prognosis, after a therapeutic intervention, without the need 
for an invasive biopsy. 
 
The favourable biodistribution of the LEsiRNA nanoparticles to tumours and the 
subsequent successful functional delivery of Survivin siRNA, with simultaneous 
monitoring by MRI, suggests that these LEsiRNA nanoparticles have real 
potential for the future treatment of cancer. The ability to non-invasively detect 
the effect of the LEsiRNA nanoparticles on tumours in vivo, afforded by the 
apoptotic targeted contrast agent, is also paramount for future clinical 
applications. Therefore, these two agents have great potential in the treatment 
and prognosis of cancer. 
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1 INTRODUCTION 
1.1 Molecular Imaging 
Molecular imaging can be broadly defined as the in vivo characterisation and 
measurement of biological processes at the cellular and molecular level.1 
Molecular imaging is a newly emerging field where the tools of molecular and 
cell biology are combined with non-invasive imaging techniques, with the aim to 
advance our understanding of biology and medicine by investigating cellular 
and molecular events involved in normal and pathological processes, in vivo. 
 
Molecular imaging exploits specific molecular probes, as well as intrinsic tissue 
characteristics to generate the image contrast required to allow the 
characterisation of different tissue pathologies, both temporally and spatially. 
The major advantage of this is that it can provide more realistic insights into the 
dynamic complex biological networks involved.2 The precise anatomical 
localisation and quantification allows investigation of spatial and temporal 
dynamics of disease specific processes. This can be performed on whole intact 
organisms, in vivo, repetitively over a time course, which harnesses the 
statistical power of longitudinal studies whilst also reducing the number of 
animals required.3 This has led to molecular imaging becoming a key 
technology in translational research by aiding the improvement of disease 
models and experimental procedures. The majority of the molecular imaging 
techniques that are used in pre-clinical research are also widely available in the 
clinical setting, allowing a direct translation of protocols and potentially a better 
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understanding of the biological processes involved in a variety of diseases. 
Molecular imaging is being widely used to elucidate the mechanisms and 
pathways in cancer and to assess the effect of therapy. 
 
1.2 Cancer 
Cancer is a class of diseases in which a collection of cells grow with defects in 
regulatory circuits that govern normal cell proliferation and homeostasis. There 
are more than a hundred distinct types of cancer, with subtypes of tumours 
found within specific organs. The classification of the tumour is defined by the 
cells or tissue it most resembles and therefore is originally derived from. Cancer 
is a leading cause of death worldwide, accounting for 7.4 million deaths (or 
around 13% of all deaths worldwide) in 2004, according to the World Health 
Organisation.4 It has been suggested that the vast catalogue of cancers all 
possess the same six essential alterations in cell physiology that dictate tumour 
growth: self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, tissue invasion and metastasis (Figure 1.2.1).5  
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Figure 1.2.1. The six hallmarks of cancer; proposed by Hanahan and 
Weinberg, that  most if not all cancers have acquired the same set of functional 
capabilities during their development, albeit through various mechanistic 
strategies.5 
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1.2.1 Self-Sufficiency in Growth Signals 
Many cancer cells have acquired the ability to synthesise growth factors 
inducing a positive feedback loop, promoting proliferation. This is unlike the 
usual process, in which one cell type produces growth factors to stimulate 
another cell type to proliferate. This positive feedback loop of growth factor 
production avoids the dependence on growth factors from other cells and leads 
to an increase in proliferation, which has been shown previously by the increase 
in platelet-derived growth factor and tumour growth factor α (TGFα) in 
glioblastomas and sarcomas, respectively.5 Cell surface growth factor receptors 
have also been shown to be altered in tumours, many being over-expressed, 
allowing cells to become hypersensitive to ambient levels of growth factors. The 
over-expression of the growth factor receptor EGF-R/erbB has been shown in 
stomach, brain and breast tumors,6-8 while the HER2/neu receptor is over-
expressed in stomach and mammary carcinomas9 and gross over-expression 
has been shown to produce ligand independent signalling, where signals are 
generated without the requirement of an external ligand.10 
 
1.2.2 Insensitivity to Anti-Growth Signals 
The maintenance of cellular quiescence and tissue homeostasis is sustained in 
normal tissue by multiple anti-proliferative signals, however, in cancer cells 
these anti-proliferative signals are circumvented. The majority, if not all, of anti-
proliferative signals are processed through the retinoblastoma protein (pRb), 
which blocks cell proliferation. Disruption of this pathway renders the cells 
insensitive to anti-growth signals. The pRb signalling pathway has been found 
to be disrupted in a variety of ways in different cancer types.11 It has been 
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shown that some cancers have lost their responsiveness to TGFβ, a regulator 
of the pRb signalling circuit, via down-regulation of the TGFβ receptor.12 
 
Another mechanism that normal cells use to control growth is terminal 
differentiation.  A strategy that some tumour cells have been shown to use to 
avoid entering into terminal differentiation involves the c-myc oncogene, the 
over-expression of which impairs the differentiation and promotes growth.5 
 
1.2.3 Limitless Replicative Potential 
An additional characteristic that all tumours are believed to have obtained is 
limitless replicative potential, which is different to normal cells that have an 
intrinsic program that limits their multiplication. The disruption to the normal 
pathway causes the cancer cells to multiply without limit, which has been 
termed immortalisation.13 The up-regulation of the telomerase enzyme has been 
shown to immortalise cells in the majority of cancers by keeping the telomeric 
DNA at the end of every chromosome above a certain threshold. In normal 
cells, dropping below this threshold would result in termination of replication.14 
 
1.2.4 Tissue Invasion and Metastasis 
The ability of a tumour to invade and metastasise enables the cancer cells to 
form a new colony in an area of the body where there is an excess of nutrients 
and space. In the majority of epithelial cancers there is a loss of E-cadherin 
function, which causes the tethering to other tumour cells to be lost and the 
cells can thereby detach and metastasise to a new location.15 Similar effects 
have been reported by the change in expression of N-CAM, which changes 
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from a highly adhesive form to a poorly adhesive form or shows a reduction in 
expression in a range of cancers.16 
 
1.2.5 Sustained Angiogenesis 
For a tumour to progress and grow, a supply of oxygen and nutrients is required 
from the vasculature. When a tumour is less than 2 mm in diameter it can 
receive oxygen and nutrients by simple diffusion. However, any further increase 
in tumour size requires the acquisition of a functional vascular supply by the 
formation of new vessels, termed angiogenesis.17 Angiogenesis is stimulated by 
the release of specific growth factors, such as vascular endothelial growth factor 
(VEGF), which are up-regulated by pathophysiological conditions associated 
with the tumour microenvironment.18,19  
 
1.2.6 Apoptosis Evasion 
Apoptosis, or programmed cell death, is a highly regulated process that results 
in the removal of cells during normal tissue homeostasis and differentiation. 
Apoptosis is a morphological phenomenon characterised by chromatin 
condensation, nuclear fragmentation, cell shrinkage and plasma membrane 
‘blebbing’. The process of apoptosis occurs without the breakdown of the 
plasma membrane and therefore avoids inciting an inflammatory response, 
unlike in necrosis, and the cells are then eradicated by macrophages.20 This 
eradication is signalled by the translocation of phosphatidylserine from the 
cytoplasmic side of the cell membrane to the outer surface.21  
 
A disruption or cancellation of apoptosis can lead to the development of cancer 
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and is actually a prerequisite for tumour formation (Figure 1.2.2).22,23 The 
capability of cells to avoid apoptosis is another key feature associated with the 
majority of cancers. Resistance to apoptosis can be acquired by cancer cells in 
a variety of ways and one of the most common is the mutation of the tumour 
suppressor gene p53. The resulting loss of p53 functionality is believed to occur 
in the majority of cancers and results in the breakdown of the DNA damage 
sensing system that can initiate apoptosis and hence this leads to prolonged 
survival and replication.24  
 
 
 
Figure 1.2.2. Tumours acquire a multitude of growth promoting features, such 
as escape from apoptosis or cellular senescence (limitless replicative potential) 
and gradual acquisition of growth properties provided by the tumour 
environment, such as self sufficiency of growth signals and induction of 
angiogenesis.22 
 
 
Another gene involved in the evasion of apoptosis is the Survivin gene, from the 
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inhibitor of apoptosis protein (IAP) gene family, which is also known as 
baculoviral IAP repeat-containing protein 5 (BIRC5).25,26 Survivin has been 
proposed to perform roles in tumour formation and tumour cell resistance to 
anti-cancer agents27 and is significantly over expressed in a wide variety of 
cancers, which has been shown to correlate with an increased rate of tumour 
recurrence and resistance to therapy.28-33 The increased over expression of 
Survivin present in tumour cells and the lack of expression in any other 
terminally differentiated cell type, makes the knock down of Survivin an ideal 
target for potential cancer therapy.34-36  
 
1.2.7 Enhanced Permeability and Retention Effect 
Tumour vasculature is distinct from ‘normal’ vasculature as it comprises of high 
proportions of proliferating immature endothelial cells. The vessels are 
therefore, usually tortuous, elongated, often dilated and ‘leaky’. These factors 
contribute to the accumulation of macromolecular structures by passive 
diffusion within the tumour tissue due to the enhanced permeability and 
retention (EPR) effect (Figure 1.2.3). This is especially true for lipid and 
macromolecular agents. The EPR effect has become a standard model for anti-
tumoural therapies and also for targeting tumours with liposomal 
macromolecules.37 The maximum particle size that can extravasate through the 
endothelial layer due to the EPR effect is approximately 400 nm, which is 
considerably larger than normal endothelium where the pore size is usually less 
than 6 nm.38  
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Figure 1.2.3. Enhanced permeability and retention. Schematic of the structure 
of normal intact tissue (bottom) and the leaky tumour tissue (top).39 
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1.3 Molecular Imaging Modalities 
The choice of imaging platform is obviously paramount and the contrast 
generated to differentiate the processes involved in the disease of interest can 
also be tailored to meet specific needs. More recently even the use of multiple 
modalities in combination have been used. There are now numerous imaging 
modalities that can be utilised for molecular imaging, each with their own 
advantages and disadvantages (Figure 1.3.1).  
 
 
 
Figure 1.3.1. Properties of several commercially available non-invasive in vivo 
imaging modalities that are used in molecular imaging studies, with their 
advantages and limitations.3 
 
 
1.3.1 Optical Imaging 
Optical imaging can be broadly divided into two groups: fluorescence and 
bioluminescence imaging. 
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1.3.1.1 Fluorescence Imaging 
In fluorescence imaging, the properties of certain molecules, known as 
fluorochromes are exploited; their ability to fluoresce. Fluorescence is the ability 
to absorb energy from an external excitation light of a particular wavelength and 
to re-emit the light at a longer wavelength and lower energy, which can be 
detected by ultrasensitive cameras. The phenomenon has been known since 
the middle of the nineteenth century and was utilised in medical applications in 
the early twentieth century.40 Fluorescence techniques, mainly fluorescence 
microscopy, have been routinely used for in vitro and ex vivo applications in 
molecular and cell biology, which has since been extended into non-invasive in 
vivo imaging applications.2  
 
Although fluorescence imaging, using excitation in the visible range (400 – 600 
nm), has been widely used in vitro and ex vivo, it is limited in vivo by the 
penetration depth of the excitation light (1 – 2 mm). This can be increased up to 
10 cm, depending on tissue imaged, by using light in the near infrared (NIR) 
region of the spectrum (650 – 900 nm), which has deeper penetration, as the 
absorption from haemoglobin and water is low.41 A number of NIR 
fluorochromes are now available that have been conjugated to peptides42 and 
antibodies43 and it is also possible to measure the activity of enzymes in vivo.44 
 
1.3.1.2 Bioluminescence Imaging 
In bioluminescence imaging, light is generated by a chemiluminescent reaction 
between the luciferase enzyme, from firefly, and its substrate luciferin, with the 
light produced dependent on the luciferase expression level and the amount of 
substrate administered. The advantage over fluorescence imaging is that there 
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is no background and it is therefore more sensitive. Bioluminescence imaging 
has proved useful in monitoring gene expression,45 cell tracking46 and 
monitoring the effects of therapy on established tumours,47 but due to limited 
depth of penetration and the need for genetic engineering it is unlikely to 
translate from its pre-clinical role directly to the clinic in the near future.41 
 
Due to the importance attached to NF-κB, a transcription factor, in the 
inflammatory process, molecular imaging studies have focused primarily on this 
molecule. This has been achieved by the development of transgenic mice that 
have been engineered to express luciferase from firefly, as a reporter gene, 
emitting light upon activation by NF-κB. The production of light from luciferase 
was shown to correlate with  increases in NF-κB activity during the development 
of arthritis, which was subsequently reduced after anti-inflammatory 
administration.48 This has lead to a wide variety of studies which have examined 
the effect of NF-κB in various inflammatory processes due to the ability to get 
real time visual data in individual mice over time.49 
 
1.3.2 Ultrasound 
Ultrasound is a very widely used imaging modality due to its low cost, 
availability and safety. Images are obtained by emitting high frequency sound 
waves from a transducer, which are reflected back to the transducer by the 
organs of interest, with the contrast generated dependent on the algorithm 
used, backscatter, attenuation of the sound and the sound speed.2  
 
Contrast agents, such as microbubbles filled with different gases, can be used 
in ultrasound to improve the inherently low image quality due to their different 
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acoustic properties. This is due to the high impedance difference between body, 
fluid consisting mainly of water, and the microbubble contrast agents.50 
Microbubbles can also be used to encapsulate therapies, which can be 
selectively released by focused sonication.51 The microbubble shell can be 
modified to incorporate targeting ligands, which causes accumulation of the 
microbubbles at the site of interest. However, due to their relatively large size, 1 
– 4 µm, they can only be used to target the intravascular space.52 This does, 
however, make the microbubbles ideal for measuring tumour angiogenesis, with 
addition of neo-vascular targeting ligands and also for measuring blood 
perfusion within tumours.53 
 
Chronic systemic inflammation is a key risk factor for the early development of 
atherosclerosis and therefore the non-invasive identification and quantification 
of inflammation in the vasculature by molecular imaging may provide valuable 
insights into the prognosis and clinical outcome.54 There are several potential 
markers of endothelial cell inflammation, one of which is intercellular adhesion 
molecule-1 (ICAM-1). To test the potential of photoacoustic imaging to visualise 
vascular inflammation, gold nanorods were conjugated to anti-ICAM-1and tuned 
to a wavelength of 700 nm to avoid background absorption. These particles 
were then used in a highly localised model of inflammation in the inferior vena 
cava, with the photoacoustic intensities significantly higher in the experimental 
group when compared to the healthy control group, identifying the primary 
inflammatory site in vivo.54-56  
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1.3.3 Computed Tomography 
In computed tomography (CT), X-rays are emitted from a focused X-ray source 
and detector that rotate around a subject in the scanner, acquiring a series of 
projections. These projections are then used to create a three dimensional 
image, with the contrast generated from the different absorption of the X-rays 
through different tissues.  CT can produce very high resolution images, up to 50 
µm in small animal scanners in just 10 – 15 minutes, with high contrast images 
of anatomical structure, but it is limited by a lack of soft tissue contrast.57 
However, due to CT using ionising radiation, the dose of radiation received is 
not negligible and therefore can limit repeated imaging on the same subject. 
Another drawback of CT is the large amounts of contrast agent required, such 
as iodine and difficulties associated with labelling molecular probes with these 
agents. This means that CT is not routinely used as a molecular imaging tool 
alone, but due to its high quality anatomical resolution, it is often used in 
combination with other molecular imaging techniques such as PET and 
SPECT.3  
 
1.3.4 Positron Emission Tomography 
In positron emission tomography (PET) imaging, radioisotopes emit a positron 
that annihilates with an electron of a neighbouring atom, producing two 511-keV 
γ-rays at ~180o apart. These two γ-rays are detected almost simultaneously by 
an array of detectors surrounding the subject and this allows the localisation 
and quantification of the radioisotope in the subject (Figure 1.3.2).58 The 
sensitivity is very high, in the picomolar range, meaning that many biological 
processes can be investigated and the signal detected is virtually independent 
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of the depth of the radioisotope in the subject. The spatial resolution of PET 
images are approximately 1 – 2 mm3, which is relatively low when compared to 
CT and MRI.  
 
Figure 1.3.2. The basic physics of positron emission tomography (PET) 
imaging. A compound labelled with a radioisotope emits a positron, which 
annihilates with a nearby electron producing two 511-keV γ-rays at ~180o. The 
gamma ray detectors register the hits simultaneously and the spatial localisation 
is calculated.59 
 
 
A major advantage of PET imaging is the availability of positron emitting 
radioisotopes which have stable counterparts in most biologically active 
compounds. Radioisotopes such as 11C, 13N, 15O and 18F can be substituted for 
their stable counterparts in compounds of interest or for hydrogen in the case 
with the latter, generally without altering the biological function.60 In addition, 
purposefully changing the structure of particular compounds creates labelled 
tracers that can potentially isolate particular steps in a metabolic pathway.59 
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One drawback, however, is the half life of the radioisotopes, most of which are 
relatively short, meaning they need to be generated on site and introduced into 
the compounds and then the subject in a short period of time. 
 
The most valuable data in Parkinson’s disease has been generated using PET, 
which has given detailed insights into the mechanisms of neuronal degeneration 
and into the in vivo assessment of disease progression.61 The now ‘gold 
standard’ for assessment of neuronal integrity for Parkinson’s is the use of the 
PET tracer 6-[18F]-fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA), the uptake of 
which correlates with nigral cell counts and reflects clinical severity of the 
disease.62 
 
There are currently no definitive diagnostic routines for Alzheimer’s disease and 
therefore the use of molecular imaging in animal models of Alzheimer’s, to 
directly visualise the pathologies, might contribute significantly to the early 
detection and prognosis of treatment. In an attempt to find an early diagnostic 
marker a novel PET tracer termed Pittsburgh Compound-B (PIB) was created, 
that showed marked retention of PIB in areas of the cortex known to contain 
large amounts of amyloid deposits in Alzheimer patients, when compared to the 
control group. These results suggested that PET imaging with PIB, could 
provide quantitative information on amyloid deposits in living subjects.63 
However, when this paradigm was used in a transgenic mouse model of 
Alzheimer’s disease, PIB did not accumulate in the areas known to contain 
plaques, although this is thought to be due to the lack of high affinity binding 
sites for the compound.64,65 
  
42 
 
Atheromas, are accumulations of cells, cell debris, lipids, calcium and fibrous 
connective tissue. These can be located and monitored using 18F-FDG PET 
scans. This is because the high concentration of macrophages present in the 
atheroma use exogenous glucose to meet their energy needs due to their 
increased metabolic rate. Therefore they posses a greater uptake of 18F-FDG, a 
radioactive glucose analogue.66 
 
PET imaging has also been largely used to gain highly specific quantitative 
information on various processes related to the increase in metabolic rate within 
tumours. 18F-FDG is a commonly used radiotracer, which is widely used to 
quantify the increased activity of membrane transporters for glucose, as well as 
increased expression of cellular hexokinase and to give information on energy 
metabolism of the tumours.67 
 
1.3.5 Single Photon Emission Computed Tomography 
Single photon emission computed tomography (SPECT) uses compounds 
labelled with radioisotopes that emit γ-rays of characteristic energies, such as 
99mTc, 111In, 123I. The γ-rays are detected using γ-cameras that rotate around the 
subject producing a tomographic image using a back projection technique. The 
different energies of the SPECT tracers allows two different radioisotopes to be 
used simultaneously and the effect of each compound can be distinguished 
through the different signatures of each radioisotope.68 
 
A major benefit of SPECT over PET is that the tracers used generally have half-
lives in the order of days compared to hours in the case of PET tracers and are 
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therefore generally cheaper to produce and use. However, SPECT is at least 
ten times less sensitive than PET and also has a lower resolution.41 
 
1.3.6 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a powerful non-ionising, non-invasive 
imaging tool, with high tissue contrast, making it ideal for longitudinal studies on 
the same subject, hence why it is widely used in pre-clinical and clinical 
studies.40 The signal detected in MR is from particular nuclei, most commonly 
hydrogen, that precess when placed in a large external magnetic field. MR, 
unlike nuclear imaging techniques such as PET and SPECT, is relatively 
insensitive, but it has better spatial resolution and can be used repeatedly on 
the same subject without any adverse effects. As the signal is dependent on 
local environment, experiments can be tailored to exploit this and image various 
pathologies. See Appendix for a more detailed description on magnetic 
resonance imaging. 
 
1.3.6.1 Magnetic Resonance Spectroscopy 
While early data from positron emission tomography (PET) suggested that the 
motor and cognitive function impairment in Parkinson’s disease was due to 
dopamine deficiency, it was later discovered using MRI that this is not solely the 
case and that the disease is more complex.69 Further to this MR spectroscopy 
(MRS) revealed that Parkinson’s patients had a decreased N-acetyl-aspartate 
to creatine ratio in the striatum when compared to controls, suggesting that this 
could be used as an early marker for diagnosis, although comparing various 
studies the data appears to be too varied.69,70 
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MRS has also been proposed as a sensitive detection tool for 
neurodegenerative processes, as mentioned for Parkinson’s disease, as it has 
been shown that Alzheimer’s patients and transgenic mouse models of 
Alzheimer’s have a significant decrease in the N-acetylaspartate peak and this 
correlated well with plaque formation and therefore has potential to be exploited 
as a pre-clinical and clinical marker of drug efficacy.71 
 
To increase the sensitivity of MR a new technique involving the 
hyperpolarisation of 13C has been developed which increases the sensitivity 10 
– 50,000 fold.72,73 This dynamic nuclear polarisation (DNP) of carbon has been 
used to image metabolism in vivo by labelling pyruvate, which in cancerous 
cells is broken down into lactate. This can then be detected using MR, non-
invasively and used to differentiate the metabolic differences between normal 
and cancerous tissue.74 The versatility of DNP has led to further studies using 
various 13C labelled substrates for cancer response to treatment. An example of 
this is fumarate, which breaks down to malate and has been shown to be a 
sensitive marker of tumour cell death.75 Hyperpolarised bicarbonate has been 
used as a measure of pH and showed that tumour interstitial pH was 
significantly lower than surrounding tissue,76 which was previously achieved 
using 31P MRS.41 
 
1.3.6.2 Diffusion Tensor Imaging 
The most common technique for investigating models of Alzheimer’s disease is 
MRI and has been used both clinically and pre-clinically due to the structural 
information gained, such as the level of brain atrophy. Another study using MRI 
showed that intrinsic contrast could be generated using a technique called 
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diffusion tensor imaging (DTI) and that differences in white matter tracts could 
be visualised in aged transgenic mice, which was not seen in young mice.77  
 
Another MRI based technique, diffusion weighted (DW-) MRI, measures the 
apparent diffusion coefficient (ADC) of the water inside the tumour being 
imaged. An increase in ADC is caused by an increase in water mobility, which is 
associated with decreased cellularity. Therefore the technique is being 
assessed as a prognostic indicator and as a marker of therapeutic efficacy.78 It 
has been demonstrated that the use of DW-MRI to measure ADC, can predict 
chemotherapy outcome, as mice with a low pre-treatment ADC value did not 
have regrowth, whereas animal with a high pre-treatment ADC value did show 
regrowth.79,80  
 
1.3.6.3 Gadolinium Based Contrast Agents 
MR contrast agents are used to improve the detection of a particular tissue or a 
change in pathology by changing the inherent T1 or T2 relaxation times. This 
change can then be visualised by the selection of appropriate imaging 
sequences and parameters leading to either a hyperintense signal - positive 
contrast, or a hypointense signal - negative contrast depending on the contrast 
agent chosen. 
 
Paramagnetic species such as transition metal and lanthanide ions are often 
used as MR contrast agents as they have magnetic moments that are much 
stronger than nuclear magnetic moments. The large magnetic moment of the 
paramagnetic ions cause a relaxation enhancement in nearby protons and 
hence, changes the relaxation times T1 and T2. 
46 
 
Gadolinium is one of the most popular ions to use as a contrast agent as it is 
the most paramagnetic element and hence, is a very efficient enhancer of 
relaxation. As a free ion, however, it is toxic and therefore for in vivo use it is 
chelated into a variety of ligands that render the gadolinium safe, but still allow 
access of water to the ion.  
 
Gadolinium is often said to be a T1 agent as it affects T1 relaxation rates more 
than T2. This is because it can be shown that the observed effects of a contrast 
agent depends on the intrinsic relaxation measured in the absence of the agent 
and due to T2 being considerably less than T1 in vivo, the effect of gadolinium 
as a contrast agent exerts a smaller proportional effect on T2 than it does on T1. 
Gadolinium chelated contrast agents have predominantly been utilised to 
enhance blood vessels for MRI angiography,81 cardiovascular MRI,82 and to 
detect brain tumours due to break down of the blood brain barrier.83 
 
An early attempt involved labelling a probe that targeted β-amyloid plaques with 
gadolinium so that the plaques became visible in MR images after intravenous 
administration with the hope that it would allow early diagnosis and be a direct 
measure of the efficacy of anti-amyloid therapies.84 An advancement on this 
technique was the design of an 19F-containing amyloidophilic compound that 
targeted the β-amyloid plaques in a live transgenic mouse and due to the use of 
the fluorine label there was no endogenous background signal, allowing for 
differentiation of plaques in the MR images from potential false positives.85 
However, the large amount of 19F required to generate an image has halted the 
progress of 19F MRI. 
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The change in tumour size following therapy is not always an indication of better 
clinical outcome, as it can be dependent on the therapy used and due to this 
other imaging markers of response have been developed and are required.86-88 
The ability of dynamic contrast enhanced (DCE-) MRI to measure blood flow 
and vascular permeability has led to this being used increasingly as a predictive 
and response biomarker for anti-angiogenic therapies.89 
 
1.3.6.4 Manganese Based Contrast Agents 
Manganese is another T1 agent as it affects T1 relaxation rates more than T2. It 
is often used in pre-clinical neuroimaging studies as it is an analogue of calcium 
and is therefore taken up by active neurons allowing the visualisation of active 
brain regions to a given stimulus. This use of manganese in functional MRI is 
known as Manganese Enhanced MRI (MEMRI).90 However, MEMRI is not used 
as a clinical tool due to the toxicity of manganese. 
 
1.3.6.5 Iron Based Contrast Agents 
Iron oxide based contrast agents are another large group of widely used MR 
contrast agents. However, unlike gadolinium and manganese these are 
superparamagnetic, which means they create a greater magnetic moment. This 
leads to a high magnetic susceptibility causing rapid depashing, effecting T2 
and T2* and hence, these agents are said to be T2 agents. 
 
Iron containing contrast agents come in a variety of sizes ranging from micron 
sized iron oxide particles (MPIO), superparamagnetic iron oxide particles of 
~500 nm (SPIO) to ultrasmall superparamagnetic iron oxide (USPIO) particles 
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of less than 100 nm diameter, all with varying biocompatible coatings. Iron oxide 
particles are often used to investigate diseases associated with the liver due to 
the uptake of the particles by the kupffer cells in the liver.91 More recently the 
iron oxide particles have been used to label cells and to act as cell tracking 
agents even down to the single cell.92-95 
 
The infiltration of macrophages into atheromas has been shown to be a key 
marker for the plaque being vulnerable, therefore macrophages have become a 
target of molecular imaging.54,96,97 An early attempt to target the macrophages 
used superparamagnetic iron oxide (SPIO) particles and ultrasmall 
superparamagnetic iron oxide (USPIO) particles that are spontaneously 
phagocytosed by the macrophages in the plaque causing a hypointense region 
on the MR images, which corresponded to plaque location and macrophage 
activity.97-100 However, the persistent effects of the iron in the circulating 
particles meant that the imaging window for MRI of the plaques was delayed 
until 24 – 72 hours post injection, complicating clinical implementation.101    
 
1.3.6.6 Intrinsic  
In the early 1990’s the intrinsic contrast agent deoxyhaemoglobin, was utilised 
to measure the blood oxygen level with gradient echo techniques. This blood 
oxygenation level dependent (BOLD) contrast provided real time imaging of 
regional neural activity due to the change in oxygenated and deoxygenated 
blood during cognitive tasks, allowing functional MRI (fMRI) studies of the brain, 
non-invasively.102-105 
 
Further experiments to look at the accumulation of β-amyloid deposits in 
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Alzheimer’s Disease, have been based on the fact that the plaques contain iron, 
which is detectable in MRI as a hypointense region.106-108 It has even been 
possible to visualise single amyloid plaques in a transgenic mouse model of 
Alzheimer’s disease, with corroboration with histology.109 However, these 
protocols are imaging the disease at a later stage of the disease process so 
there is a need for the development of imaging probes that target the plaques at 
an early stage so that detection can be identified before clinical signs manifest.  
 
1.3.6.7 Chemical Exchange Saturation Transfer 
Chemical exchange saturation transfer (CEST) is an MR technique that has 
been around since the 1960’s, but has recently generated new interest as a 
means of producing contrast. CEST involves two magnetically distinct pools that 
are chemically exchanging. If a saturating RF pulse is applied to one pool, the 
chemical exchange that is occurring causes the second pool to become more 
saturated leading to a decreased MR signal, as seen in Figure 1.3.3.110 
 
Contrast agents containing certain paramagnetic compounds can be utilised in 
CEST to increase the contrast further, these agents are known as PARACEST 
agents. PARACEST agents have been devised to measure pH, temperature, 
lactate, glucose and zinc sensors.111 
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Figure 1.3.3. A schematic representation of CEST, displaying the spins aligned 
with and against the field (above) and the NMR signal detected (below) for the 
two magnetically distinct pools (left), after a saturation pulse has been applied 
to one pool (middle) and after chemical exchange has occurred.112 
 
1.3.7 Multimodality Imaging 
Recently the benefit of amalgamating one anatomical modality and one 
functional modality has been realised, such as PET with CT. This multi-modality 
system improves the spatial resolution of PET, allowing for more detailed 
localisation of the PET tracer through the high resolution CT images, without 
requiring image registration. Such is the popularity of the combination of PET 
and CT modalities used in the clinic as well as pre-clinically, that it is now 
almost impossible to purchase PET scanners without a CT scanner 
incorporated.113 
 
In the last few years a new multi-modality system has been developed 
combining the high sensitivity of PET, with the high soft-tissue contrast, 
spectroscopic information and functional information of MRI. This new PET-MRI 
system could potentially be a powerful tool for studying biology and pathology 
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pre-clinically and in the future hopefully the clinic too.114 
 
Figure 1.3.4 shows a comparison between the various molecular imaging 
techniques, of their respective sensitivities and resolution. The advantages of 
MRI over the various other modalities as a molecular imaging tool can be seen 
due to its unlimited depth penetration, high spatial resolution and due to it being 
non-ionising.   
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Figure 1.3.4. Comparison of sensitivity versus spatial resolution (a) and depth 
of penetration/field of view versus spatial resolution (b) for different molecular 
imaging modalities, including green fluorescent protein (GFP), optical (OPT), 
magnetic resonance (MR), positron emission tomography (PET), single photon 
emission computed tomography (SPECT), diffuse optical tomography (DOT), 
near infrared (NIR) and bioluminescence (BLI). 68 
a 
b 
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1.4 Molecular Imaging of Cancer 
One target for molecular imaging is apoptosis, or programmed cell death. The 
initiation of apoptosis in tumours following chemotherapy or other anti-tumoural 
therapies and the extent and speed of onset of apoptosis has shown to be a 
good prognostic indicator of treatment outcome.115 This is especially valuable 
as the hope that levels of pro- or anti-apoptotic proteins would be predictive of 
response so far seem to be unfounded.116 Therefore the non-invasive detection 
of apoptosis is likely to be a useful clinical tool to monitor disease progression 
and response to therapy. 
 
There are a variety of markers that can be used to identify cells undergoing 
apoptosis, including morphological changes, DNA fragmentation and caspase 
activity.117 An early event in apoptosis is the translocation of phosphatidylserine 
from the cytoplasmic side of the cell membrane to the outer surface, which is a 
signal for the cell to be eradicated by macrophages.21 This translocation of 
phosphatidylserine can be detected by the binding of the cellular protein 
annexin V, labelled with fluorescein isothiocyanate (FITC) and measured using 
flow cytometry.118 In an attempt to detect apoptosis in vivo in a murine tumour 
model treated with a cytotoxic drug, Blankenberg et al 119 labelled annexin with 
99mTc and used radionuclide imaging to detect apoptosis. However, this method, 
although very sensitive, has a relatively low spatial resolution when compared 
to MRI. MRS has also been used in an attempt to measure the biochemical 
changes that are associated with apoptosis and therefore could potentially be 
used as a clinical diagnostic tool. Using 1H MRS Blankenberg et al120 found that 
the ratio of methylene (CH2) resonance to the methyl (CH3) resonance was 
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directly proportional to the percentage of apoptosis in lymphoblast cells. 
Williams et al121 measured the levels of cytidine diphosphocholine (CDP-
choline) and fructose-1,6-bisphosphate using 31P MRS as a marker of apoptosis 
in human promyelocytic leukemia (HL-60) and Chinese hamster ovary (CHO-
K1) cells. Hakumaki et al122 used 1H MRS to measure the levels of 
polyunsaturated fatty acids that accumulated during anti-tumoural therapy as a 
detector of apoptosis. However, like radionuclide imaging techniques the spatial 
resolution of MRS is relatively low, therefore with these limitations in mind 
contrast agents directed to apoptotic markers were developed for MRI 
detection. Zhao et al and Krishnan et al used the C2 domain of synaptotagmin I, 
which binds to anionic phospholipids in cell membranes when apoptotic and 
conjugated this to a superparamagnetic iron oxide particles and to a gadolinium 
chelate respectively. 123,124 
 
As mentioned previously the formation of new blood vessels, known as 
angiogenesis, is an important biosignature of cancer and therefore is a target of 
interest for molecular imaging. One molecular signature that has been identified 
as a marker of tumour therapy outcome is the vascular endothelial growth factor 
(VEGF), which is overexpressed in angiogenesis. A large amount of research 
has focused on the development of targeting molecules which are labelled for 
imaging with PET, SPECT, optical imaging, MRI or ultrasound.125  
 
Another key signature of angiogenesis is the expression of integrins that are 
significantly up-regulated during angiogenesis. A widely studied integrin is αvβ3 
because it is expressed on the luminal surface of activated endothelial cells, but 
not on mature cells. It has been shown to be expressed on a variety of cell 
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types, including macrophages, endothelial cells, lymphocytes, platelets and 
tumour cells. Due to this the development of targeting agents has utilised 
nanoparticles, which due to size constraints, remain in the vasculature and 
therefore only interact with neovascular specific αvβ3-integrins.
101 αvβ3-targeted 
perfluorocarbon nanoparticles labelled with the SPECT detectable 
radionucleotide 111In showed an increase in activity in the tumours when 
compared to controls.126 A wide variety of αvβ3-integrin targeted nanoparticles 
have been developed, with imaging labels for PET using adenovirus and 
nanotubes,127-129 optical imaging with peptide conjugated quantum dots,130 
ultrasound taking advantage of microbubbles131 and MRI utilising liposomes 
(Figure 1.4.1).132-134 
   
 
 
Figure 1.4.1. Various nanoparticle imaging agents used for targeting 
angiogenesis.125 
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1.5 Liposomes 
The structure of liposomes was first described in the 1960’s by Bangham et al in 
two papers using an electron microscope.135,136 The term liposome was coined 
soon after by Sessa and Weissmann in 1968.137 Liposomes are microscopic 
vesicles that are formed when lipids, which consist of a hydrophillic head group 
and a hydrophobic tail, are placed into an aqueous environment. The 
interactions of the hydrophilic and hydrophobic regions of the lipids cause a 
spherical bilayer to form, such that the liposome is in its most stable 
confirmation, with the hydrophilic head groups on the external surface and the 
hydrophobic tails internalised (Figure 1.5.1.). The lipids chosen in the liposome 
formulation affect its properties and due to the huge range of potential lipid 
combinations, the liposome platform is extremely versatile, with numerous 
potential applications.   
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Figure 1.5.1. A schematic diagram of a liposome, showing the hydrophilic head 
groups (blue) and the hydrophobic tails (yellow) that self assemble to form a 
spherical bilayer with an aqueous core. Modifications of the lipids can allow the 
addition of molecular imaging contrast agents, biocompatibility lipids and the 
encapsulation of a variety of drugs and therapies. 
 
 
Liposomes have traditionally been used in medicine as a delivery vehicle for 
various drugs and therapies, by encapsulation of the drug into the core of the 
liposome, leading to an increase in the blood half-life, stability and delivery to 
sites of disease138 and thus increasing the bioavailability of the drug.139 These 
attributes of liposomes have led to a large increase in interest in recent years. 
Cationic liposomes, liposomes with an overall positive charge, have to date 
been the most widely employed systems for the delivery of nucleic acid with 
some formulations recently progressing to phase II 140-142 and phase III clinical 
trials.143 The pioneering work by Felgner and co-workers showed that liposomes 
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could be used as an efficient delivery vehicle for DNA in 1987144 and RNA in 
1989.145 Since then there has been an exponential rise in studies using cationic 
liposomes for in vitro and in vivo delivery of nucleic acids. 
 
The formulation of cationic liposomes requires the incorporation of a cationic 
lipid into the lipid bilayer. The cationic lipids play two crucial roles in the delivery 
of siRNA/DNA therapy to cells. Firstly, the positive charge interacts with the 
negatively charged siRNA/DNA and causes it to encapsulate within the 
liposome, affording the protection required. Secondly, the overall positive 
charge of the liposome generated by the cationic lipids enable binding to the 
anionic cell membranes and allows for the delivery of the therapeutic payload 
into the cell.146 
 
The addition of neutral helper lipids into the liposome formulation has been 
shown to increase the levels of transfection. This is due to the neutral helper 
lipids having a preference for a hexagonal structure and this conformational 
change disrupts the endosomal membrane and enhances siRNA/DNA escape 
into the cell cytoplasm.147 
 
To protect liposomes from removal from the circulation by the 
reticuloendothelial system (RES), polyethylene glycol (PEG) is added to the 
formulation. The addition of the so called stealth lipid, PEG, into the liposome 
bilayer increases the circulation half-life,148 significantly reduces the cytotoxic 
effect of toxic compounds encapsulated within the liposome,149 and prevents 
aggregation of the liposomes.150 Furthermore, such stabilized liposomes 
accumulate passively in tumours due to the enhanced permeability and 
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retention effect (EPR) present in tumours, as described in section 1.2.7.37,151 
 
In order to further increase the accumulation within tumours or to decrease 
uptake in other tissues, a targeting lipid can be incorporated into the liposome 
formulation. This active targeting improves tumour specific accumulation, 
facilitates intracellular delivery and increases the specificity of the targeting by 
binding of the liposomes to cell surface proteins.152-154 
 
Recently, the formulation of liposomes either incorporating a contrast agent 
chelating lipid or encapsulating a contrast agent, has led to liposomes being 
used as molecular imaging agents to generate greater contrast in a variety of 
modalities including MRI,139,155-160 PET,161,162 SPECT,162-164 CT,165-167 optical,168-
170 ultrasound50-52 and also multimodal systems.134,171-173 
 
The use of liposomes as a delivery agent for siRNA therapy is described in 
greater detail in section 1.6.5.5. 
 
1.6 RNA Interference 
RNA interference (RNAi), is a term which was coined in 1998 by Fire and Mello 
to describe their surprise results that the addition of double stranded RNA to 
Caenorhabditis elegans resulted in a potent and specific reduction in gene 
expression.174,175 Their work on RNAi led them to be awarded the Nobel Prize in 
Physiology or Medicine in 2006.  
 
Previous to this however, it was discovered that in plants the addition of 
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antisense RNA, which is single stranded RNA complementary to messenger 
RNA (mRNA), led to specific inhibition of gene expression.176 Not long after this 
discovery it was found that the addition of double stranded RNA to plant cells, in 
an attempt to increase the pigmentation of petunia petals, actually caused a 
decrease due to downregulation of the targeted gene.177 This mechanism was 
termed co-suppression and later renamed post-transcriptional gene silencing, 
as it was discovered that the reduction in expression was not due to a decrease 
in transcription of the mRNA, but was in fact a result of a mechanism which 
occurred after transcription.178 Around the same time other plant biologists also 
reported similar findings179-181, and similar processes were also discovered in 
insects182, protozoa183, mammals184 along with a process known as quelling 
fungal systems185, which has the same characteristics.  
 
These independent investigations, post-transcriptional gene silencing in plants, 
quelling in fungi and RNAi in animals, all turned out to involve the same 
components. All of the processes are induced by double stranded RNA, the 
target RNA is degraded in a homology dependent manner and the proteins 
involved are all similar in structure and function across the species.186 These 
RNA silencing mechanisms were first recognised as antiviral mechanisms, 
protecting organisms from RNA viruses.187 It was quickly realised that the RNAi 
pathway would have a large impact on the way scientists investigate the 
functions of particular proteins and also its potentially massive role in novel 
therapeutics due to its ability to knockdown virtually any gene.188-191 
 
1.6.1 RNA Interference Mechanism 
RNAi is initiated by long double stranded RNA, which is processed into double 
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stranded RNA of 21 – 25 nucleotides in length known as small interfering RNA 
(siRNA), by the enzyme Dicer in the cytoplasm of cells.192-195 The siRNA is then 
incorporated into the RNA-induced silencing complex (RISC). The sense strand 
of the siRNA is then degraded by the enzyme argonaute 2, which is part of 
RISC, forming an activated RISC containing the antisense siRNA strand to a 
specific mRNA.196-198 The activated RISC then binds in a sequence dependent 
manner using the antisense siRNA strand to guide the complex to the 
homologous mRNA. The RISC then cleaves the mRNA, leading to a reduction 
in expression, as seen in Figure 1.6.1.199-204 Activated RISC can induce 
cleavage of approximately 1000 mRNA molecules from just one siRNA 
molecule, leading to a highly potent knockdown of gene expression that can last 
3 – 7 days in rapidly diving cells and for several weeks in non-dividing cells.205-
207   
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Figure 1.6.1. A schematic of the cellular mechanism of RNAi. The long double 
stranded RNA is processed by the enzyme dicer into siRNA. The siRNAs, which 
can alternatively be introduced directly into the cells, are then incorporated into 
RISC, where the strands separate. The RISC containing the antisense strand 
seeks out and cleaves the complementary mRNA with the argonaute enzyme 
leading to specific gene silencing.189 
 
 
1.6.2 RNAi Therapeutics 
The first demonstration of RNAi in mammals in vivo, was to reduce the 
luciferase activity, in a murine model of hepatitis C co-transfected with 
luciferase plasmid and luciferase siRNA.208 This was shortly followed by the use 
of siRNA to initiate RNAi to protect mice from liver failure and fibrosis in two 
models of autoimmune hepatitis.209 siRNAs have since been made synthetically 
to elict gene silencing in a variety of eukaryotic organisms via RNAi without 
producing an immune response, providing a route for gene silencing for protein 
63 
 
function or therapy.175,210-212 Other diseases have also been targeted for gene 
silencing in vivo using siRNAs, including, but not limited to 
hypercholesterolaemia,213 liver cirrhosis,214 hepatitis B virus,215  human 
papilloma virus,216 ovarian cancer217 and bone cancer218. In recent years the 
RNAi field has progressed rapidly, so much so that siRNA therapeutics directed 
at various diseases have already progressed into clinical trials, as can be seen 
in Table 1.6.1.219 
 
 
Drug Type Target Disease Stage 
Bevasirinab  
 
 
siRNA VEGF Age-related macular 
degeneration (AMD) 
Diabetic macular oedema 
Phase III 
 
Phase II 
Sirna-027 siRNA VEGFR1 Age-related macular 
degeneration  
Phase II 
ALN-RSV01 siRNA  Nucleo-
capsid  
Respiratory synical virus 
infection 
Phase II 
RTP801i-14  siRNA RTP801  Age-related macular 
degeneration 
Phase I 
TD101  siRNA Keratin 6a Pachyonychia congenita Phase I 
CALAA-01  
 
siRNA M2 subunit 
of RRM2 
Solid tumours Phase I 
 
SPC3649  miRNA miR-122 Hepatitis C Phase I 
I5NP  siRNA p53 Acute renal failure Phase I 
Proteasome 
siRNAs 
 
siRNA Immuno-
proteasome 
β-subunits  
Metastatic melanoma Phase I 
 
Anti-tat/rev  shRNA Tat/rev AIDS lymphoma Pilot study 
Table 1.6.1. RNAi-based therapeutics currently in clinical trials. Modified from 
Tiemann and Rossi, 2009.219 
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Despite the recent success and excitement generated from pre-clinical and 
clinical experiments using siRNA to elict gene silencing through RNAi, there are 
still several challenges to overcome.  
 
1.6.3 Off-Target Effects 
An early setback to siRNA therapy was the discovery that not all synthetically 
generated siRNAs are as specific as initially anticipated. In a study by Jackson 
et al in 2003, they showed that addition of several siRNAs all targeted to the 
same gene, produced a unique off-target profile for each siRNA.220 These 
unintended effects on gene expression caused by siRNA were termed off-target 
effects. The off-target effect was shown to be relatively modest, 1.5 – 4 fold 
changes in expression, but it affected dozens to hundreds of genes220 and has 
since been revealed that it can potentially induce measurable phenotypes.221  
 
It was later speculated that off-target effects of siRNA were due to a similar 
mechanism of gene regulation that was mediated by mircoRNA.222 The siRNA 
and microRNA pathways functionally overlap and share the same silencing 
machinery, so it is believed that the siRNA functions as microRNAs targeting 
sequences with partial sequence homology to the siRNA guide strand.223,224 
These off target effects of siRNA can lead to complications in determining the 
therapeutic benefits of siRNAs as mediators of RNAi pathways. 
 
Various methods are now used to mitigate the off-target effect of siRNAs. One 
method to reduce the off-target effects is the chemical addition of an O-methyl 
group at the 2’ position of the ribosyl ring on the antisense strand of the siRNA. 
When this was combined with 2’-O-methyl modification of positions 1 and 2 of 
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the sense strand, further reduction of off-target effects occurred whilst retaining 
the intended silencing activity.225 This modification has not yet been tested in 
vivo, but it appears likely to improve the specificity of therapeutic siRNAs.223 
 
Another method used recently to reduce the off-target effects, was to pool 
multiple siRNAs to the same target. A pool around five siRNAs silences only the 
intended gene, but due to the individual siRNAs having unique off-target effects, 
the overall off-target effect is effectively reduced.226 
 
It has more recently been demonstrated that synthesis of siRNAs with a two 
nucleotide 3’-overhang on the antisense strand leads to more effective silencing 
and reduced off-targeting effects compared to siRNAs with 3’-overhangs at both 
ends, and that this was due to preferential loading of the antisense strand in to 
the RISC.227 
 
1.6.4 Innate Immune Response  
Initial experiments with siRNA suggested that siRNA of 21 – 23 nucleotides in 
length would not initiate an immune response.210 However, subsequent studies 
have since shown that siRNAs can indeed induce the innate immune 
response.228-230 This is due to long double stranded RNA being interpreted by 
mammalian cells as unwanted gene activity from virus replication and 
consequently the cells initiate an immune response.231-233 To minimise the 
innate immune response, chemical modifications to alter the sequence and 
structure have been used, but with varying response.223  
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1.6.5 siRNA Delivery 
The most essential issue with using siRNAs as a therapeutic tool in the clinic is 
the successful delivery of the siRNA to the cytoplasm of the cell of interest, 
whilst being non-toxic. This is a major hurdle in the RNAi therapeutics field and 
one which a great amount of time and effort has been invested into worldwide.  
 
1.6.5.1 Localised siRNA Delivery 
Potentially the easiest and most effective administration route for siRNA is 
localised delivery, where the siRNA is applied directly to the target tissue. The 
benefits of this method are that there is a higher bioavailability and there are 
reduced adverse effects.234 However, this route of administration is only 
practical for a few tissues including the nasal passageway,235 eye,236 skin,237 
lungs,238,239 mucus membranes240 and local tumours.216,241  
 
1.6.5.2 Systemic siRNA Delivery 
Due to the reasons mentioned above, there is a need for the development of 
siRNA delivery systems that can be administered systemically, which can still 
reach the target tissues, whilst leading to efficient gene silencing and be non-
toxic. A major drawback of systemic administration of unmodified ‘naked’ siRNA 
as a therapy is that siRNA has a very short blood half life due to rapid excretion 
via the kidneys, due to its small size. It is also prone to degradation by enzymes 
in the blood and non-specific cell uptake.242-244 This along with naked siRNAs 
inability to permeate cellular membranes, suggests that systemic application of 
unmodified siRNAs as a therapeutic application is unlikely to be successful.245 
However, the rapid injection under high pressure of naked siRNA in a large 
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volume of physiological buffer, known as hydrodynamic injection, in mice was 
shown to produce gene silencing in the liver, kidneys, spleen, pancreas and 
lungs.246 Unfortunately this method cannot be translated to clinical use due to 
the large injection volume required and the toxicities caused by the high 
pressure.247  
 
Another method that was considered as a delivery method for siRNAs was the 
use of virus delivery vectors. These vectors have a high transfection efficiency 
for various cell types and produce long term gene silencing. However, they 
were found to have high levels of toxicity and immunogenicity and one trial of 
virus vectors lead to the development of leukaemia, therefore they have been 
discounted as in vivo delivery vectors.248,249 
 
This necessitates that siRNA has to either be modified or be administered in 
combination with a non-viral delivery agent. The in vivo hurdles that 
systemically injected delivery agents face before the siRNA reaches the target 
cells cytoplasm can be seen in Figure 1.6.2.  
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Figure 1.6.2. The various physiological barriers to the systemic delivery of 
siRNA nanoparticles. (a) The nanoparticles must avoid filtration, phagoctytosis 
and degradation in the bloodstream, (b) be transported across the vascular 
endothelial barrier, (c) then diffuse through the extracellular matrix, (d) then be 
taken up into the cell, (e) escape the endosome and (f) finally release the 
siRNA to the RNAi machinery.234 
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The ideal systemic delivery system would be one that circumvents off-target 
silencing, the immune response and non-specific degradation of siRNA, whilst 
still allowing efficient gene silencing. Various methods of modifications and 
delivery strategies have been attempted to achieve this, but as yet a single 
method has not been found to achieve all the requirements. 
 
The first obstacle that a systemic delivery agent would have to overcome is 
phagocytosis by cells such as macrophages and monocytes in the bloodstream 
and the extracellular matrix. These phagocytic cells act as an immunological 
barrier protecting the body against viruses, bacteria and fungi, by removing 
foreign material. Unfortunately siRNA delivery agents can potentially be 
removed in this manner and hence, the design of the agents must be 
considered.250 
 
Another major obstacle for siRNA delivery agents is crossing the endothelial 
barrier of the bloodstream, as molecules with a diameter of more than 5 nm do 
not readily cross. There are however, several tissues that do allow larger 
particles, upto 200 nm, to egress from the bloodstream, such as the liver, 
spleen and some tumours.234 
 
Further obstacles for siRNA delivery agents to overcome arise after leaving the 
bloodstream. The diffusion through the extracellular matrix can create 
resistance to the transport and increase the likelihood of the particles being 
taken up by macrophages.251 If the particles succeed in being taken up by the 
target cell the particles must then escape the endosome to reach the cytoplasm 
and avoid degradation by the lysosome.252,253 
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1.6.5.3 Chemical Modifications of siRNAs 
Chemical modifications of siRNAs have been developed in an attempt to evade 
the immune response and hence, potentially be used as systemic therapies, as 
seen in sections 1.6.3 and 1.6.4, along with other strategies to improve the 
therapeutic efficacy by conjugating small molecules to the siRNA. In vitro the 
addition of membrane-permeant peptides254 and polyethylene glycol (PEG)255 to 
siRNAs increased the target gene knockdown. The synthesis of cholesterol 
modified siRNAs allowed for systemic administration of the siRNA targeted to 
the gene encoding apolipoprotein B (apoB) in the liver and jejunum and showed 
that simple modifications could lead to silencing and ultimately a reduction in 
cholesterol levels.256 However, the majority of tissues are not amenable to the 
delivery of chemically modified siRNAs, so nanoparticles that incorporate 
siRNAs have been developed to allow systemic administration. 
 
1.6.5.4 Cationic Polymers 
Cationic polymers are able to act as efficient transfection agents because they 
have the ability to bind and condense nucleic acids such as siRNA into stable 
nanoparticles.257 Polyethyleneimine (PEI) is a widely studied delivery agent for 
siRNA and has a high transfection efficiency as it has the ability to exit the 
endosome of the cells protecting the siRNA from degradation.258 The primary 
use of cationic polymers thus far has been for local administration. A siRNA-PEI 
complex selectively targeted to the pain receptor subunit NR2B of N-methyl-D-
aspartate (NMDA) in rats, lead to modulation of pain259 and another complex 
targeted to the influenza viral nucleocapsid protein resulted in a 94% drop of the 
virus in the lungs of mice.260 A PEI complexed to siRNA targeting the over-
expressed tumour gene HER-2, showed that systemic delivery via the 
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intraperitoneal (i.p.) route possibly lead to a reduction in tumour growth.261 A 
novel delivery strategy was created using PEI that is PEGylated with an Arg-
Gly-Asp (RGD) peptide ligand to target tumour neovasculature to deliver siRNA, 
inhibiting vascular endothelial growth factor receptor-2 (VEGF R2) expression 
and thereby tumour angiogenesis. Intravenous delivery of this complex gave 
selective tumour uptake and inhibition of both tumour angiogenesis and growth 
rate.262 However, there is a significant concern about using PEI as a therapeutic 
delivery vehicle as there is high cytotoxicity at high doses.234,263 
 
1.6.5.5 Cationic Liposomes 
Cationic liposomes have been extensively used for the delivery of nucleic acids 
for over 20 years, by using the cationic lipid DOTMA (N-[1-(2,3-
dioleyloxy)propyl]-N,N,Ntrimethlylammonium chloride) to deliver both DNA and 
RNA into mouse, rat and human cell lines.144,145 For in vitro transfections there 
are now numerous commercially available liposome siRNA delivery systems 
including, Lipofectin, RNAifect, Oligofectamine and Lipofectamine.264 The first 
use of liposomes encapsulating siRNA in vivo was reported in 2003 
independently by Sorensen et al and Verma et al. In the Verma study they 
encapsulated siRNA targeted to β-catenin, an up-regulated gene in colon 
cancer, into Oligofectamine liposomes. This was then administered to a murine 
model of colon cancer intravenously and produced a decrease in β-catenin 
protein that subsequently resulted in reduced tumour growth.265 Sorensen et al 
used the cationic lipid DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) to 
form liposomes and encapsulate both the plasmid encoding for green 
fluorescent protein (GFP) and its associated siRNA, which inhibited GFP gene 
expression in various organs of mice when administered intravenously.266  
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Since these two early experiments, there has been extensive research into 
using cationic liposomes as siRNA delivery agents to a variety of diseases for 
both local and systemic administration.267 Recently, it was shown that 
liposomes encapsulating siRNA targeted to hepatitis B virus (HBV) could be 
administered by intravenous injection into mice carrying replicating HBV. This 
caused inhibition of HBV replication and a reduction in the serum levels of HBV 
in a dose dependent manner for up to seven days after dosing and overall 
reductions were seen for up to 6 weeks.215 Following this Zimmermann and 
colleagues demonstrated the ability of liposomes to silence ApoB in non-human 
primate livers with the biological effect lasting up to eleven days after dosing 
with a single intravenous injection.268 These studies were well tolerated, with 
transient increases in liver enzymes only seen at the highest dose and thus 
demonstrated that liposomes encapsulating siRNAs can have an immediate, 
potent and lasting biological effect.  
 
An area of increasing interest in numerous publications is the successful anti-
tumoural effects following administration with liposomes encapsulating siRNAs 
to a particular gene of interest.269-278 In a recent study siRNA targeted to an 
important therapeutic target in cancer, cyclooxygenase-2 (COX-2), was 
encapsulated into cationic liposomes and the delivery to a murine model of 
breast cancer was confirmed using MRI. The liposomes were injected 
intravenously via the tail vein resulting in intratumoral delivery of siRNA. These 
data demonstrate the feasibility of liposomal mediated delivery of anti-tumoural 
siRNAs to cancer cells and multi-modality imaging of the delivery of specific 
siRNA in tumours.169 
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The use of liposomes shows great potential for future use in the clinic as 
delivery vectors for siRNA. This is evident through the approval of doxorubicin 
and amphotericin B delivery by the US Food and Drug Administration.234 
 
1.7 Thesis Synopsis 
Since the discovery that siRNAs can initiate the RNAi mechanism in C.elegans 
by Fire and Mello,174 the potential of siRNA to act as a highly target-specific 
therapeutic agent, able to knockdown virtually any gene of choice, has been 
widely recognised.188-191 This has led to a substantial range of studies 
performed to elucidate the mechanisms, actions and development of RNAi-
based therapeutics for a wide range of diseases.245,267 
 
One area of great interest is the use of RNAi to treat cancers where genes 
upregulated in tumours can be targeted for knockdown leading to changes in 
tumour growth rates and survival. One potential target gene for RNAi 
therapeutic intervention is the gene Survivin, a member of the inhibitor of 
apoptosis family (IAP), that is clearly upregulated in many different cancers, but 
not expressed in normal tissue.34 However, despite the potential therapeutic 
advantages of RNAi, delivery of siRNAs to tumour cells has encountered many 
obstacles in vivo. In the case of naked siRNAs, they are prone to enzymatic 
degradation in the blood, as well as non-specific, limited cellular uptake due to 
their sustained, negative overall charge.242,244,279 Therefore, in common with 
many biopharmaceutical agents and therapeutic nucleic acids, siRNAs require 
the involvement of a delivery system or vector to protect the siRNA from the 
point of administration until delivery to the target site. Furthermore, once there, 
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it should facilitate the functional delivery of the RNAi effector payload into the 
required target cells.138,280  
 
A possible solution to this delivery problem is the use of cationic liposome 
based systems, which have been used as vectors for the delivery of therapeutic 
agents in vivo.281 Encapsulation of siRNAs into liposomes, termed lipoplex 
nanoparticles, is mediated by charge-charge interactions between the cationic 
liposome and anionic siRNA, thereby affording some protection in vivo from 
enzyme degradation and non-specific uptake in the blood.242 However, lipoplex 
nanoparticles per se can be colloidally unstable with respect to aggregration in 
biological fluids, prone to immunostimulation, and lacking in cell-specific 
targeting, so additional chemical modification is usually required to promote 
their utility in vivo.282 In particular, improved nanoparticle stability in biological 
fluids, reduced interactions with the reticulo-endothelial system (RES) and 
improved circulation half-lives can be brought about using a polyethylene glycol 
(PEG) polymer layer to cover the outer surface of lipoplex nanoparticles. 
Furthermore, such stabilized lipoplex nanoparticles are enabled for passive 
targeting to tumours.37,151 
 
Passive targeting exploits the fact that the tumour vasculature is distinct from 
‘normal’ vasculature, leading to accumulation of liposomes within the tumour 
tissue due to the enhanced permeability and retention (EPR) effect.37 This EPR 
effect has also assisted the use of stabilized liposome-based nanoparticles in 
tumour imaging that make use of lipids which comprise contrast agents for 
magnetic resonance imaging (MRI),139,157,158 fluorescence imaging283 or 
both.171,284 These labels have the potential to enable the tracking and 
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monitoring of stabilised lipoplex nanoparticles with encapsulated therapeutic 
agents to tumours over time. Nanoparticles that simultaneously deliver 
therapeutic agents and imaging agents to tissues of interest have recently been 
termed theranostic nanoparticles since they combine potentially the delivery of 
a therapeutic agent with the opportunity for simultaneous real-time monitoring of 
delivery, and may allow for diagnostic imaging of therapeutic effects as 
well.285,286 
 
1.8 Aims and Objectives 
1.8.1 Aims 
The principal aims of this project were to design, formulate and characterise 
novel multifunctional nanoparticles that mediate siRNA tumour delivery, 
visualisation and therapeutic retardation of tumour growth in vivo. The second 
aim was the development of a contrast agent to allow detection of apoptosis by 
MRI to confirm the therapeutic effect of the nanoparticle siRNA delivery in vivo. 
 
1.8.2 Objectives 
 To synthesise a gadolinium containing lipid to allow incorporation into a 
liposome formulation 
 To formulate, develop and characterise liposome formulations capable of 
encapsulating siRNA, being monitored by MRI and conveying 
fluorescence so that MR results can be corroborated ex vivo 
 To determine the particles potential use as a therapy, in vitro, with 
respect to uptake within cells, toxicity and delivery of active siRNA 
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 To develop an in vivo xenograft tumour model for the assessment of the 
siRNA delivery  
 To assess the in vivo applicability of the particles as MRI contrast agents 
and the time course of tumour accumulation 
 To determine the ability of the liposomes to deliver functional siRNA into 
tumour cells in vivo and to assess the effect of this delivery on tumour 
size and the targeted protein knock down 
 To establish the potential of a novel synthesised apoptotic targeted MRI 
contrast agent in vitro and in vivo 
 To monitor the therapeutic effect of the nanoparticle siRNA delivery by 
administration of the apoptotic targeted contrast agent in vivo 
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2 LIPOSOME FORMULATION AND CHARACTERISATION 
2.1 Introduction 
In this chapter novel theranostic PEGylated siRNA nanoparticles, termed 
liposome-encapsulated siRNA (LEsiRNA) nanoparticles are designed, 
formulated and characterised. The aim of these LEsiRNA nanoparticles is to be 
biologically compatible and be able to mediate the functional delivery of anti-
cancer Survivin siRNA to tumour cells in vivo. Moreover, these LEsiRNA 
nanoparticles need to be equipped with MR agents and fluorophores for MRI 
and fluorescence microscopy so that both nanoparticle accumulation and siRNA 
delivery in tumours can be observed simultaneously in real-time and allow for 
ex vivo histological corroboration.  
 
In the first instance the design of cationic liposomes is required such that they 
are smaller than 100 nm in diameter so that they can enter the tumour via the 
enhanced permeability and retention (EPR) effect, secondly they are stable so 
they do not breakdown before administration and thirdly they need to 
encapsulate the siRNA stably at a high level for in vivo delivery. For the 
LEsiRNA nanoparticles to achieve these goals the formulation requires a variety 
of lipids to be incorporated into the bilayer; the labelling lipids for monitoring and 
corroboration, biocompatibility lipids to increase the blood half life and uptake in 
the tumour, cationic lipids to increase the delivery of siRNA within the cell and 
fusogenic lipids to expedite the release of siRNA from the endosome into the 
cytoplasm where the siRNA has its functional effect. 
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2.1.1 Aims 
 To synthesise a gadolinium containing lipid to enable MRI visualisation 
 To prepare a range of liposome formulations and asses the; stability over 
time and MR relaxivity properties 
 To encapsulate siRNA into the chosen liposome formulation, determine 
optimal siRNA:lipid weight to weight ratio, measure the stability over time 
and establish the MR relaxivity 
 
2.2 Methods 
2.2.1 Materials 
Cationic lipids tested for incorporation into the liposome bilayer were N1-
cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine (CDAN) and 1,2-dioleoyl-
3-trimethylammonium-propane (DOTAP). The lipid used to increase blood-half 
life and the bioavailability within the tumour was 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy(polyethylene glycol)-2000 (DSPE-PEG2000). 
The helper lipid 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) was included 
in order to increase fusogenicity and stability to the liposomal lipid bilayer. To 
increase the transfection efficiency of the liposomes 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (DOPE-Rhodamine) 
was added, which also carries a fluorescence label to allow ex vivo histological 
corroboration.287,288 All of the above were purchased from Avanti Polar Lipids 
Inc. (Alabaster, AL, USA). The second label containing lipid incorporated into 
the liposome bilayer for MRI visualisation was gadolinium(III) 2-[4,7-bis-
carboxymethyl-10-[(N,N-distearylamidomethyl-N′-amidomethyl]-1,4,7, 
10-tetraazacyclododec-1-yl] acetic Acid (Gd.DOTA.DSA), which was 
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synthesized in-house as shown in section 2.2.2.159 All lipids were stored as 
stock solutions in anhydrous organic solvents (CHCl3, MeOH or a mixture of 
both), at – 20ºC. All other chemicals were of analytical grade or the best grade 
available and purchased from Sigma-Aldrich (Dorset, UK) or Macrocyclics 
(Dallas, USA). 
 
The structures of all the lipids introduced in the formulations of the liposomes 
can be seen in Table 2.2.1. 
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Lipid Structure 
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Table 2.2.1. The chemical structures of the lipids incorporated into the liposome 
bilayer. 
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2.2.2 Lipid Gd.DOTA.DSA Synthesis 
Gadolinium was chosen as the contrast molecule for MRI because it creates a 
signal enhancement (positive contrast) in the images, due to a decrease in T1, 
unlike iron, which cause signal reduction and hence, hypointense regions. As 
tumours can be necrotic and already have hypointense regions, using an iron 
agent would make the viable tumour tissue appear dark and distinguishing the 
two would be very difficult. Also, iron has a blooming effect where the 
susceptibility effect caused by the iron extends further than its true location. 
This leads to hypointense regions, which do not actually contain iron and 
therefore can lead to over estimating the area where the iron is present. 
Gadolinium, however, due to the positive contrast generated does not have this 
problem when determining necrotic from viable tumour tissue.  
 
Previous work in the group had shown that a novel gadolinium containing lipid 
Gd.DOTA.Chol (Figure 2.2.1) was an effective MR signal enhancer and that a 
liposome formulation containing this lipid was an efficient cellular labelling and 
transfection vehicle.160 
 
 
 
Figure 2.2.1. Chemical structure of Gd.DOTA.Chol, a lipidic contrast agent 
component of MAGfect.160 
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However, formulation of high concentrations of this lipid into liposomes was 
problematic due to the poor anchoring of the cholesterol tail in the bilayer. 
Therefore, due to this limitation, a novel gadolinium chelating lipid was 
conceived providing a more robust membrane anchor for in vivo applications 
and this was designed in-house.159 This novel cationic paramagnetic lipid, 
Gd.DOTA.DSA, was synthesised using a combination of solution and solid 
phase chemistries to allow a high concentration of liposome for in vivo 
applications.  
 
Briefly, the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 
chelate was conjugated to the lipid via a stable, yet biodegradable, amide 
functional group. The gadolinium lipid was designed to include a five-atom 
spacer between the gadolinium chelator, DOTA and the lipidic alkyl chain 
moieties. This spacing between the head group and the lipidic alkyl tail was 
considered to be optimal in order to ensure maximum exposure of the 
gadolinium chelate to water on the hydrophilic surface of the liposome particles. 
Furthermore, gadolinium lipid was also designed with the DOTA ligand rather 
than the more frequently used diethylenetriaminepentaacetic acid (DTPA), since 
the former macrocyclic ligand is considered to be a more effective chelator of 
gadolinium, with the ability to retain the metal ion even in the acidic environment 
of the endosome.289 In addition, the FDA approved Gd.DOTA chelates are 
known to be more stable in vivo in comparison to DTPA ligands.290 
 
2.2.2.1 Synthesis of Lipidic Tail 
The precursor amine N,N-distearylamidomethylamine (DSA), was synthesised 
in two steps. The first step involved an amide coupling of Boc-glycine with 
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distearylamine using O-benzytriazol-1-N,N,N’,N’-tetramethyluronium 
Hexafluorophoshate (HBTU) and N,N-dimethylaminopyridine (DMAP) at room 
temperature for 12 hours to give the protected lipid, followed by a simple 
deprotection with trifluoroacetic acid (TFA): CH2Cl2 at room temperature for 3 
hours to afford the DSA lipid (Figure 2.2.2). 
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1 2
 
Figure 2.2.2. Scheme showing the synthesis of the lipidic tail DSA, from the 
coupling of Boc-glycine (a) to distearylamine (b) to give the protected lipid (c) 
followed by deprotection to yield the lipid chain DSA (d). 
 
 
2.2.2.2 Synthesis of DOTA.DSA 
A fast and facile route for the synthesis of DOTA.DSA was carried out by using 
the commercially available, previously activated DOTA-NHS-ester, followed by 
coupling of the amine with the activated DOTA ester, in basic and dry conditions 
(Figure 2.2.3). 
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Figure 2.2.3. Scheme showing the synthesis of DOTA.DSA from the coupling of 
the synthesised amine DSA (a) to the activated DOTA-NHS-ester (b) to form 
DOTA.DSA (c). 
 
 
2.2.2.3 Synthesis of Gd.DOTA.DSA 
With the DOTA.DSA lipid synthesised, a simple stoichiometric addition of 
GdCl3.6H2O to DOTA.DSA in water, accomplished the complexation of 
Gd.DOTA.DSA, (Figure 2.2.4). This stoichiometric addition ensures that no free 
gadolinium is present in the final compound, which would be toxic in vivo. 
a b 
c 
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Figure 2.2.4. Scheme showing the Gd.DOTA.DSA complexation from the 
stoichiometric addition of GdCl3 to DOTA.DSA (a) forming Gd.DOTA.DSA (b). 
 
 
2.2.3 Liposome Formation and Stability 
Liposomes were made with a range of defined molar ratios of individual lipids, 
to give a predetermined total lipid concentration in HEPES (4 mM, NaCl 135 
mM, pH 6.5) as seen in Table 2.2.2, Table 2.2.3 and Table 2.2.4. Appropriate 
volumes of each lipid stock were placed in a round bottom flask (typically 5 mL) 
and the solvent slowly removed in vacuo at 30oC using a rotary evaporator 
(Bucchi, Oldham, UK) for approximately half an hour to ensure production of an 
even lipid film. Any excess solvent was removed by blowing with argon, before 
the film was re-hydrated with HEPES at a defined volume. The resulting 
a 
b 
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solution was sonicated, using a sonicating water bath (Grant Instruments, 
Cambridge, UK), for approximately an hour at 30oC in the dark, in order to form 
liposomes of an appropriate size. The pH of the liposomal suspension was 
checked by pH Boy (Camlab Ltd., Cambridge, UK) and if required it was 
adjusted.  
 
To confirm the formation and stability of the liposomes, the particles underwent 
size measurements over 18 days by photon correlation spectroscopy (PCS; 
Coulter Scientific Instruments, California, USA). 
 
 
Liposome 
Number 
 Molar Percentage (%) Total Lipid 
Concentration 
(mg/ml) 
 
DOTAP 
Gd.DOTA. 
DSA 
DOPC 
DSPE-
PEG 
DOPE-
Rhodamine 
1  46 0 46 7.5 0.5 1.2 
2  41 10 41 7.5 0.5 1.2 
3  36 20 36 7.5 0.5 1.2 
4  31 30 31 7.5 0.5 1.2 
5  26 40 26 7.5 0.5 1.2 
6  21 50 21 7.5 0.5 1.2 
Table 2.2.2. PEGylated bimodal imaging cationic liposomes formulated with 
cationic lipid DOTAP, the MRI labelled lipid Gd.DOTA.DSA, the neutral helper 
lipid DOPC, the biocompatibility lipid DSPE-PEG and the fluorescent labelled 
lipid DOPE-Rhodamine. 
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Liposome 
Number 
Molar Percentage (%) Total Lipid 
Concentration 
(mg/ml) CDAN 
Gd.DOTA. 
DSA 
DOPC 
DSPE-
PEG 
DOPE-
Rhodamine 
7 46 0 46 7.5 0.5 1.2 
8 41 10 41 7.5 0.5 1.2 
9 36 20 36 7.5 0.5 1.2 
10 31 30 31 7.5 0.5 1.2 
11 26 40 26 7.5 0.5 1.2 
12 21 50 21 7.5 0.5 1.2 
Table 2.2.3. PEGylated bimodal imaging cationic liposomes formulated with 
cationic lipid CDAN, the MRI labelled lipid Gd.DOTA.DSA, the neutral helper 
lipid DOPC, the biocompatibility lipid DSPE-PEG and the fluorescent labelled 
lipid DOPE-Rhodamine. 
 
2.2.4 Liposome Relaxivity  
The PEGylated bimodal imaging cationic liposomes were formulated as 
described in section 2.2.3 at the molar ratios defined in Table 2.2.4, and 
reconstituted in HEPES (4 mM, 135 mM NaCl, pH 6.5), to give a range of 
concentrations so that relaxivity could be measured. 
 
Liposome 
Number 
Molar Percentage (%) Total Lipid 
Concentration 
(mg/ml) CDAN 
Gd.DOTA. 
DSA 
DOPC 
DSPE-
PEG 
DOPE-
Rhodamine 
13 31 30 31 7.5 0.5 2.88 
14 31 30 31 7.5 0.5 1.44 
15 31 30 31 7.5 0.5 0.72 
16 31 30 31 7.5 0.5 0.36 
17 31 30 31 7.5 0.5 0.18 
18 31 30 31 7.5 0.5 0.09 
Table 2.2.4. PEGylated bimodal imaging cationic liposomes formulated to allow 
measurement of r1.  
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MR imaging was performed on a 4.7T Varian Direct Drive MRI scanner (Palo 
Alto, USA), with the dilution series placed into 250 µl PCR tubes, loaded in a 
Perspex holder, positioned inside the RF coil and then into the centre of the 
magnetic field. Shimming was carried out to create as homogeneous a field as 
possible and the linewidth was generally 15 – 50 Hz. A three plane scout image 
was taken for positioning of the slices on further scans. T1 values were 
measured from a series of spin echo multi slice scans; with an echo time (TE) of 
10.97 msecs, field of view (FOV) of 40 x 40 mm, matrix size of 256 x 256, one 
average, four 2 mm thick coronal slices and 10 repetition times (TR) of 15000, 
10000, 7000, 5000, 3000, 1000, 700, 500, 300, 100 msecs. A saturation 
recovery method was used instead of the more accurate inversion recovery 
method due to scanner software limitations. 
 
Images were analysed using ImageJ software (National Institutes of Health, 
USA), with a region of interest (ROI) drawn to encompass as much of the 
sample as possible (Figure 2.2.5), whilst ensuring that no air is included, for 
each sample. The T1 values were calculated by plotting the mean signal 
intensity (Mz) over the ROI taken for each TR and each sample and fitted to the 
equation below using Prism (GraphPad, San Diego, USA).  
 
Mz = M0(1 – e
-TR/T1) 
 
The longitudinal relaxivity r1 was determined from a linear fit of 1/T1 as a 
function of gadolinium (III) concentration. 
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Figure 2.2.5. Placement of the region of interest (white circle) to allow the 
measurement of the T1 of each liposome formulation and subsequently 
calculation of the r1 of the nanoparticles. 
 
 
2.2.5 Liposomal Encapsulated siRNA (LEsiRNA) Nanoparticle Formulation 
To form the liposomal encapsulated siRNA (LEsiRNA) nanoparticles, siRNA 
(Qiagen, Crawley, UK) was encapsulated into the liposome number 13 (Table 
2.2.4) by vortexing the appropriate amount of siRNA into the liposome solution 
to give a weight to weight ratio of 1:4, 1:6, 1:8, 1:10, 1:12, 1:14, 1:16 and 1:20 
(siRNA:lipid). The percentage of a fixed concentration of siRNA encapsulated 
into nanoparticles was calculated using the nucleic acid binding stain propidium 
iodide (Sigma-Aldrich) and comparing it to the same fixed concentration of free 
siRNA with the excitation and emission wavelengths set at 535 and 617 nm, 
respectively. The following equation was used to calculate encapsulation 
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percentage (EP), from siRNA alone (S), nanoparticle encapsulated siRNA (Ls) 
and cationic liposome only (L). 
 
 
 
2.2.6 LEsiRNA Stability 
To measure the stability of the LEsiRNA nanoparticles, both size and the 
percentage of siRNA encapsulated into the nanoparticles were measured over 
a 10 day period. The sizes of the LEsiRNA nanoparticles at the 1:12 siRNA:lipid 
weight to weight ratio were measured using photon correlation spectroscopy, to 
determine nanoparticle stability with respect to time. The percentage of siRNA 
encapsulated into the LEsiRNA nanoparticles at the 1:12 siRNA:lipid weight to 
weight ratio were measured periodically using the nucleic acid binding stain 
propidium iodide (Sigma-Aldrich), as described in section 2.2.5 
 
2.2.7 LEsiRNA Relaxivity  
The PEGylated bimodal imaging cationic liposomes were formulated as 
described in section 2.2.3 at the molar ratios defined in Table 2.2.4. They were 
reconstituted in HEPES (4 mM, 135 mM NaCl, pH 6.5) to give a range of 
concentrations so that relaxivity could be measured and siRNA was added to 
each in the appropriate amount as detailed in section 2.2.5 at a 1:12 siRNA:lipid 
weight to weight ratio. 
 
The relaxivity, r1, of the LEsiRNA nanoparticles was measured as described in 
section 2.2.4. 
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2.3 Results  
2.3.1 Gd.DOTA.DSA Synthesis 
The synthesis of the MRI contrast enhancing lipid Gd.DOTA.DSA was found to 
be very successful with high yields of up to 99% of the expected amount and no 
significant amount of free gadolinium present.  
 
2.3.2 Liposome Formation and Stability 
The PEGylated bimodal imaging cationic liposomes 1 – 6 formulated with 
DOTAP as the cationic lipid (Table 2.2.2) failed to form liposomes. This was 
confirmed by the inability to size the particles by PCS and also due to the visibly 
cloudy appearance, suggesting very large and/or aggregated lipids. 
 
However, the substitution of the cationic lipid from DOTAP to CDAN (Table 
2.2.3) did result in the formation of liposomes, as measured by PCS (Table 
2.3.1 and Figure 2.3.1). There was no apparent trend in the change of the 
liposome sizes over time or as the amount of Gd.DOTA.DSA increased and 
DOPC and CDAN decreased.  
 
Liposome 9 was found to be the largest overall particle measuring 110.4 (±4.2) 
nm at day 1, which increased to 196 (±3.3) nm from day 3 onwards. The only 
other liposome formulation to go above the 100 nm cut-off was liposome 11, 
which was found to be 98.7 (±8.7), 104.9 (±1.8) and 112.8 (±15.8) nm at days 1, 
3 and 5 respectively. All the other liposomes remained at the desired size of 
less than 100 nm, over the 18 day period.  
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Days 
Post  
Particle Diameter (nm) 
Liposome 
7 
Liposome 
8 
Liposome 
9 
Liposome 
10 
Liposome 
11 
Liposome 
12 
1 
96.9  
(±2.7) 
64.7  
(±2.7) 
110.4 
(±4.2) 
88.1  
(±4.2) 
98.7  
(±8.7) 
81.4  
(±1.3) 
3 
98.9  
(±2.0) 
63.8  
(±3.0) 
196.4 
(±3.3) 
88.9  
(±1.7) 
104.9 
(±1.8) 
81.8  
(±0.5) 
5 
86.4  
(±4.2) 
68.0  
(±1.4) 
198.6 
(±13.9) 
88.6  
(±3.0) 
112.8 
(±15.8) 
82.2  
(±3.7) 
18 
80.6  
(±2.5) 
57.9  
(±4.8) 
188.1 
(±21.0) 
85.5  
(±9.5) 
71.6 
(±15.0) 
87.7  
(±9.4) 
Table 2.3.1. Table displaying the formation and stability of liposome 
formulations 7 – 12 over the 18 days that measurements were made by photon 
correlation spectroscopy (PCS). 
 
 
 
 
Figure 2.3.1. Graph displaying the formation and stability of liposome 
formulations 7 – 12 over the 18 days that measurements were made by photon 
correlation spectroscopy (PCS). 
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2.3.3 Liposome Relaxivity  
The relaxivity, r1, of the liposomes was determined from the gradient of a plot of 
1/T1 versus the concentration of gadolinium from the series of liposomes 
formulated, with decreasing concentration of gadolinium (see Table 2.2.4). The 
subsequent plot (Figure 2.3.2) resulted in a gradient equal to 3.9 (± 0.044) mM-
1s-1, which is equivalent to the r1 value of the liposome solution. This is 
substantially better than the clinical contrast agents Dotarem (2.8 mM-1s-1), that 
the lipid is based on and Gd-DTPA, known as Magnevist (3.2 mM-1s-1).291 
 
 
Figure 2.3.2. Relaxivity of PEGylated bimodal imaging cationic liposomes. 
Relaxivity, r1 was calculated for the liposomes by plotting 1/T1 against 
concentration of gadolinium with the slope of the gradient equal to r1. 
Liposomes were determined to have an r1 of 3.9 (± 0.044) mM
-1s-1 and the fit of 
the line was R2 = 0.999. 
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2.3.4 Liposomal Encapsulated siRNA (LEsiRNA) Nanoparticle Formulation 
Increasing the amount of lipid compared to the amount of siRNA present from 
1:4 to 1:20 siRNA:lipid weight to weight ratio, led to an increase in the 
percentage of siRNA encapsulated into the liposomes (Table 2.3.2 and Figure 
2.3.3).  
 
 
siRNA:Lipid Ratio  Percentage siRNA Encapsulated (%) 
1:4 35.1  (±5.7) 
1:6 42.6  (±1.6) 
1:8 50.8  (±2.1) 
1:10 48.8  (±4.3) 
1:12 65.4  (±2.7) 
1:14 67.5  (±1.0) 
1:16 77.3  (±1.2) 
1:20 87.0  (±4.8) 
Table 2.3.2. siRNA:lipid weight to weight ratio was incrementally increased from 
1:4 to 1:20, resulting in an increase in the percentage siRNA encapsulated 
within the liposomes. 
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Figure 2.3.3. siRNA to lipid weight to weight ratio was incrementally increased 
from 1:4 to 1:20, resulting in an increase in the percentage siRNA encapsulated 
within the liposomes. 
 
 
2.3.5 LEsiRNA Stability 
The stability of the LEsiRNA nanoparticles was tested by measuring the size 
and percentage of siRNA retention within the nanoparticles, over a 10 day 
period. The average size of the LEsiRNA nanoparticles was 88 (± 1.6) nm, with 
no significant change in the average size over the 10 day period (Figure 2.3.4). 
The siRNA encapsulation appeared stable up to day 4, with a peak of 76% at 
day one. After approximately 6 days the encapsulation percentage dropped to 
40% (Figure 2.3.5).  
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Figure 2.3.4. LEsiRNA nanoparticle stability observed over a 10 day period. 
The size was measured using photon correlation spectroscopy and was shown 
to be stable over the 10 day period. 
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Figure 2.3.5. LEsiRNA nanoparticle stability observed over a 10 day period. 
Percentage siRNA encapsulated by PEGylated bimodal imaging cationic 
liposomes was calculated, using the nucleic acid binding reagent propidium 
iodide. This was compared to a solution of free siRNA and showed that the 
nanoparticles were stable up to day 4. 
 
 
2.3.6 LEsiRNA Relaxivity  
Relaxivity, as determined by r1, of the PEGylated bimodal imaging cationic 
liposomes was calculated by plotting 1/T1 against the concentration of 
gadolinium (III). The r1 of the LEsiRNA nanoparticles was found to be 4.1 (± 
0.043) mM-1s-1 (Figure 2.3.6).  
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Figure 2.3.6. Relaxivity of the liposomal encapsulated siRNA (LEsiRNA) 
nanoparticles. Relaxivity, r1 was calculated for the liposomes by plotting 1/T1 
against concentration of gadolinium with the slope of the gradient equal to r1. 
Liposomes were determined to have an r1 of 4.1 (± 0.043) mM
-1s-1 and the fit of 
the line R2 = 0.999. 
 
 
There were no significant differences in r1 between the cationic liposomes 
without siRNA and the LEsiRNA nanoparticles, 3.9 mM-1s-1 and 4.069 mM-1s-1 
respectively. These r1 values were substantially greater than the clinical 
contrast agent Dotarem, which has been previously reported to be 2.8 (± 0.1) 
mM-1s-1.291 Indeed relative signal intensities between cationic liposomes without 
siRNA and LEsiRNA nanoparticles revealed no discernable difference and did 
not vary significantly at the different dilutions (Figure 2.3.7). 
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Figure 2.3.7. MR image of liposomes and LEsiRNA nanoparticles showing 
differences in signal intensity. Top row L – R shows a decreasing dilution series 
of PEGylated bimodal imaging cationic liposomes alone (- siRNA). Bottom row 
L – R shows the same dilutions, but for LEsiRNA nanoparticles (+ siRNA). 
 
 
2.4 Discussion 
The synthesis of the Gd.DOTA.DSA lipid allowed the possibility to generate 
liposomes for MRI tracking and monitoring of liposomes, whilst having the 
potential to introduce therapies targeted to tumours, such as siRNA. The first 
set of liposomes formulated included the regularly used cationic lipid DOTAP to 
aid the transfection efficiency of the siRNA into cells. However, not one of the 
six formulations formed liposomes. This is most likely due to steric hindrance of 
the lipid headgroups forcing the particles apart and thus impairing the formation 
of liposomes. The inclusion of CDAN into the liposome formulation, as a 
replacement cationic lipid for DOTAP, led to liposome formation. The reason for 
the ability of these lipids to form liposomes is probably due to CDAN’s chemical 
(a) 
- siRNA 
+ siRNA 
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structure, which is based on one of the naturally abundant cell membrane lipids 
– cholesterol. This causes a separation of the headgroups, minimising the steric 
hindrance and increasing the fluidity of the liposome bilayer, hence permitting 
the formation of liposomes. 
 
The stability of liposomes 7 – 12 was determined by measuring the size with 
respect to time and all bar one were found to be stable for more than eighteen 
days. Liposome 9 was found to be significantly larger than all the other 
liposome formulations from day three onwards. This was surprising as it was a 
formulation in the middle of the range with respect to amount of the gadolinium 
lipid present, suggesting that as the particles reach approximately 110 nm in 
size they start to loose the single bilayer structures and possibly form 
multilamellar liposomes of larger sizes. The liposomes that were deemed 
suitable for tumour delivery, under 100 nm at all timepoints, were 7, 8 10 and 
12. For further studies it was decided that liposome 10 formulation would be 
used, as it appeared to be the best compromise between a high amount of the 
gadolinium lipid and the highest molar ratio of the cationic and fusogenic lipids. 
The ratio chosen was the 1:12 siRNA:lipid weight to weight ratio, as it was 
deemed a good compromise on cost of lipids, while still possessing a high 
encapsulation percentage in comparison. It has also been previously shown 
that ratios above 1:12 can be toxic in in vivo animal models.292,293 
 
The encapsulation of siRNA into the liposomes and the subsequent formation of 
LEsiRNA nanoparticles had no discernable effect on the size and stability of the 
liposomes over the ten day period. The encapsulation of the siRNA also had no 
significant effect on the relaxivity, r1, between liposomes and LEsiRNA 
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nanoparticles, which was particularly encouraging as it was superior to the 
clinical agent Dotarem. The stability of the LEsiRNA nanoparticles with respect 
to encapsulation percentage of the siRNA allows a window of up to four days 
after production for the nanoparticles to be used before they appear to lose 
stability.  
 
These properties of the LEsiRNA nanoparticles, which are comparable to other 
liposome based nanoparticles used in tumour imaging,294 suggest that they 
would be sufficiently MR sensitive to allow for the in vivo monitoring of 
nanoparticle accumulation in tumours by MRI and could potentially deliver 
therapeutic siRNA to tumours. 
 
 
 
102 
 
3 IN VITRO ASSESMENT 
3.1 Introduction 
The promising results of the liposome formulation and the subsequent formation 
of the LEsiRNA nanoparticles by encapsulating siRNA, described in Chapter 2, 
lead to the testing of the particles in vitro.  
 
Various in vitro tests were performed to asses the particles for their potential 
use as a tumour therapy in vivo including; uptake of the liposomes into the cells 
by MRI, utilising the gadolinium containing lipid. The potential toxicity that the 
particles may induce within the cells was measured. Survivin protein level was 
also measured to determine knock down of the Survivin protein mediated by the 
delivery of the Survivin siRNA by the nanoparticles. The OVCAR-3 cells that are 
used in these in vitro experiments are a cell line commonly used in in vivo 
tumour models and therefore appropriate as an in vitro model.  
 
3.1.1 Aims 
 To measure the cellular uptake of the liposomes with MRI utilising the 
incorporated gadolinium containing lipid 
 To determine the potential cell toxicity of the nanoparticles 
 To assess the effect of the nanoparticles on the Survivin protein 
expression levels 
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3.2 Methods 
3.2.1 Cellular Uptake of Liposomes 
The human ovarian cancer cell line, OVCAR-3, was seeded at 2.5 x105 cells 
per T-25 flask (Nunc, Rochester, USA) in five separate flasks. These were 
grown as a monolayer in Dulbecco's Modified Eagle Medium (DMEM) (Sigma-
Aldrich, Dorset, UK), supplemented with 10% fetal calf serum (FCS) for 24 
hours in an incubator at 37oC with 5% CO2. 
 
Liposomes were prepared as described in section 2.2.3, as formulation number 
14 from Table 2.2.4 and 75 µl was added to four of the 5 flasks with the fifth 
having 75 µl of HEPES added as a control. The cells were then incubated at 
37oC in a humidified incubator with 5% CO2 for 2, 16, 24 and 48 hours before 
the liposome containing media was removed and replaced with fresh media. 
The HEPES containing control was incubated for 48 hours. The media was 
removed, the cells washed with phosphate buffered saline (PBS), which was 
then removed and trypsin (Sigma-Aldrich) was used to detach the cells. The 
cells were re-suspended in 1 ml of media, then centrifuged at 300 rpm for 5 
mins and the pellet was collected and re-suspended in 25 µl of PBS and 25 µl 
of 2% agar and put in to 250 µl PCR tubes for MRI scanning.  
 
T1 measurements were determined as described in section 2.2.4. 
 
3.2.2 Cellular Toxicity of LEsiRNA Nanoparticles 
Cell viability was assessed using an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazoliumbromide) assay (Sigma-Aldrich, UK) to determine the in 
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vitro effects of the LEsiRNA nanoparticles, over a period of 72 hours. 
Liposomes were formulated as described in section 2.2.3 and LEsiRNA 
nanoparticles were formulated as described in section 2.2.5, with Survivin 
siRNA, termed Survivin LEsiRNA nanoparticles. A control siRNA, Allstars 
siRNA, was also used, which is scrambled and therefore is not targeted to any 
gene and these particles were termed Allstars LEsiRNA. The effect of both the 
Allstars and Survivin naked siRNA, empty liposomes and both the LEsiRNA 
nanoparticle groups was assessed. 
 
A total of eight 96-well plates (Nunc, USA) were seeded with OVCAR-3 cells at 
2 x103 cells per well, grown as described in section 3.2.1. Administration of the 
five groups was performed in six replicates, at six different concentrations and 
for four incubation times.  After 24 hours, when the cells were approximately 
60% confluent, the media was removed, the cells washed with PBS and serum 
free DMEM and the various complexes were added. The six groups were as 
follows: (i) control cells with only media added, (ii) Allstars siRNA alone, (iii) 
Survivin siRNA alone, (iv) liposomes alone, (v) Allstars LEsiRNA nanoparticles 
and (vi) Survivin LEsiRNA nanoparticles. These groups were made up in phenol 
red free media at the following concentration of siRNA: 0.00625, 0.0125, 0.025, 
0.05, 0.1, 0.2 mg/mL. Where siRNA was not used, the same amount of 
liposomes was added in replicates of six. At 2, 24, 48, and 72 hours after the 
addition of the complexes, the MTT cell proliferation kit was used to assess the 
viability of the cells by measuring the activity of mitochondrial dehydrogenases. 
The media and complexes were removed, the cells were washed with PBS and 
100 µL of DMEM, without phenol red or FCS (Gibco, UK), was added, followed 
by 10 µL of the MTT reagent re-suspended in phenol red free media. The cells 
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were then incubated at 37oC in a humidified incubator with 5% CO2 for 2 hours, 
to allow for purple spots to become visible at the bottom of the well, which is 
consistent with formazan crystal formation by cleavage of the tetrazolium ring. 
100 µL of the MTT solubilisation solution was then added to the cells and 
thoroughly mixed to dissolve the crystals, resulting in a purple solution. The 
absorbance of each well was read on a plate reader (Labsystems, UK) at 560 
nm and the background of the plates was measured at 620 nm. As change in 
cell viability is proportional to the amount of formazan formed, this allows for cell 
viability to be calculated using the equation below:  
 
                        
                       
                          
 
 
 
Any significant changes found using a Students t-test were recorded. 
 
3.2.3 Effect of LEsiRNA Nanoparticles on Survivin Protein Levels 
The effect of the LEsiRNA nanoparticles on the Survivin protein level was 
measured using an enzyme-linked immunosorbent assay (ELISA) specific for 
human Survivin (R&D Systems, Abingdon, UK). As a control the Allstars siRNA 
was utilised, as described in section 3.2.2, and compared to Survivin siRNA 
alone. As a positive control, the widely used in vitro transfection agent 
Lipofectamine (Invitrogen, Paisley, UK) was used to encapsulate the Allstars 
siRNA and Survivin siRNA. This allowed a direct assessment of the LEsiRNA 
nanoparticles to a well established in vitro transfection agent. 
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T-25 flasks (Nunc, USA) were seeded with OVCAR-3 cells at approximately 1 
x106 cells per flask and grown as described in section 3.2.1. After the 24 hour 
incubation, 100 µl of the respective solution was added to each flask along with 
10 ml of serum free media and left to incubate for 48 hours at 37oC in a 
humidified incubator with 5% CO2. The administration groups were; siRNA 
alone, Lipofectamine encapsulating siRNA as a positive control and LEsiRNA 
nanoparticles. All three groups having the control siRNA Allstars and the 
targeted siRNA Survivin, giving a total of six groups. 
 
The cells were harvested from each flask by removing the media, washing with 
ice-chilled PBS, followed by addition of 500 µl of ice-chilled lysis buffer 
(Promega, Southampton, UK) to each flask. The cells were then scraped, in 
order to loosen them and were then transferred into a cold eppendorf tube for 
centrifugation at 4oC, for 10 minutes at 14000 rpm. The supernatant was then 
transferred to a fresh, chilled eppendorf and the cell lysates were then 
subjected to the ELISA. 
 
Equal volumes of supernatant from each sample and assay diluent, 100 µl of 
each, were added to each well in triplicate and incubated at room temperature, 
on a horizontal plate shaker for 2 hours. The plate was aspirated and washed 
using the supplied wash buffer to remove any unbound antigen and this was 
performed three times. 200 µl of the Survivin conjugate was added to each well 
and incubated at room temperature for 2 hours, on a plate shaker. The solution 
was aspirated and the wells were washed three times using the wash buffer, 
and were then incubated with 200 µl per well of the substrate solution, at room 
temperature, for 30 minutes whilst protected from light. The reaction was 
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terminated by the addition of 50 µl of the stop solution to each well and the 
absorbance was measured at wavelengths of 450 and 540 nm using a plate 
reader, within 30 minutes of the addition of the stop solution. The concentration 
of Survivin in each of the samples was determined in triplicate by comparing to 
a standard curve generated by a serial dilution of the Survinin standard. The 
knockdown due to the Survivin siRNA calculated as a percentage of the Allstars 
siRNA for each group and any significant changes found using a Students t-test 
were recorded. 
 
3.3 Results 
3.3.1 Cellular Uptake of the Liposomes 
The uptake of the liposomes into the cells was measured by re-suspending the 
cell pellets in agar and measuring their respective T1, using MRI. A decrease in 
T1 would coincide with an increase of liposome uptake due to the presence of 
gadolinium in the liposome that causes a decrease in the T1. 
 
There was no change in the T1 values between the control and 2 hours of 
incubation (Figure 3.3.1). At 16 hours there was an increase in the T1 values of 
the cell pellets, but this did not reach significance. Following the 16 hour time 
point T1 decreased back to a similar value as the control at 24 hours, which 
then decreases further at the 48 hour time point, but this did not reach 
significance. 
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Figure 3.3.1. Liposome uptake into OVCAR-3 cells re-suspended in agar as 
measured by MRI over a 48 hour time period. 
 
 
3.3.2 Cellular Toxicity of LEsiRNA Nanoparticles 
The percentage cell viability, relative to cells with no treatment, was measured 
by the MTT assay to determine the potential toxicity of the LEsiRNA 
nanoparticles. A range of concentrations were prepared and compared at 2, 16, 
24, 48 and 72 hours incubations times, using a Students t-test.  
 
3.3.2.1 Two Hour Incubation Period 
An incubation time of 2 hours with the non-encapsulated Allstars and Survivin 
siRNA showed no significant changes at any of the concentrations. There was a 
decrease in cell viability as the concentration of Allstars siRNA was increased, 
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from 108 (±5.7) % to 73 (±7.1) %, at 0.00625 and 0.2 mg/ml, respectively. 
However this decrease was not seen in the Survivin siRNA group, which was 
found to be 85 (±14.2) % at 0.00625 mg/ml and 93 (±14.4) % at 0.2 mg/ml 
(Figure 3.3.2).  
 
 
 
Figure 3.3.2. Cell viability as measure by the MTT assay after a two hour 
incubation with non-encapsulated Allstars siRNA and Survivin siRNA. No 
significant changes within the concentrations were found. 
 
 
The cells exposed to liposomes alone and both LEsiRNA formulations, for 2 
hours showed no change in cell viability with increasing concentration. 
However, at 0.025 mg/ml the Survivin LEsiRNA treated cells had a significantly 
reduced cell viability of 82 (± 12.8) %, when compared to that of the liposome 
alone group, 101 (± 8.1) % (p < 0.05). At the highest concentration of 0.2 mg/ml 
both Allstars LEsiRNA nanoparticles, 79 (± 11.0) % and Survivin LEsiRNA 
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nanoparticles, 75 (± 12.6) % were found to have a significantly decreased cell 
viability, when compared to the liposomes alone 93 (± 8.4) % (p<0.05, Figure 
3.3.3).  
 
 
 
Figure 3.3.3. Cell viability as measure by the MTT assay after a two hour 
incubation with liposomes alone, Allstars LEsiRNA and Survivin LEsiRNA (* = p 
< 0.05). 
 
 
3.3.2.2 Twenty Four Hour Incubation Period 
At the 24 hour incubation time with non-encapsulated Allstars siRNA and 
Survivin siRNA, the only significant change was found at the lowest 
concentration of 0.00625 mg/ml. At this concentration Allstars siRNA was found 
to be 107 (± 11.0) % and the Survivin siRNA 82 (± 16.4) %, (p < 0.05). No other 
significant changes or trends over the concentration range was observed 
(Figure 3.3.4).  
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Figure 3.3.4. Cell viability as measure by the MTT assay after a twenty four 
hour incubation with non-encapsulated Allstars siRNA and Survivin siRNA (* = p 
< 0.05). 
 
 
After 24 hours of incubation with liposomes alone, Allstars LEsiRNA 
nanoparticles and Survivin LEsiRNA nanoparticles no clear trends over the 
concentration range was observed (Figure 3.3.5). However, at the 0.025 mg/ml 
concentration it was found that both the Allstars LEsiRNA and Survivin 
LEsiRNA nanoparticles, 74 (± 14.1) % and 73 (± 14.5) %, respectively, had a 
significantly lower cell viability than the liposome alone group 97 (± 11.9) % (p < 
0.05). 
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Figure 3.3.5. Cell viability as measure by the MTT assay after a twenty four 
hour incubation with liposomes alone, Allstars LEsiRNA and Survivin LEsiRNA 
(* = p < 0.05). 
 
 
3.3.2.3 Forty Eight Hour Incubation Period 
In the 48 hour group, again there were no significant changes found between 
the non-encapsulated Allstars siRNA and the Survivin siRNA. There were no 
trends found as a function of concentration, however there was a trend towards 
an increase in cell viability in the three higher concentration groups versus the 
lower three concentrations, which did not reach significance (Figure 3.3.6). 
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Figure 3.3.6. Cell viability as measure by the MTT assay after a forty eight hour 
incubation with non-encapsulated Allstars siRNA and Survivin siRNA. No 
significant changes within the concentrations were found. 
 
 
In the liposome only, Allstars LEsiRNA and Survivin LEsiRNA nanoparticle 
treated cells, there was only one significant change found. This was at 0.025 
mg/ml, where liposomes only had a cell viability of 124 (± 17.4) %, the Allstars 
LEsiRNA had a significant decrease to 73 (± 19.5) % (p < 0.001) and the 
Survivin LEsiRNA nanoparticles caused a decrease to 86 (± 20.5) % (p < 0.01). 
There were no trends found as concentration changed, however, a considerable 
increase in the cell viability, up to 178 (± 63.5) %, for the liposomes alone was 
observed (Figure 3.3.7). 
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Figure 3.3.7. Cell viability as measure by the MTT assay after a forty eight hour 
incubation with liposomes alone, Allstars LEsiRNA and Survivin LEsiRNA (** = 
p < 0.01, *** = p < 0.001). 
 
 
3.3.2.4 Seventy Two Hour Incubation Period 
The 72 hour incubation time showed only one significant change in cell viability 
in the non-encapsulated Allstars siRNA and Survivin siRNA treated cells. At 
0.025 mg/ml, there was a decrease from 126 (± 8.9) % to 85 (± 14.2) % for 
Allstars siRNA and Survivin siRNA, respectively (p < 0.01). There were no 
changes found across the range of concentrations (Figure 3.3.8). 
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Figure 3.3.8. Cell viability as measure by the MTT assay after a seventy two 
hour incubation with non-encapsulated Allstars siRNA and Survivin siRNA (** = 
p < 0.01). 
 
 
The liposome only, Allstars LEsiRNA and Survivin LEsiRNA treated cells 
showed no change after a 72 hour incubation with the nanoparticles at any 
concentration. There were no changes or trends found for any of the three 
groups as concentration was increased (Figure 3.3.9). 
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Figure 3.3.9. Cell viability as measure by the MTT assay after a seventy two 
hour incubation with liposomes alone, Allstars LEsiRNA and Survivin LEsiRNA. 
No significant changes within the concentrations were found. 
 
 
3.3.3 Effect of LEsiRNA Nanoparticles on Survivin Protein Levels 
To test the effectiveness of the LEsiRNA nanoparticles in mediating siRNA 
delivery to the cells and the subsequent knockdown of the Survivin target gene, 
an Enzyme-linked immunosorbent assay (ELISA) was performed.  
 
The addition of non-encapsulated Survivin siRNA alone to the cells caused a 
slight decrease, 14 (± 21) % in Survivin levels when compared to the scrambled 
control Allstars siRNA, however this was not significant (p = 0.45, Figure 
3.3.10). A larger effect was seen in the positive control of Lipofectamine, with a 
31 (± 13) % drop in the Survivin level, but again this did not reach significance 
against the control Allstars lipofectamine (p = 0.08). The addition of the Survivin 
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Survivin protein level 25 (± 4.2) %, when compared to the Allstars LEsiRNA 
nanoparticles (p < 0.05). 
 
 
 
Figure 3.3.10. Survivin knockdown as measured by enzyme-linked 
immunosorbent assay (ELISA). Comparing siRNA alone, positive control 
Liopfectamine and LEsiRNA nanoparticles with either the control siRNA Allstars 
or the targeted siRNA Survivin. (* = p < 0.05). 
 
3.4 Discussion 
The in vitro results detailed within this chapter show that the LEsiRNA 
nanoparticles system has potential for functional in vivo delivery of Survivin 
siRNA to tumours. The significant Survivin knockdown mediated by the 
LEsiRNA nanoparticles was highly encouraging, especially as the widely used 
positive control of Lipofectamine had a similar reduction, although it did not 
reach significance. This suggests that these particles could indeed be used in 
siRNA Alone Lipofectamine LEsiRNA
0
10
20
30
40
50
60
70
80
90
100
110
Allstars
Survivin
R
e
la
ti
v
e
 S
u
rv
iv
in
 E
x
p
re
s
s
io
n
 (
%
)
* 
118 
 
vivo. The efficiency of knockdown was slightly lower than expected, but this 
could be due to the small nanoparticles not sedimenting onto the cells. As it has 
been recently reported, centrifugation increases the efficiency, due to increased 
particle-cell contact.295 
 
The MRI of the cell pellets after incubation with the liposomes showed a trend 
towards a decrease in T1 after 48 hours, although it did not reach significance. 
This suggests that the liposomes might be taken up in to the cells, as 
demonstrated by the increase in gadolinium within the cells over time. As 
mentioned above, the small changes in T1 could be due to insufficient particle-
cell contact, due to lack of centrifugation. 
  
The cell viability studies were less conclusive than the other experiments in 
determining the future use of the LEsiRNA nanoparticles in an in vivo setting. 
There were no obvious trends for any of the groups used, liposomes alone, both 
LEsiRNA nanoparticles and both non-encapsulated siRNAs, at any of the 
concentrations or time points. There were numerous significant differences as 
described in the results, but these did not appear consistent over time or at 
higher/lower concentrations. The LEsiRNA nanoparticles had the lowest overall 
viability after 2 and 24 hours of incubation, but after 48 and upto 72 hours the 
cell viability had recovered. This was slightly surprising as the hope was that the 
Survivin LEsiRNA nanoparticles would have caused a significant decrease of 
cell viability, due to the action of the Survivin siRNA. The lack of an increase in 
toxicity could be due to the fact that the knockdown of Survivin was shown here 
to be c.a. 25%. This might not be large enough to cause a decrease in cell 
viability and therefore could not be detected by the MTT assay. However, the 
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reduction in expression of Survivin, might not actually be toxic to cells. 
 
Despite the inconclusive cell viability results, the overall in vitro results appear 
very encouraging, as not only are the particles non-toxic, but they can not only 
be detected using MRI, but also knockdown Survivin. This is in strong 
agreement with other work carried out targeting the overexpressed iNos protein, 
with iNos LEsiRNA nanoparticles, which showed decreased iNos and cellular 
uptake, as measured by MRI.296 It has also been shown previously that the 
addition of PEG into the liposome bilayer decreases the siRNA delivery 
efficiency into cells in vitro297,298 suggesting that even better results could be 
obtained with un-PEGylated formulations. Furthermore, it should be of note that 
previous reports suggest that in vitro data does not always predict good in vivo 
outcomes.89 
 
Overall, these results suggest that these LEsiRNA nanoparticles appear to be a 
good candidate system to deliver siRNA to tumour cells in vivo. 
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4 IN VIVO OPTIMISATION 
4.1 Introduction 
In Chapters 2 and 3 it has been shown that the LEsiRNA nanoparticles appear 
to have potential as a theranostic agent, by mediating the functional delivery of 
siRNA therapy. Previous work has demonstrated that liposomes can be used 
for simultaneous monitoring by MRI in vivo, 89, 299 even after potentially negative 
results in vitro.89,160,299 To test this, a suitable animal model of cancer was 
required. The model must have Survivin up-regulated, although as mentioned 
early most cancers posses this trait. Also, the tumours should be generally 
viable, as necrotic areas would inhibit the successful detection of accumulation 
of MR contrast agents due to tissue signal variations.   
 
In this chapter a variety of murine xenograft cancer models were assessed to 
find the most appropriate model for the LEsiRNA nanoparticles testing in vivo. 
This model was then used to assess the ability of the LEsiRNA nanoparticles to 
deliver the Survivin siRNA to the tumour cells. MRI parameters and analysis 
techniques were optimised to allow monitoring of the liposome delivery to 
tumours, utilising the gadolinium lipid within the liposome bilayer and to 
simultaneously allow monitoring of liver and kidney uptake. To determine if the 
delivery of the siRNA was successful, the size of the tumours was measured. 
This allowed visualisation of the effect of Survivin siRNA delivery on tumour 
size, over the 24 hour time period. 
 
121 
 
4.1.1 Aims 
 To develop a suitable murine xenograft tumour model to allow 
assessment of the LEsiRNA nanoparticles 
 To optimise MRI techniques to allow detection of the LEsiRNA 
nanoparticles in vivo 
 To evaluate the LEsiRNA nanoparticle bio-distribution using MRI and to 
assess the effect of siRNA delivery on tumour size 
 
4.2 Methods 
All in vivo animal experiments were carried out with licences issued in 
accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 
(UK). All mice were female balb/c nude, aged 6 – 8 weeks (Harlan UK). Upon 
arrival, they were acclimatised for at least 7 days prior to any experimentation. 
Mice were grouped as 8 per cage in individually ventilated cages (IVCs) at 
22ºC, 70 % humidity and a 12:12 (6.30 am – 6.30 pm) light:dark cycle. Mice had 
free access to water and an autoclaved standard mouse diet (RM3, Special 
Diets Services Ltd., Essex, UK). Balb/c nude mice were chosen due to their 
availability, cost and widespread use as mouse xenograft tumour models. 
 
4.2.1 In Vivo Tumour Model Development  
Ovarian carcinoma cell lines, OVCAR-3 and IGROV-1, were grown as a 
monolayer in DMEM (Sigma-Aldrich, Dorset, UK), supplemented with 10% fetal 
calf serum (FCS). MDA-MB-231 human breast cancer cells and LNCaP human 
prostate cancer cells were grown as a monolayer in RPMI media (Sigma-
Aldrich, Dorset, UK), supplemented with 10% FCS. All four cell lines were 
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incubated at 37oC in a humidified incubator with 5% CO2, with the media 
changed every 2 – 3 days. Once the cells reached approximately 95% 
confluency, they were harvested by removal of the media, washing with PBS, 
and then addition of trypsin (Sigma-Aldrich) for 5 – 10 minutes. Cells were re-
suspended in fresh media without FCS and centrifuged at 1,000 RPM for 5 
minutes. The media was removed and cells were re-suspended and spun down 
a further two times in serum free media before they were counted on a 
haemocytometer. Cells were finally re-suspended at 5 x107 cells per ml of FCS 
free media, for injections into the mice. 
 
For the injections, eight female balb/c nude mice, per group, were 
anaesthetised with 4 – 5 % isoflurane (Baxter International Inc, Deerfield, IL, 
USA) with 2 l/min oxygen. Mice were inoculated subcutaneously into the right 
flank with 5 x106 cells in 100 µl of serum free media, for the four cell lines, using 
a 25 gauge needle. Mice were recovered in a heated recovery box before being 
housed back in their cages.  
 
Once tumours were palpable, they were measured every other day, using 
callipers, and the volume estimated assuming an ellipsoid shape using the 
following equation:  
 
volume = length x width x depth x π/6 
 
4.2.2 In Vivo Magnetic Resonance Imaging 
Once tumours reached approximately 50 mm3, mice were anaesthetised with 2 
– 3% isoflurane 2 l/min oxygen, placed prone into the RF coil with the tumour at 
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the centre of the coil. A breathing pad was used to monitor respiration rate and 
a rectal probe was used to measure core temperature, which was maintained at 
37oC with a warm air blower.  
 
The field homogeneity was optimised by shimming on the water signal of the 
whole mouse. A three plane scout image was taken in order to plan a series of 
contiguous axial slices over the mouse abdomen to give full tumour coverage. A 
series of spin echo multi slice scans were run with an echo time (TE) of 14.98 
msec, field of view (FOV) of 45 x 45 mm, matrix size of 256 x 128, one average 
and 20 slices of 2 mm thickness, with repetition times (TR) of 5000, 2800, 1500, 
700 and 410 msecs, to allow for T1 calculations. Total scanning time was 
approximately 30 mins per animal. 
 
4.2.3 MRI Data Analysis Optimisation 
All MR data were analysed using ImageJ software (National Institutes of Health, 
USA). Regions of interest (ROI) were defined around the tumour on each slice 
where the tumour was apparent, whilst taking care to avoid skin and non-
tumour tissue, as seen in Figure 4.2.1., circular ROIs were also placed in the 
liver and kidneys to measure LEsiRNA nanoparticles uptake in these organs.  
 
 
 
 
 
 
 
Slice 1 
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Figure 4.2.1. Montage MR image of the twenty axial slices through the mouse 
abdomen, from slice 1 at the top of the abdomen to slice 20 at the bottom of the 
abdomen. The placement of regions of interest around the tumour are shown 
(red lines). TR = 1500 msecs 
 
 
For the T1 measurements, the ROI was defined on the highest TR (5000 msecs) 
for all slices and the signal intensity was measured for each TR and plotted to fit 
a curve given by the equation below to gain T1 values using Prism (GraphPad, 
San Diego, USA). 
 
Mz = M0(1 – e
-TR/T1) 
 
Three methods were considered for measuring the accumulation of the 
nanoparticles within the tumour, firstly direct comparison of T1 values, across 
eight mice. Secondly, T1 at specific locations within the tumour (Figure 4.2.2), in 
Slice 5 
Slice 9 
Slice 13 
Slice 17 
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a single mouse and thirdly, percentage change from baseline for individual 
mice, tested across three mice over 24 hours. The comparison of T1 maps was 
considered not to add any further advantage over the second method of ROI 
placements due to being unable to relocate the specific locations. 
 
 
Figure 4.2.2. MR image of a xenograft tumour from a mouse with three circular 
regions of interest (ROI) drawn within the tumour to measure the T1 at specific 
locations within the tumour. 
 
 
The percentage change in T1 (relative to the pre-dose value) was calculated for 
all timepoints using the following equation:  
 
% change = (post-pre)/pre*100 
 
Any significant changes were found using a Students t-test and recorded. 
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4.2.4 Inter Examination Variability  
To assess the variation in drawing of the ROIs and the effect this may have on 
the final outcome, the coefficient of variance was measured. To measure the 
coefficient of variance, ROIs were drawn around the three tumours on three 
separate occasions with at least a week in between sessions. The T1 was 
measured for each tumour on each of the three occasions and the percentage 
difference for each tumour was recorded.    
 
4.2.5 In Vivo MRI Assessment of LEsiRNA Delivery 
To assess the accumulation of the LEsiRNA nanoparticles in the xenograft 
tumours, MRI was performed over a twenty four hour period and the T1 values 
of the tumours were measured and compared. An OVCAR-3 ovarian cancer 
xenograft model was grown in female balb/c mice, as described in section 4.2.1. 
Survivin LEsiRNA nanoparticles were formulated as described in section 2.2.5  
and the mice were administered with 200 µl via the tail vein, equivalent to 1.25 
mg/kg of the Survivin siRNA (n = 7). The clinical MRI agent Dotarem, that the 
Gd.DOTA.DSA lipid within the liposome bilayer was based on, was 
administered , 200 µl via the tail vein, at an equivalent gadolinium concentration 
to the LEsiRNA nanoparticles. As a second control 200 µl of saline was 
administered via the tail vein (n = 7). MRI was performed pre administration of 
the compounds and two, sixteen and twenty four hours post administration as 
described in section 4.2.2 and the data were analysed as percentage change of 
T1, as described in section 4.2.3. Tumour volumes were measured pre 
administration and twenty four hours post. Any significant changes in tumour 
volume, T1 percentage changes in the tumour, liver and kidneys were recorded 
using a Students T-Test.  
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4.3 Results  
4.3.1 In Vivo Tumour Model Development 
The IGROV-1 ovarian cancer cell line failed to form tumours of a usable size. In 
addition those tumours that did grow, became necrotic and ulcerated at a very 
early stage. This meant the animals could not be kept for any reasonable period 
of time, without causing severe distress to the mice. The LNCaP prostate 
cancer cell line also failed to form tumours after injection. The MDA-MB-231 
breast cancer cell line had a 50% take rate, but the tumours were very slow to 
grow, taking 35 days after inoculation for the first tumour to show, moreover 
once the tumours had appeared, there was a large variation in volumes across 
the innoculated mice (Figure 4.3.1). 
 
 
 
Figure 4.3.1. Tumour growth curves of the MDA-MB-231 human breast cancer 
cell line inoculated into female balb/c mice (n = 8). 
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The OVCAR-3 ovarian cancer cell line was found to be taken up in all eight of 
the mice injected and tumours were apparent after only a week. Futhermore, 
the variance across the group was relatively small (Figure 4.3.2). 
 
 
 
Figure 4.3.2. Tumour growth curve of the OVCAR-3 ovarian cancer cells 
inoculated into female balb/c mice (n = 8). 
 
 
4.3.2 MRI Data Analysis Optimisation  
The first of the three methods of analysis of the MRI data (Figure 4.3.3) was a 
direct comparison of T1 values in an attempt to monitor the accumulation of the 
nanoparticles within the tumour. However, it was apparent that this would not be 
possible as the T1 variation pre administration was relatively large (Figure 
4.3.4.).  
6 7 8 9 10 11 12 13 14 15 16 17 18
0
200
400
600
800
1000
1200
1400
Days Post Inoculation
T
u
m
o
u
r 
V
o
lu
m
e
 (
m
m
3
)
129 
 
 
Figure 4.3.3. Typical MR image of a mouse with the tumour apparent on slices 
six through to ten. TR = 1500 msecs. 
 
 
 
Figure 4.3.4. Tumour T1 variation across mice pre administration each point 
represents a single mouse and the line is the average (n = 8). 
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The second method of measuring T1 values in specific locations was also not 
plausible, as it was difficult to accurately identify the same region at the various 
time points or each mouse. Moreover, it was not possible to draw ROIs in the 
same location in the same animal at different time points (Figure 4.3.5). 
 
 
 
Figure 4.3.5. ROI placement for specific locations within the same xenograft 
tumour pre and post administration of saline. (a) tumour pre administration, (b) 
tumour two hours post administration, (c) tumour pre administration with ROIs 
and (d) tumour two hours post administration with attempted identical 
placement of ROIs. 
 
 
 
a b 
c d 
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The third method of normalising each mouse to its own pre dose T1 value, was 
more successful (Figure 4.3.4). Calculating the percentage change from the pre 
dose for each further time point, allowed the most realistic comparisons , due to 
the smaller variance (Table 4.3.1). 
 
 
Mouse 
Number 
T1 Values (msecs) Percentage Change (%) 
Pre 2 hr 16 hr 24 hr 2 hr 16 hr 24 hr 
1 1985 2054 1899 2174 3.5 -4.3 9.5 
2 2110 2142 2451 2238 1.5 16.2 6.1 
3 3027 2902 3140 2824 -4.1 3.7 -6.7 
Table 4.3.1. T1 values of tumours pre, 2, 16 and 24 hours post and the 
respective percentage change in T1 at the given time. 
 
  
4.3.3 Inter Examination Variability 
The coefficient of variance was measured for ROIs drawn around three tumours 
on three separate occasions, with at least a week in between sessions and the 
T1 was calculated and the percentage difference for each tumour was recorded. 
The variance was found to be 0.5 (± 0.23) % over the three separate 
measurements on the three different tumours.   
 
4.3.4 In Vivo MRI Assessment of LEsiRNA Delivery 
The T1 values of the livers, kidneys and tumours were compared to determine if 
the Survivin LEsiRNA nanoparticles had accumulated in any of the organs of 
the mice. To asses this two control groups were utilised; the clinical contrast 
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agent Dotarem and saline. 
 
4.3.4.1 Liver 
The T1 changes within the liver of mice dosed with Dotarem showed no change 
(± 13.3%) at 2 hours, a decrease of 7 (± 8.5) % at 16 and an increase of 3 (± 
10.3) % at 24 hours post administration. The saline group had increases in T1 of 
1 (± 10.2) %, 7 (± 16.7) % and 2 (± 19.8) % at 2, 16 and 24 hours post 
administration respectively. The Survivin LEsiRNA nanoparticles administered 
group had decreases in T1 of 19 (± 12.2) % and 27 (± 2.4) % at 2 and 16 hours 
repectively, which was significantly decreased when compared to both control 
groups at 16 hours (p < 0.05). By 24 hours post administration, the T1 of the 
Survivin LEsiRNA group had returned to normal levels with a small increase of 
3 (± 8.9) %, (Figure 4.3.6).    
 
 
Figure 4.3.6. T1 percentage changes over twenty four hours in the livers of 
mice dosed with the clinical MR contrast agent Dotarem (n = 4), saline (n = 7) 
and Survivin LEsiRNA nanoparticles (n = 7), via the tail vein (* = p < 0.05). 
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4.3.4.2 Kidneys 
The T1 changes in the kidneys of mice dosed with Dotarem showed an increase 
of 5 (± 9.7) %, 6 (± 9.3) % and 16 (± 8.0)% at 2, 16 and 24 hours post 
administration respectively. The saline dosed group showed a T1 decrease of 8 
(± 2.3) % after 2 hours, which returned to its initial value (± 3.7%) at 16 hours 
and increased to a 10 (± 17.6) % after 24 hours. Mice that were administered 
with the Survivin LEsiRNA nanoparticles were found to have T1 decreases of 13 
(± 7.9) %, 21 (± 6.7) % and 5 (± 10.0) % at 2, 16 and 24 hours post dose. The 
decrease of 21% at 16 hours was found to be significantly different (p < 0.05) 
when compared to the Dotarem and saline dosed mice (Figure 4.3.7). 
 
 
 
Figure 4.3.7. T1 percentage changes over twenty four hours in the kidneys of 
mice dosed with the clinical MR contrast agent Dotarem (n = 4), saline (n = 7) 
and Survivin LEsiRNA nanoparticles (n = 7), via the tail vein (* = p < 0.05). 
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4.3.4.3 Tumour 
The T1 values of the tumours dosed with Dotarem had a 21 (±3.3) % rise in T1 
at 2 hours post administration, which decreased to 18 (± 3.9) % and then 13 (± 
8.3) % at 16 and 24 hours post, respectively. The saline group had a decrease 
of 1 (±12.8) % at 2 hours post administration, which increased to 6 (± 10.4) % 
and returned to 2 (± 10.2) % at 16 and 24 hours, respectively. The group 
administered with Survivin LEsiRNA nanoparticles, had a decrease in the 
tumour T1 values of 7 (± 3.3) %, 21 (± 3.9) % and 5 (± 8.3) % at 2, 16 and 24 
hours post administration (Figure 4.3.8). 
 
There were no significant differences between the two control groups of 
Dotarem and saline administered mice. The Survivin LEsiRNA nanoparticles 
were found to cause a significant decrease (p < 0.05) in the tumour T1 values at 
16 hours post administration when compared to saline, but not at any other time 
point. The Survivin LEsiRNA nanoparticles were found to cause a significant 
decrease (p < 0.01) in the tumour T1 values at both 2 and 16 hours post 
administration, when compared to Dotarem, but not at 24 hours. 
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Figure 4.3.8. T1 percentage changes over twenty four hours in the tumours of 
mice dosed with the clinical MR contrast agent Dotarem (n = 4), saline (n = 7) 
and Survivin LEsiRNA nanoparticles (n = 7), via the tail vein. (* = p < 0.05 for 
Survivin LEsiRNA compared to Saline; ** = p < 0.01 for Survivin LEsiRNA 
compared to Dotarem). 
 
 
4.3.4.4 Tumour Volume 
Tumour volumes were calculated pre and 24 hours post dose, for each 
administration group. The Dotarem group had an increase of  30 (± 38.9) %, the 
saline group an increase of 34 (± 10.3) % and the Survivin LEsiRNA 
nanoparticle administered group just 7 (± 10.3) %. However, despite these large 
differences, it did not reach significance (Figure 4.3.9). 
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Figure 4.3.9. Tumour growth percentage change over twenty four hours of mice 
dosed with the clinical MR contrast agent Dotarem (n = 4), saline (n = 7) and 
Survivin LEsiRNA nanoparticles (n = 7), via the tail vein. 
 
 
4.4 Discussion 
It has previously been reported that IGROV-1, OVCAR-3, MDA-MB-231 and 
LNCaP cell lines showed an up-regulation in the Survivin gene.300-303 Therefore, 
these cell lines were investigated to determine the most suitable for assessing 
the LEsiRNA nanoparticles, in vivo. The LNCaP prostate cancer cell line did not 
form tumours in any of the mice tested, whereas the IGROV-1 ovarian cancer 
line did lead to tumour formation, but the tumours became necrotic and 
ulcerated at a very early stage. This meant that these could not be used as a 
model for the LEsiRNA nanoparticles assessment. The MDA-MB-231 breast 
cancer cell line had a 50% take rate, but the rate of growth was extremely low, 
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becoming measurable only after thirty four days. In addition, not all started to 
grow at the same point in time, one taking a further eleven days and the fourth 
was only measurable fifty two days after inoculation. The low uptake rate, the 
time taken for tumours to be measurable and the large variation in tumour 
growth rate, as well as the previously reported metastastic growths,304 meant 
that the MDA-MB-231 cells were deemed unsuitable as a potential tumour 
model for the LEsiRNA nanoparticles assessment.   
 
The OVCAR-3 ovarian cancer cell line, as the tumour xenograft model, appears 
extremely well suited for assessing the LEsiRNA nanoparticles. This is due to 
the up-regulated Survivin levels, the high uptake rate, the short period of time 
before the tumour starts to grow and the relatively small variance between the 
tumour volume and growth rate. 
 
The MRI analysis techniques tested led to the choice of using the percentage 
change in T1 values as the most appropriate. This was due to the fact that direct 
comparison of T1 values was extremely difficult due to the large variance in T1 
values pre administration, due to the heterogeneous nature of tumours, which 
could potentially bias the results one way or another. In an attempt to 
circumvent this potential problem, various individual ROIs were placed within 
the tumour to get more precise T1 values in specific locations. However, it was 
not possible to reposition the ROIs in the exact location within the tumour at the 
different time points after administration. This arose from the difficulty in the 
positioning of the mouse within the coil, the positioning of the slice pack across 
the tumour and the apparent changes within the tumour over time. A way to 
circumvent this problem would be to use an implanted catheter to administer the 
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nanoparticles and image in real time allowing the ROIs to remain in place. 
However, this would only be possible for the first two time points, as animals 
can not be kept anaesthetised for longer periods of time. This led to the use of 
comparing percentage change of T1 from baseline. In this way each animal 
acted as its own control and group analyses could then be performed. Further 
confidence was gained due to the very small coefficient of variance that was 
found between separate drawings of ROIs. This could be further enhanced by 
referencing to an internal standard such as muscle, where there is little or no 
uptake of the nanoparticles, confirming the effects are due to the nanoparticles 
and not external factors.  
 
Once the methodology of analysing the MRI data was tested, it was 
implemented to measure the accumulation of the Survivin LEsiRNA 
nanoparticles within tumours, livers and kidneys of inoculated animals. A 
significant decrease in T1 values was observed at sixteen hours post 
administration of Survivin LEsiRNA nanoparticles in both the kidneys and liver, 
when compared to the two control groups, suggesting that the blood half life 
was increased, probably due to the presence of the stealth PEG lipid in the 
bilayer. As the liver and kidneys are the two main routes of clearance from the 
blood it was extremely encouraging to observe a significant reduction in the 
tumour T1 values at 2 hours when compared to Dotarem and again at 16 hours 
post administration when compared to both controls. This suggests that the 
Survivin LEsiRNA nanoparticles have indeed accumulated within the tumour 
due to the EPR effect, confirming previous results.37 
 
As the delivery of the LEsiRNA nanoparticles was confirmed by MRI, tumour 
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volumes were measured to determine the effect of Survivin siRNA delivery. 
Relative to the two control groups, which both had large increases in size over 
the 24 period, there was no significant increase in size of the tumours. However 
due to the large variations across groups and low n number in the Dotarem 
group, due to inability to cannulate, this difference did not reach significance. 
 
Thus, the accumulation of the Survivin LEsiRNA nanoparticles in the tumours 
and the potential reduction in tumour growth rate suggests that these particles 
could be used as a tumour therapy.  
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5 IN VIVO TUMOUR THERAPY 
5.1 Introduction 
In this chapter the results from the previous chapters, in particular the in vivo 
work, was further investigated. The particles were assessed over a longer time 
period than before due to the particles only reaching the tumours after 16 hours 
and the effects of the siRNA not generally seen for a further 24 to 48 hours. Due 
to the apparent halt in growth of the tumours in the Survivin LEsiRNA 
nanoparticles dosed mice, the dose was increased to 2.5 mg/kg in an attempt to 
achieve a significant change. 
 
The accumulation of the particles within the tumour was monitored by MRI 
utilising the gadolinium containing lipid and further corroborated by fluorescent 
microscopy, using ex vivo histology visualising the fluorescent lipid. To confirm 
the delivery of siRNA into the cells themselves, both Western blots and ELISAs 
were performed. 
 
5.1.1 Aims 
 To assess the delivery of the LEsiRNA nanoparticles to livers, kidneys 
and tumours over an extended 72 hour time period using MRI 
 To corroborate the MR findings by ICP-MS and ex vivo fluorescence 
microscopy of histology slices 
 To determine the effect of the delivery of Survivin siRNA, mediated by 
the LEsiRNA nanoparticles, on Survivin protein levels 
141 
 
5.2 Methods 
5.2.1 In Vivo MRI Assessment of LEsiRNA Delivery 
To assess the potential use of Survivin LEsiRNA nanoparticles as a tumour 
therapy, the OVCAR-3 xenograft tumour model was used and MRI performed 
over a 72 hour period and the signal intensities of the tumours measured and 
compared. OVCAR-3 ovarian cancer xenograft model was grown in female 
balb/c mice as described in section 4.2.1. Three groups were assessed, which 
were: Survivin LEsiRNA (n = 8), a positive control of Allstars LEsiRNA (n = 7) 
and a negative control of Dotarem (n = 4). 
 
LEsiRNA nanoparticles were formulated as described in section 2.2.5 using 
Survivin siRNA, labelled with an Alexa Fluor 488 label (Qiagen, Crawley, UK) to 
allow ex vivo visualisation of siRNA location and the mice were administered 
with 200 µl via the tail vein, equivalent to 2.5 mg/kg of the Survivin LEsiRNA (n 
= 8). The first control was a LEsiRNA formulation, encapsulating a mismatched 
siRNA, known as Allstars negative control siRNA (Qiagen, Crawley, UK). This 
Allstars siRNA does not target any mRNA and the nanoparticles were termed 
Allstars LEsiRNA (n = 7) and administered the same as the Survivin LEsiRNA 
nanoparticles. The clinical MRI agent Dotarem, that the Gd.DOTA.DSA lipid 
within the liposome bilayer was based on, was administered, 200 µl via the tail 
vein, at an equivalent gadolinium concentration to the LEsiRNA nanoparticles 
and this acted as a second control (n = 4). MRI was performed pre 
administration of the compounds and 2, 16, 24, 48 and 72 hours post 
administration. In an attempt to increase the efficiency of scanning time and 
simultaneously decrease any distress to the mice due to anaesthesia, a faster 
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sequence was used. The mice were scanned using a T1 weighted fast spin 
echo multi slice scan with a TR of 2 secs, echo train length of 8, echo spacing 
of 10 msecs, kspace zero of 1, effective TE of 10 msecs, FOV of 45 x 45 mm, 
matrix size of 256 x 256, five averages and 20 slices of 2 mm thickness. 
Analysis of the images was performed by comparing the signal intensities of the 
tumours (by drawing of an ROI as described in section 4.2.3), livers and 
kidneys. The signal intensities of the livers, kidneys and tumours were divided 
by the signal intensity of muscle, in the same slice, to act as an internal 
reference accounting for external variance. The adjusted values were then 
compared across the groups. Tumour volumes were measured pre 
administration and daily afterwards. Any significant changes in tumour volume, 
signal enhancement percentage changes in the tumour, liver and kidneys were 
recorded using a Students T-Test.  
 
5.2.2 Inductively Coupled Plasma Mass Spectrometry of Tumour Samples 
To confirm that changes in signal intensity were due to the gadolinium present 
in the lipid bilayer, inductively coupled plasma mass spectrometry (ICP-MS) 
was performed on the tumour samples. Tumour samples were freeze-dried 
overnight and the dry weight measured. To each sample, 5 ml of nitric acid was 
added and heated at 90oC for five hours, after which the total volume was made 
up to 25 ml with ultrapure water. A set of standards were made to give a range 
of 0.1 µg/l to 1000 µg/l of gadolinium, to allow quantification of the amount of 
gadolinium within each sample. 
 
Standards and tumour samples were further diluted 1 in 10 in diluent (70% nitric 
acid, butanol and 10% Triton X-100) and lutetium was added as an internal 
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standard. All samples were run on a PerkinElmer SCIEX Elan DRC II ICP-MS 
system.   
 
5.2.3 Tumour Histology 
At the last time point mice were culled by cervical dislocation and tumours, 
frozen over liquid nitrogen and stored at -80oC until sectioned. Frozen tumours 
were cut into 7 µm sections using a cryostat (Leica, Milton Keynes, UK) and 
microscopy images (Olympus 251) of rhodamine and Alexa Fluor 488 were 
obtained to image the liposomes and to visualise the siRNA, respectively. 
 
5.2.4 Western Blots of Tumour Samples 
To measure levels of the Survivin protein in the tumour samples, Western 
blotting was performed on selected samples. Tumours were homogenised by 
roughly chopping the tumour tissue samples with scissors in an Eppendorf and 
200 µl of homogenisation buffer (50 mM tris, 5 mM sodium pyrophosphate, 50 
mM sodium fluoride, 1 mM EDTA and 0.25 M Sucrose) in the presence of 
protease inhibitors. Samples were briefly homogenised while maintaining a 
constant temperature and 20 µl of 10% Triton X-100 added and left to incubate 
on ice for 10 minutes, spun at 14,000 rpm for fifteen minutes at 4oC and the 
supernatant collected. 
 
Protein concentration of the tumour samples was measured in triplicate by the 
addition of 10 µl of each tumour sample per well in a 96 well plate. To this 200 
µl of Dye Reagent concentrate, diluted 1:4 (Bio-Rad, Hemel Hempstead, UK) 
was added, then gently mixed and left to incubate for five minutes. To calculate 
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the protein concentration a serial dilution of BSA protein standard was prepared 
(Bio-Rad, Hemel Hempstead, UK), varying from 0 mg/ml to 0.5 mg/ml. The 
standards were added to the plate as described above, with 10 µl of each 
standard and 200 µl of Dye Reagent per well. The plates were then read on a 
plate reader at 595 nm, a standard curve generated from the protein standards 
and then the individual sample concentrations were calculated from the curve. 
 
The appropriate amount of each sample was taken so that a total of 50 µg of 
protein was present for the Western blot and to this 5 µl of x4 sample buffer 
(Invitrogen, Paisley, UK), 2 µl reducing agent (Invitrogen, Paisley, UK) and 10 µl 
of water was added. The samples were heated in a heat block at 95oC for five 
minutes and the total volume was loaded into wells of a 4 – 12% precast Bis-
Tris gel (Bio-Rad, Hemel Hempstead, UK), 4 µl of a protein ladder was added 
for size differentiation. The gel was run in NuPAGE® MES SDS running buffer 
(Invitrogen, Paisley, UK) at 160V for approximately ninety minutes or until the 
proteins reached the bottom of the gel. 
 
The transfer was performed in NuPAGE® Transfer Buffer (Invitrogen, Paisley, 
UK) onto an Immobilon transfer membrane (Millipore,Watford, UK), which had 
been soaked in absolute methanol for fifteen seconds, at 100 V for ninety 
minutes. 
 
After transfer, the membrane was removed and blocked in 5% non-fat dry milk 
in TBST (50 mM Tris, 150 mM sodium chloride and Tween-20) for 1 hour at 
room temperature. Following this the membrane was washed with TBST three 
times at room temperature with each wash lasting ten minutes. 
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The membrane was cut in between the Survivin band (16kDa) and the β-actin 
band (42kDa), so that simultaneous probing of the proteins could be carried out 
with the different primary antibodies. β-actin was used as a loading control so 
the amount of Survivin can be quantified across the various samples. The 
membrane was incubated overnight at 4oC with primary antibodies, targeted to 
Survivin, raised in rabbit (1:200; AbCam, Cambridge, UK) or for 1 hour with β-
actin, raised in mouse (1:10000, AbCam, Cambridge, UK), which were diluted in 
5% milk.  
 
The primary antibodies were removed and the membrane was washed with 
TBST three times at room temperature with each wash lasting ten minutes. 
Horseradish peroxidase-conjugated secondary anti-rabbit and anti-mouse 
antibodies, diluted 1/2000 in 5% non-fat dry milk in TBST (Santa Cruz 
Biotechnology, London, UK), were added and left to incubate at room 
temperature for an hour. 
 
The secondary antibodies were removed and the membrane was washed with 
TBST three times at room temperature with each wash lasting ten minutes. The 
membrane was further washed three times with PBS the same way and the 
proteins were visualised using enhanced chemiluminescence (Amersham GE 
Healthcare, Amersham, UK). 
 
5.2.5 Enzyme Linked Immunosorbent Assay of Tumour Samples 
A second measure of the knockdown of the Survivin protein was attempted 
using an enzyme-linked immunosorbent assay (ELISA) specifically for human 
Survivin (R&D Systems, Abingdon, UK). Tumour homogenates were produced 
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by roughly chopping tumour tissue with scissors in an Eppendorf tube and 200 
µl of homogenisation buffer (50 mM tris, 5mM sodium pyrophosphate, 50 mM 
sodium fluoride, 1 mM EDTA and 0.25 M Sucrose) with protease inhibitors was 
added to each sample. Samples were briefly homogenised, while maintaining a 
constant temperature and 20 µl of 10% Triton X-100 was added and left to 
incubate on ice for 10 minutes, spun at 14,000 rpm for fifteen minutes at 4oC, 
the supernatant collected and diluted 1:50 with water. The supernatant was 
then transferred to a fresh chilled Eppendorf tube and then the cell lysates were 
subjected to the ELISA. 
 
Equal volumes of supernatant from each sample and assay diluent, 100 µl of 
each, were added to wells in triplicate and incubated at room temperature on a 
horizontal plate shaker, for 2 hours. The plate was aspirated and washed using 
the supplied wash buffer to remove any unbound antigen, which was performed 
three times. Then 200 µl of the Survivin conjugate was added to each well and 
incubated at room temperature for 2 hours on a plate shaker. The solution was 
aspirated and the wells were washed, three times, using the wash buffer and 
incubated with 200 µl of the substrate solution per well at room temperature, for 
30 minutes whilst protected from light. The reaction was terminated by the 
addition of 50 µl of the stop solution per well and the absorbance was measured 
at wavelengths of 450 and 540 nm using a plate reader, within 30 minutes of 
the addition of the stop solution. The concentration of Survivin in each of the 
samples was determined in triplicate by comparing to a standard curve 
generated by serial dilution of the standard supplied within the ELISA kit.  
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5.3 Results 
5.3.1 In Vivo MRI Assessment of LEsiRNA Delivery 
To monitor the accumulation of the LEsiRNA nanoparticles within the tumour 
over 72 hours, a T1 fast spin echo sequence was acquired. The signal 
intensities of the livers, kidneys and tumours were divided by the signal intensity 
of muscle to act as an internal reference, accounting for potential external 
variance. The adjusted values were then compared across the groups. 
 
5.3.1.1 Livers 
Signal changes in the livers were highly variable in all groups over the 72 hours. 
The Dotarem group showed signal decreases of 2 (± 6.1) %, 8 (± 11.5) %, 7 (± 
10.4) % at 2, 16 and 24 hours post administration, which then increased to 19 
(± 27.2) % and 28 (± 1.4) % at 48 and 72 hours, respectively. The Allstars 
LEsiRNA nanoparticles group had an increase over the whole time course of 5 
(± 12.3) %, 2 (± 10.5) %, 19 (± 27.1) %, 10 (± 20.0) % and 3 (± 13.3) % for the 
respective times. As with the Allstars LEsiRNA group, the Survivin LEsiRNA 
nanoparticles elicted an increase in signal at all time points. The increases were 
found to be; 17 (± 6.3) %, 5 (± 6.3) %, 7 (± 6.9) %, 10 (± 20.8) % and 19 (± 1.5) 
%, at 2, 16, 24, 48 and 72 hours, respectively. The 72 hour post administration 
was found to be significantly increased, when compared to the respective 
Dotarem signal change (p < 0.05, Figure 5.3.1). 
 
 
 
 
148 
 
 
Figure 5.3.1. Signal enhancement percentage changes over 72 hours in the 
livers of mice dosed with the clinical MR contrast agent Dotarem (n = 4), Allstars 
LEsiRNA nanoparticles (n = 7) and Survivin LEsiRNA nanoparticles (n = 8), via 
the tail vein (* = p < 0.05). 
 
 
5.3.1.2 Kidneys 
The control Dotarem group produced variable signal change over time within 
the kidneys, with a -6 (± 8.6) % decrease at 2 hours, an 8 (± 4.3) % increase at 
16 hours, followed by another decrease to -4 (± 8.8) % at 24 hours, which 
returned back to a positive 14 (± 21.6) % and then 4 (± 3.8) % at 48 and 72 
hours, respectively. The administration of Allstars LEsiRNA nanoparticles 
produced an increase in signal of 9 (± 7.3) %, 19 (± 7.0) %, 15 (± 0.8) %, 18 (± 
7.5) % and 8 (± 13.2) % at the respective times. The Survivin LEsiRNA 
nanoparticles group had a similar pattern to the Allstars LEsiRNA group, apart 
from 2 and 16 hours post administration, which were -6 (± 4.6) % and 1 (± 3.6) 
% respectively, with the 16 hour time point significantly lower than the Allstars 
LEsiRNA (p < 0.05). The signal then increased further to 9.5 (± 5.6) %, 15 (± 
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5.8) % and 19 (± 12.9) % at 24, 48 and 72 hours, respectively (Figure 5.3.2). 
 
 
 
Figure 5.3.2. Signal enhancement percentage changes over 72 hours in the 
kidneys of mice dosed with the clinical MR contrast agent Dotarem (n = 4), 
Allstars LEsiRNA nanoparticles (n = 7) and Survivin LEsiRNA nanoparticles (n = 
8), via the tail vein (* = p < 0.05). 
 
 
5.3.1.3 Tumours 
Signal enhancement percentage change measured in the Dotarem control 
group (n = 4) were -16 (± 13.4) %, -3 (± 3.0) %, -2 (± 3.1) %, 1 (± 14.3) % and -
2 (± 3.5) % at 2, 16, 24, 48 and 72 hours, respectively. The Allstars LEsiRNA 
nanoparticles showed a decrease of -9 (± 7.2) % at 2 hours that reverted to an 
11 (± 4.6) % increase at 16 hours post administration, which declined over time 
to 8 (± 1.2) % at 24 and then 5 (± 8.6) % and 5 (± 8.2) %, at 48 and 72 hours 
post administration, respectively. The Survivin LEsiRNA nanoparticles followed 
a similar pattern to the Allstars LEsiRNA group, with a signal decrease of 6 (± 
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4.8) % after 2 hours that increased to 12 (± 5.5) % at 16 hours, then decreased 
to 5 (± 6.9) % and -2 (± 0.9) % at 24 and 48 hours, respectively and showed a 
final rise to 4 (± 0.4) % at 72 hours post administration (Figure 5.3.3. and Figure 
5.3.4). 
 
The Allstars LEsiRNA nanoparticles were found to elict a significantly enhanced 
signal intensity (p < 0.05), at both 16 and 24 hours post administration, when 
compared to the imaging clinical contrast agent Dotarem. The Survivin 
LEsiRNA nanoparticles also produced a significant enhancement in signal 
intensity (p < 0.05), 16 hours post administration, when compared to Dotarem. 
Comparison of both the Allstars and Survivin LEsiRNA nanoparticles 
administration groups showed an almost identical signal enhancement time 
course over the 72 hour period, with no significant differences found at any time 
point. 
 
 
 
Figure 5.3.3. T1 weighted fast spin echo image of mouse xenograft OVCAR-3 
tumours with a colour intensity map. Signal intensity prior to administration of 
the LEsiRNA nanoparticles is reduced (a) when compared to the signal intensity 
sixteen and twenty four hours post iv administration (b). Colour scale bar units 
are of signal intensity and are arbitrary units (AU).  
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Figure 5.3.4. Signal enhancement percentage changes over 72 hours in the 
tumours of mice dosed with the clinical MR contrast agent Dotarem (n = 4), 
Allstars LEsiRNA nanoparticles (n = 7) and Survivin LEsiRNA nanoparticles (n = 
8), via the tail vein (* = p < 0.05). 
 
 
5.3.1.4 Tumour Volume 
The administration of Survivin LEsiRNA nanoparticles led to a significant (p < 
0.05) reduction in tumour growth when compared to both Allstars LEsiRNA 
nanoparticles (positive control) and Dotarem groups both at 48 and 72 hours 
post administration (Figure 5.3.5).  
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Figure 5.3.5. Tumour volume change after iv injection of the different 
treatments 24, 48 and 72 hours post dose.  Survivin LEsiRNA nanoparticle 
administration significantly reduced the tumour growth at 48 and 72 hours post 
administration when compared to control Allstars LEsiRNA nanoparticle and 
Dotarem administration (* = p < 0.05). 
 
 
5.3.2 Inductively Coupled Plasma Mass Spectrometry of Tumour Samples 
A tumour sample from each of the three experimental groups was subjected to 
ICP-MS in order to confirm that the signal changes observed in mice were 
indeed produced by the gadolinium within the LEsiRNA nanoparticles. The 
animal dosed with the imaging clinical agent Dotarem was found to have 0.35 
µg/g of gadolinium per tumour tissue weight. The Allstars LEsiRNA dosed 
tumour was determined to contain 0.85 µg/g of gadolinium per tumour tissue 
weight. The Survivin LEsiRNA administered group had 1.55 µg/g of gadolinium 
per tumour tissue weight (Error! Reference source not found.).  
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Figure 5.3.6. ICP-MS of tumour samples 72 hours post administration with 
Dotarem, Allstars LEsiRNA nanoparticles and Survivin LEsiRNA nanoparticles 
(n = 1 per group). 
 
 
5.3.3 Tumour Histology 
To further corroborate that the signal enhancement was indeed due to the 
presence of the LEsiRNA nanoparticles, ex vivo fluorescent microscopy of the 
histology slices was performed to visualise the rhodamine from the lipid bilayer. 
In addition to this the subsequent delivery of Survivin siRNA by the Survivin 
LEsiRNA nanoparticles was also measured using the Alexa Fluor 488 label on 
the Survivin siRNA.  
 
The tumours of the Dotarem dosed mice were found to have no signal from 
either rhodamine or Alexa Fluor 488 (Figure 5.3.7). 
Dotarem Allstars LEsiRNA Survivin LEsiRNA
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
G
a
d
o
lin
iu
m
 p
e
r 
T
u
m
o
u
r 
T
is
s
u
e
 (

g
/g
)
154 
 
 
Figure 5.3.7. Fluorescence microscopy of tumour slices 72 post iv 
administration of Dotarem. Rhodamine was used to visualise the LEsiRNA 
nanoparticles (a) and the Alexa Fluor 488 to visualise the Survivin siRNA (b). 
 
 
Tumours from mice that had been injected with Allstars LEsiRNA nanoparticles 
displayed signal from the rhodamine in the lipid bilayer (Figure 5.3.8a), but no 
signal from Alexa Fluor 488 (Figure 5.3.8b). 
 
 
 
Figure 5.3.8. Fluorescence microscopy of tumour slices 72 post iv 
administration of Allstars LEsiRNA nanoparticles. Rhodamine was used to 
visualise the LEsiRNA nanoparticles (a) and the Alexa Fluor 488 to visualise the 
Survivin siRNA (b). 
(a) (b) 
(a) (b) 
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Survivin LEsiRNA nanoparticles administration to mice led to visualisation of 
both rhodamine from the lipid bilayer (Figure 5.3.9a) and Alexa Fluor 488 from 
the labelled Survivin siRNA (Figure 5.3.9b) in fluorescence microscopy 72 hours 
post dose. 
 
 
 
Figure 5.3.9. Fluorescence microscopy of tumour slices 72 hours post iv 
administration of Survivin LEsiRNA nanoparticles. Rhodamine was used to 
visualise the LEsiRNA nanoparticles (a) and the Alexa Fluor 488 to visualise the 
Survivin siRNA (b). 
 
5.3.4 Western Blot of Tumour Samples 
Western blot analysis of the OVCAR-3 xenograft tumours, harvested 72 hours 
post systemic administration of the various treatments, showed a substantial 
reduction in the expression of Survivin protein post the Survivin LEsiRNA 
nanoparticles administration (Figure 5.3.10). This was significant when 
compared to the control group Dotarem (p < 0.05), but did not reach 
significance when compared to Allstars LEsiRNA nanoparticles (p = 0.09, 
Figure 5.3.11). β-actin was used as a loading control. 
(a) (b) 
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Figure 5.3.10. Western blot analysis of Survivin protein in OVCAR-3 xenografts 
systemically injected with Dotarem (lanes 1 + 2), control Allstars LEsiRNA 
nanoparticles (lanes 3 + 4) and Survivin LEsiRNA nanoparticles (lanes 5 + 6) 72 
hours post administration. β-actin loading control (upper image) and Survivin 
protein (lower image).  
 
 
Figure 5.3.11. Western blot relative intensities of Survivin  protein in OVCAR-3 
xenografts systemically injected with Dotarem, Allstars LEsiRNA nanoparticles 
and Survivin LEsiRNA nanoparticles 72 hours post administration (* = p < 0.05).  
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5.3.5 Enzyme Linked Immunosorbent Assay of Tumour Samples 
To further confirm that the Survivin LEsiRNA nanoparticles did mediate the 
functional delivery of the Survivin siRNA, an ELISA was performed to measure 
the amount of the Survivin protein present in the tumour tissue 72 hours post 
administration of the two LEsiRNA nanoparticles groups. The administration of 
the Survivin LEsiRNA produced a significant decrease (p < 0.01) in the amount 
of Survivin protein from 392 pg/ml in the Allstars LEsiRNA dosed animals to 83 
pg/ml in the Survivin LEsiRNA nanoparticles dosed mice (Figure 5.3.12). 
 
 
 
 
Figure 5.3.12. Survivin concentration in tumours 72 hours after administration 
with Allstars LEsiRNA nanoparticles and Survivin LEsiRNA nanoparticles, 
detected by an ELISA (** = p < 0.01). 
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5.4 Discussion 
Here the LEsiRNA nanoparticle platform was tested as a potential tumour 
therapy agent by mediating the functional delivery of siRNA to tumours and in 
this case Survivin siRNA. In the previous chapter it was demonstrated that the 
LEsiRNA nanoparticles accumulate in tumours around 16 hours post 
administration, as determined by the decrease in tumour T1. In this chapter a 
different MRI method is used in order to cut down the imaging time by a third, 
but still retain the sensitivity required to monitor the accumulation, when 
compared to the T1 method. The fast spin echo sequence employed was just as 
sensitive to the changes caused by the LEsiRNA nanoparticles as significant 
increases in the signal intensities were found again at 16 hours post 
administration. However, this method did not appear to be as sensitive to 
changes within the liver, as no obvious patterns could be deciphered, in 
contrast with the T1 method. This is probably due to the fast spin echo being 
optimised for tumours and not livers, the latter having a lower T1 value. The fast 
spin echo method also appears validated for measuring changes in the kidneys 
as a signal enhancement was observed for the LEsiRNA nanoparticles, in good 
agreement with the change in T1 values seen previously. 
 
To verify that the changes in tumour signal arose from the gadolinium lipid of 
the nanoparticle, inductively coupled plasma mass spectrometry (ICP-MS) was 
carried out. This allows a direct measure of the amount of gadolinium in tumour 
samples. Results showed that the two LEsiRNA formulations led to a 
substantial increase in the amount of gadolinium present in the tumour, when 
compared to the Dotarem controls. This is clearly due to the enhanced 
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permeability and retention effect in tumours, which causes liposomes to 
accumulate within the tumour.  
 
As a second verification of LEsiRNA accumulation and also siRNA delivery, ex 
vivo fluorescence microscopy was performed on tumour slices. Again the 
results corroborated the MRI and ICP-MS findings, as rhodamine could be seen 
in both the LEsiRNA dosed animals, but not in the Dotarem group. Further to 
this the delivery of siRNA was confirmed as the Alexa Fluor 488 label on the 
Survivin siRNA was visualised in only the Survivin LEsiRNA treated animals, 
providing strong evidence that these particles delivered the siRNA to tumours. 
 
To confirm whether the delivery of the Survivin siRNA was in fact functional and 
hence having its expected effect within the cell, Western blots were performed 
to determine potential knockdown of the Survivin protein. The administration of 
the Survivin LEsiRNA led to a substantial decrease in the amount of Survivin 
protein produced when compared to the two control groups of Dotarem and 
Allstars LEsiRNA, suggesting that the delivery is functional and therefore that 
the siRNA does gain access to the cytoplasm of the tumour cells. 
 
As a second validation of the functional delivery of the Survivin siRNA into the 
tumour cells mediated by the LEsiRNA nanoparticles, an enzyme linked 
immunosorbent assay (ELISA) was performed. Again this demonstrated that the 
LEsiRNA nanoparticles successfully deliver the Survivin siRNA into the tumour 
cells, as the Survivin LEsiRNA nanoparticles elicted a significant reduction in 
Survivin level when compared to the control of Allstars LEsiRNA nanoparticles.  
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The knockdown of a particular protein within a tumour cell is only really effective 
if that protein has a therapeutic outcome. Here the knockdown of the Survivin 
protein led to a significant reduction in the tumour growth rate over just three 
days proving the massive potential of the LEsiRNA nanoparticle system. 
Although this has only been evaluated in one tumour type here, the 
nanoparticles have great potential in other tumour types as well. This is 
because these nanoparticles accumulate in the tumours due to the EPR effect 
and target the Survivin gene, both of which are traits in the majority of tumours.  
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6 APOPTOSIS DETECTION  
6.1 Introduction 
In the previous chapters the development and implementation of the LEsiRNA 
nanoparticle system as a tumour therapy has been shown and discussed. For 
this system to have an impact in the clinical setting, detection of the therapeutic 
effect at cellular level is also required, without the need for biopsies. With this in 
mind a novel MRI contrast agent was developed with the aim to detect 
apoptosis and hence, effect of tumour therapy. 
 
Recently it has been shown that zinc-dipicolylamine (Zn-DPA) complexes bind 
strongly and selectively to a range of phosphate species including inorganic 
phosphates and phosphorylated organics such as phospho-peptides and amino 
acids.305-307 It has also been shown more recently that Zn-DPA selectively binds 
to phosphatidylserine in a similar fashion to the widely used apoptosis detection 
agent – annexin V.308,309 Based on this, an MRI contrast agent was designed 
and synthesised that incorporates two selective phosphate-binding moiety Zn-
DPA ‘arms’, to improve the selectivity of the contrast agent, into a gadolinium 
diethylene triamine pentaacetic acid (DTPA) complex (Figure 6.1.1). The 
contrast agent was then studied in vitro as a possible apoptotic detection agent, 
which can potentially lead to an early marker of tumour therapy.   
 
6.1.1 Aims 
 To set up an in vitro model of apoptosis to allow the assessment of the 
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contrast agent 
 To assess the contrast agent in the in vitro model by MRI of the treated 
cells and determine its potential use in vivo 
 
 
 
Figure 6.1.1. Structure of the DTPA-bis amide complex incorporating the two 
DPA ‘arms’. 
 
 
6.2 Methods 
6.2.1 In Vitro Apoptosis Detection 
Murine lymphoma cells (EL4) were grown in RPMI 1640 medium (Sigma-
Aldrich, Dorset, UK) supplemented with 10% heat inactivated fetal bovine 
serum (Invitrogen, Paisley, UK). Once confluent the cell density was adjusted to 
1x106 cells/ml in a T75 flask and a further 15 ml of media was added and 
incubated at 37oC in a humidified incubator with 5% CO2 for 16 hours. In 
parallel, to induce apoptosis 15 µM Etoposide (Sigma-Aldrich, Dorset, UK) was 
added to 1 x106 cells/ml in a T75 flask and a further 15 ml of media was added 
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and incubated at 37oC in a humidified incubator with 5% CO2 for 16 hours.
124,310  
 
Cells were collected by centrifugation and the density was adjusted to 1 x106 
cells/ml in saline. To confirm and quantify the percentage of cells undergoing 
apoptosis a commercially available apoptosis kit was used with 10 µl of 
propidium iodide and 5 µl of Annexin V-FITC (Sigma-Aldrich, Dorset, UK) was 
added to 1 ml of the cell suspension. Flow cytometry was used for assessment, 
with 10,000 profiles recorded. 
 
6.2.2 In Vitro MR Imaging of Apoptotic Cells 
Murine lymphoma cells (EL4) were grown in RPMI 1640 medium (Sigma-
Aldrich, Dorset, UK) supplemented with 10% heat inactivated fetal bovine 
serum (Invitrogen, Paisley, UK). Once confluent the cell density was adjusted to 
1x106 cells/ml in a T75 flask and a further 15 ml of media added and incubated 
at 37oC in a humidified incubator with 5% CO2 for 16 hours. In parallel to induce 
apoptosis, 15 µM Etoposide (Sigma-Aldrich, Dorset, UK) was added to 1 x106 
cells/ml in a T75 flask and a further 15 ml of media was added and incubated at 
37oC in a humidified incubator with 5% CO2 for 16 hours. 
124,310   
 
Cells were collected by centrifugation and cell density adjusted to 3 x106 
cells/ml in saline. In duplicate, 1 ml of the untreated and Etoposide treated cell 
suspensions were incubated with different contrast agent concentrations (0, 
100, 300 and 600 µM) at room temperature for half an hour. 
 
Cells were collected by centrifugation, the unbound contrast agent was 
removed and the cell pellet was resuspended in 100 µl of saline, mixed with 100 
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µl of 2% agarose, in an attempt to stop cell sedimentation. This was then loaded 
into 250 µl PCR tubes for MR imaging. 
 
MR imaging was performed on a 4.7T Varian Direct Drive scanner, with the 
samples placed into a Perspex holder within a quadrature birdcage RF coil and 
then into the centre of the magnetic field. Shimming was carried out to create a 
homogeneous a field as possible with the linewidth generally between 15 – 50 
Hz. A three plane scout image was taken for positioning of the slices on further 
scans.  
 
A series of spin echo multi slice scans were run with an echo time (TE) of 10.97 
msec, a field of view (FOV) of 80 x 40 mm, a matrix size of 256 x 128, one 
average, ten dummy scans, ten 1 mm thick coronal slices and repetition times 
(TR) of 10000, 7000, 5000, 3000, 1000, 700, 500, 300 msecs, to allow for the 
measuring of T1 values. 
 
The slice with the largest amount of sample present, without any artefacts, was 
chosen as the most appropriate slice for analysis. Images were analysed using 
ImageJ software (National Institutes of Health, USA), with a region of interest 
(ROI) drawn to encompass as much of the sample as possible, whilst ensuring 
no air is included, for each sample defined on the longest TR image (Figure 
6.2.1). The mean signal intensity (Mz) over the ROI was taken for each TR and 
each sample and plotted to fit a curve given by: 
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T1 values were then calculated from this equation using Prism (GraphPad, San 
Diego, USA) and then converted to relaxation rate (R1 = 1/T1) and plotted 
against the contrast agent concentration. Students t-tests were performed to 
determine the effectiveness of the contrast agent at the various concentrations 
between apoptotic and non-apoptotic cells for both T1 and R1 data. 
 
 
 
Figure 6.2.1. An example MR image of samples displaying a region of interest 
(red - top left sample), that is used to measure the signal intensity for each 
sample at each repetition time, allowing calculation of T1. 
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The T1 weighted image with TR: 700 msec, TE: 10.97 msec, FOV: 80 x 40 mm, 
matrix size: 256 x 128, one average, ten dummy scans and ten 1 mm thick 
coronal slices was used to compare the signal intensities between the different 
concentrations and treatment groups. Students t-tests were performed to 
determine the effectiveness of the contrast agent at the various concentrations 
between apoptotic and non-apoptotic cells.  
 
6.3 Results 
6.3.1 Flow Cytometry 
The untreated and Etoposide-treated cells underwent flow cytometry with and 
without incubation with propidium iodide (PI) and annexin V-FITC to quantify the 
percentage of cells undergoing apoptosis. Two distinct populations were 
detected in all flow cytometry experiments, one of which exhibited reduced 
forward light scattering and elevated perpendicular light scattering due to 
morphological changes. These changes were a reduced size and an increased 
granularity, which is often associated with apoptosis.123 Double staining of the 
cells with PI and annexin V-FITC showed cells that were in late stage apoptosis 
and necrotic. Cells labelled with annexin V-FITC alone were cells in the early 
stage of apoptosis and cells negative for both PI and annexin V-FITC staining 
were viable cells.311 This allows for the drug treated cells to be divided into three 
populations. 
 
In the untreated cells without incubation with PI and annexin V-FITC (Figure 
6.3.1) the cells are highly viable with the majority having a reduced 
perpendicular light scattering and an increased forward light scattering profile, 
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with only a small proportion having an apoptotic appearance of increased 
perpendicular light scattering and reduced forward light scattering. The 
Etoposide-treated EL4 cells without incubation with PI and annexin V-FITC 
show a distinct variation in cell populations, with a shift towards more apoptotic 
like cells with an increased perpendicular light scattering and reduced forward 
light scattering (Figure 6.3.2). 
 
 
 
Figure 6.3.1. Untreated (non-apoptotic) EL4 cells analysed using flow 
cytometry. (a) light scattering profile, the x and y axis represent the light 
intensity from forward light scattering (FLS) and perpendicular light scattering 
(PLS), respectively. (b) the x and y axis represent fluorescent intensity profiles 
from FITC and PI respectively. Profiles from 10,000 cells are presented. 
 
 
 
 
 
a b 
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Figure 6.3.2. Etoposide treated (apoptotic) EL4 cells analysed using flow 
cytometry. (a) light scattering profile, the x and y axis represent the light 
intensity from forward light scattering (FLS) and perpendicular light scattering 
(PLS), respectively. (b) the x and y axis represent fluorescent intensity profiles 
from FITC and PI respectively. Profiles from 10,000 cells are presented. 
 
 
The addition of the apoptosis detection reagents propidium iodide (PI) and 
annexin V-FITC allowed quantification of viable, apoptotic and necrotic cell 
populations. In the untreated cell group the unstained population representing 
viable cells accounted for 84.1% of the cells, the cells stained with both PI and 
annexin V-FITC representing necrotic cells accounted for 10.5% of the cells and 
the cells labelled with annexin V-FITC alone representing early apoptotic cells 
was 0.6% (Figure 6.3.3). 
 
 
 
a b 
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Figure 6.3.3. Untreated (non-apoptotic) EL4 cells incubated with propidium 
iodide and annexin V-FITC and analysed using flow cytometry. (a) light 
scattering profile, the x and y axis represent the light intensity from forward light 
scattering (FLS) and perpendicular light scattering (PLS), respectively. (b) the x 
and y axis represent fluorescent intensity profiles from FITC and PI respectively. 
Profiles from 10,000 cells are presented with 10.5% in Q2, 84.1% in Q3 and 
0.6% in Q4 representing necrotic, viable and early apoptotic cell populations 
respectively. 
 
 
The Etoposide-treated cells incubated with PI and annexin V-FITC showed the 
three populations of cells in the FITC vs PI plot (Figure 6.3.4). The unstained 
viable cell population was 38.1% of the total, the double stained necrotic cell 
population was 19.2% and the annexin V-FITC only stained early apoptotic cells 
accounted for 19.6% of the cells. 
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Figure 6.3.4. Etoposide treated (apoptotic) EL4 cells incubated with propidium 
iodide and annexin V-FITC and analysed using flow cytometry. (a) light 
scattering profile, the x and y axis represent the light intensity from forward light 
scattering (FLS) and perpendicular light scattering (PLS), respectively. (b) the x 
and y axis represent fluorescent intensity profiles from FITC and PI, 
respectively. Profiles from 10,000 cells are presented with 19.2% in Q2, 38.1% 
in Q3 and 19.6% in Q4 representing necrotic, viable and early apoptotic cell 
populations, respectively. 
 
 
6.3.2 In Vitro MR Imaging of Apoptotic Cells  
Cells that have been treated with Etoposide and were therefore undergoing 
apoptosis showed a progressive decrease in T1 with an increase in contrast 
agent concentration, which was more pronounced than in the untreated cell 
group (Figure 6.3.5). In the absence of contrast agent both treated and 
untreated cells showed, a T1 of 3.0 (± 0.08) seconds. In the presence of 100 μM 
of contrast agent, the T1 was 1.9 (± 0.05) seconds and 2.3 (± 0.05) seconds for 
a b 
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treated and untreated, respectively (p = 0.054). In cells incubated with 300 μM 
of contrast agent, T1 values of 1.3 (± 0.04) seconds and 1.8 (± 0.05) seconds 
were observed for treated and untreated, respectively (p < 0.05). Cells 
incubated with 600 μM of contrast agent had T1 values of 0.9 (± 0.03) seconds 
and 1.5 (± 0.04) seconds for treated and untreated, respectively (p < 0.05). 
 
 
Figure 6.3.5. T1 map, in seconds, of the apoptotic and non-apoptotic EL4 cells 
with varying concentrations of the contrast agent. Rows a – d apoptotic cells 
incubated with 600, 300, 100 and 0 μM of contrast agent, respectively and rows 
e – h non-apoptotic cells incubated with 600, 300, 100 and 0 μM of contrast 
agent, respectively. 
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The relaxation rate R1 (1/T1), also confirmed that the T1 had decreased in the 
apoptotic cells more prominently when compared to the non-apoptotic cells and 
was significantly increased at 100, 300 and 600 μM concentrations of the 
contrast agent (p < 0.05, Figure 6.3.6). 
 
 
 
Figure 6.3.6. Etoposide treated (apoptotic) EL4 cells (blue) show an increase in 
relaxation rate R1 (1/T1), as the concentration of contrast agent is increased 
from 0 – 600 μM, when compared to the non-apoptotic untreated cells (red). (* = 
p < 0.05) 
 
 
The T1 weighted image (TR = 700 msecs, TE = 10.98 msecs) of the cells 
visually illustrated that the contrast agent preferentially bound to the apoptotic 
cells as there is a visibly increased signal intensity in the image (Figure 6.3.7). 
This was confirmed by measurement of the signal intensities of all the samples 
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and it was clearly shown that at the 600 μM concentration the signal intensity 
increase caused by the binding of the contrast agent is significantly larger when 
compared to the non-apoptotic cells (p < 0.05, Figure 6.3.8). The 300 μM 
concentration of contrast agent had an increased signal intensity in the 
apoptotic cells when compared to the untreated cells, but it did not quite 
achieve significance (p = 0.09). 
 
The signal intensities varied very little from concentration to concentration in the 
non-apoptotic cells with no significant change between any concentration. On 
the contrary, in the apoptotic cells there is a marked rise in signal intensity as 
the concentration of contrast agent increases from 0 – 600 μM. When the 
apoptotic cells incubated with contrast agent, are compared to the apoptotic 
cells without contrast agent they all have significantly increased signal 
intensities with 100 and 600 μM (p < 0.05) and 300 μM (p < 0.01). The addition 
of 600 μM of contrast agent to apoptotic cells caused a significant increase in 
signal intensity when compared to the 100 μM concentration (p < 0.05), but the 
increase in intensity when compared to the 300 μM concentration did not 
achieve significance (p = 0.09).  
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Figure 6.3.7. Signal intensity image of the Etoposide treated (apoptotic) and 
untreated (non-apoptotic) EL4 cells with varying concentrations of the contrast 
agent. Rows a – d show Etoposide treated EL4 cells incubated with 600, 300, 
100 and 0 μM of contrast agent respectively and rows e – h show untreated 
EL4 cells incubated with 600, 300, 100 and 0 μM of contrast agent, respectively. 
 
 
 
 
175 
 
 
 
Figure 6.3.8. Etoposide treated apoptotic EL4 cells (blue) show an increase in 
signal intensity as the concentration of contrast agent is increased from 0 – 600 
μM, when compared to the non-apoptotic untreated EL4 cells (red) in a T1 
weighted image (TR = 700 msecs). (* = p < 0.05) 
 
 
6.4 Discussion  
The data in this chapter suggest that the gadolinium containing contrast agent 
binds to apoptotic cells and thus the agent can be used as an early apoptotic 
marker in MRI scans.  
 
The stimulation of apoptosis by the addition of 15 μM Etoposide into the growth 
media of murine lymphoma cells (EL4) was determined using flow cytometry 
after the addition of PI and annexin V-FITC. EL4 cells that were untreated 
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showed only 0.6% in the early stage of apoptosis from the annexin V-FITC 
staining (Figure 6.3.3), which was in sharp contrast to the 19.6% of cells in the 
early stage of apoptosis, in the Etoposide treated group (Figure 6.3.4). This 
difference in apoptotic cell populations between the treated and untreated cells 
allowed for the assessment of the contrast agent as a measure of early 
apoptosis, by using MRI. 
 
The T1 values (Figure 6.3.5) and consequently the R1 values (Figure 6.3.6), 
decreased and increased respectively, in the Etoposide treated cells when 
compared to the untreated cells at all three of the concentrations of contrast 
agent 100, 300 and 600 μM (p < 0.05). This suggests that the contrast agent is 
binding to phosphatidylserine that is only present in early apoptosis and hence, 
decreasing the T1 to a greater extent in the early apoptotic cells that were 
treated with Etoposide than compared to the non-apoptotic cells. There is a 
slight decrease in T1 in the untreated cells as the concentration of contrast 
agent increases, but it is not as pronounced as the change in the treated cells. 
This could be due to either non-specific binding of the agent, the excess 
contrast agent not being completely removed or some of the agent binding to 
the small percentage of cells that are in the early apoptotic stage.  
 
In the T1 weighted image (Figure 6.3.7) it can be visually distinguished that the 
cells in the early stage of apoptosis treated with Etoposide (rows a – d) have a 
higher signal intensity when compared to the non-apoptotic (rows e – h). This is 
further emphasised in the apoptotic cells with 600 μM of contrast agent added, 
as it is clearly visible the signal intensity is much greater than that of the 600 μM 
in the untreated cells (a and e respectively). As the concentration of contrast 
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agent increases in the apoptotic cells the signal intensity can be seen to 
increase, but in the untreated cells there is very little discernable change in 
signal intensity. 
 
The measurement of signal intensity allowed quantification of the visual results 
from the T1 weighted image (Figure 6.3.8). The addition of the contrast agent to 
the non-apoptotic cells had no effect on the signal intensity at any of the 
contrast agent concentrations. However, the addition of the contrast agent to 
apoptotic cells increased the signal intensity as the concentration of contrast 
agent increased from 0 – 600 μM, implying that the contrast agent is binding 
specifically to the apoptotic cells. 
 
These promising results demonstrate that the contrast agent specifically binds 
to apoptotic cells, most likely via binding to phosphatidylserine and could 
therefore potentially be used in vivo as a detector of apoptosis. This ability to 
detect early apoptosis using MRI could potentially be used as marker of 
treatment response after tumour therapy.   
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7 DISCUSSION  
In this thesis the preparation and use of novel theranostic PEGylated siRNA 
nanoparticles, termed LEsiRNA nanoparticles, that successfully combine the 
delivery of therapeutic siRNA to tumours with bimodal imaging capabilities for in 
vivo monitoring and ex vivo corroboration of delivery and the effects of therapy 
has been described.  
 
Synthesis of the lipid Gd.DOTA.DSA (patent applied for), as described by 
Kamaly et al,159 allowed for the incorporation of an MR contrast agent into the 
liposome bilayer. This gave the liposomes the potential ability to be used to 
monitor the delivery of the liposomes in vivo. In addition to the MR contrast 
agent the liposomes were formulated with a rhodamine containing lipid, to allow 
corroboration of the MRI results with ex vivo fluorescence microscopy of 
histology slices. A PEG containing lipid was also incorporated, to confer the 
particles with a ‘stealth’ coating to increase the blood half life, as is required in 
vivo. A cationic lipid CDAN was also included to increase the interactions 
between the liposomes and the negatively charged cell membranes. The final 
lipid incorporated into the liposome bilayer was DOPC to stabilise the liposome 
structure and to aid endosomal escape once inside the cell membrane. These 
liposomes are similar to others previously described, suggesting that they have 
potential to be used as an in vivo MR contrast agent and therapy delivery 
vector.158,159,171,312  
 
However, before this could be attempted, characterisation and in vitro 
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assessment of the particles was required and performed. A key aspect of the 
liposomes was the particles size, as passive targeting to tumours, due to the 
EPR effect, requires particles to be around 100 nm in diameter.37 The size of 
these liposomes formulated was found to be ideal for the delivery to tumours. 
They were also found to be stable over a relatively long period of time, with 
respect to size. The MR relaxivity value, r1, of the liposomes was found to be 
superior than the clinical contrast agent Dotarem, that the Gd.DOTA.DSA lipid 
was based on.291 This was also comparable to other liposomal based 
nanoparticles used in tumour imaging.294 
 
Addition and subsequent encapsulation of siRNA to the liposomes led to the 
formation of the LEsiRNA nanoparticles. A high percentage of siRNA was 
determined to be encapsulated into the liposomes and the addition did not 
increase the size of the liposomes. The size of the LEsiRNA nanoparticles was 
stable over 10 days, however, the siRNA encapsulation decreased at day 6, 
appearing to lose stability. The MR relaxivity value, r1, of the LEsiRNA 
nanoparticles was virtually identical to the liposomes alone, providing further 
encouragement for use as an in vivo tumour delivery monitoring system. 
 
In vitro assessment of the particles showed that there did appear to be an 
increase in cell uptake over 48 hours of the liposomes. Although this was not 
significant it did provide encouragement and it is known that in vitro cell studies 
do not always predict good in vivo outcomes.89 The particles were deemed not 
to be toxic to the cells, which is essential when translating to an in vivo model. 
The most exciting in vitro result was the knockdown of protein expression of the 
targeted cancer gene, Survivin. The knockdown was comparable to the widely 
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used transfection agent, Lipofectamine and was particularly encouraging due to 
the relatively high level of PEG incorporated into the liposome bilayer, which 
often decreases efficiency in vitro.297,298 These promising findings led to the 
testing of the particles in vivo.  
 
To allow assessment of the LEsiRNA nanoparticles in vivo, a murine xenograft 
tumour model was developed. A total of 4 different cell lines were tested, all of 
which showed an over expression of Survivin. The only cell line deemed 
suitable was the OVCAR-3 cell line, which had a high take rate and was a fast 
aggressive tumour, so would allow assessment of the particles quickly. 
Previous methods of liposome detection in tumours included visual changes in 
signal intensity.313 However, this is only qualitative and for accurate assessment 
a quantifiable method was required, previous studies had shown changes in T1 
to be credible.159 To further increase the accuracy of the T1 method used by 
Kamaly et al, 5 TR’s were used instead of 3 to give better precision. Percentage 
change in T1 was determined to be the most reliable method of image analysis 
giving the lowest variation and allowing each animal to act as its own control. 
This characteristic of MRI, longitudinal studies in the same animal, allows the 
reduction of animals used and increases the statistical power. In addition to this 
it provides a direct translational link to possible clinical studies. In addition to the 
T1 method, change in signal intensity was also used as a measure of LEsiRNA 
accumulation in the tumours. This appeared as sensitive as the T1 method, but 
only took approximately a third of the time to acquire the data. 
 
In vivo MRI data were able to demonstrate LEsiRNA nanoparticle accumulation 
in the tumour 16 – 24 hours post iv administration. This was confirmed with ex 
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vivo fluorescence microscopy showing co-localisation of nanoparticles and 
siRNA within the tumour and by ICP-MS of ex vivo tumour samples. The 
delivery of the Survivin siRNA produced a reduction in Survivin expression, as 
shown in the Western blot and by the ELISA. The accumulation and delivery of 
Survivin siRNA within the tumour, mediated by these nanoparticles, was found 
to correlate with a significant reduction in tumour growth compared to controls 
at 48 and 72 hours post iv administration. The delivery of Survivin siRNA to 
tumours has previously been shown to promote apoptosis in an adenovirus-
mediated delivery system314 and also increase apoptosis and necrosis when 
delivered by a nanoparticle probe.315 Here, the use of, non-viral, Survivin 
LEsiRNA nanoparticles for tumour therapy is encouraging, especially as these 
results demonstrated both a decrease in Survivin expression and tumour 
growth.  
 
These results strongly suggest that cationic liposomes carrying siRNA can be 
tracked non-invasively and longitudinally to assess siRNA delivery to tumour 
cells and potentially monitor tumour therapy. It has recently been reported that 
the same LEsiRNA nanoparticle using a different siRNA target, iNOS, produced 
specific knockdown and again showed a reduction in tumour growth.316 This is 
especially encouraging as imaging studies are inherently sequential, so they 
lend themselves to sequential experimental designs, which utilise fewer animals 
to achieve the same statistical power as conventional designs. 
 
To be able to diagnose and assess the effect of a tumour therapy intervention, 
without the need for an invasive biopsy, a contrast agent targeted to apoptotic 
cells was investigated. In an in vitro model of apoptosis the contrast agent was 
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able to selectively bind to the apoptotic cells, when compared to non-apoptotic 
cells, as visualised by MRI. This suggests that the agent could potentially be 
useful as an in vivo early marker of apoptosis, especially as comparable agents 
displayed similar results in vitro and had been used in vivo.123,124,311 
 
As mentioned above the relatively high level of PEG incorporated into the lipid 
bilayer, reduces the transfection efficiency in vitro. Despite this, the results here 
still show LEsiRNA nanoparticles cause knockdown of the Survivin protein, both 
in vitro and in vivo. However, recently the development of cleavable PEG lipids, 
has led to higher transfection efficiencies for in vivo applications. These lipids, 
retain the biocompatible ‘stealth’ effect, thereby increasing the blood half-life 
and delivery to the tumour. However, once the particles are in the tumour the 
PEG is cleaved off and thus, the transfection efficiency of the particles is 
increased.317-320  
 
Another method widely used to increase the accumulation of the particles within 
the tumour is by the incorporation of lipids which have targeting moieties. These 
targeting moieties bind to cell surface proteins that are only up-regulated in 
tumour cells. This method has not only shown increased accumulation within 
the tumour, but also a shorter accumulation time and higher transfection 
efficiencies due to the increased time that the particles are in contact with the 
tumour cells.269,295,321,322  
 
A novel way to increase liposome release of the therapeutic agent is the recent 
development of thermo-sensitive liposomes. These liposomes can be 
formulated to have similar properties to the LEsiRNA nanoparticles, but 
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exposure to an external heat source, causes the liposomes to burst and release 
their contents, potentially increasing their therapeutic efficacy.323,324 
 
Recently, liposomes have been created that incorporate two MRI contrast 
agents. This development allows the monitoring of tumour accumulation of the 
particles, similar to the LEsiRNA nanoparticles, but also has the potential to 
demonstrate the release of the therapeutic agent, due to the shift from one 
contrast agent to the other.325 
 
Although the sensitivity of MRI is not as high as PET or SPECT, the added 
spatial information gained with MRI allows for better localisation. The use of 
PET contrast agents would be limited for liposome based delivery agents as the 
half life of the isotopes is generally shorter than what would be required to show 
accumulation. Bioluminescence could be used to visualise the delivery of siRNA 
inside the cell, by knockdown of the luciferase gene in a luciferase expressing 
cell line. However, bioluminescence can not be used to monitor accumulation of 
the particles in vivo. Ultrasound could be used to monitor the accumulation of 
the particles within the tumour, but the limited spatial resolution would make 
analysis difficult. Therefore, for this area of therapeutic delivery, MRI currently 
appears to be the best. However, multi-modality systems, incorporating both 
MRI and SPECT, would have further benefits of spatial and temporal resolution 
along with higher sensitivity.114 
 
Despite these potential limitations the results demonstrate that the LEsiRNA 
nanoparticles and the apoptotic targeted contrast agent, have the potential to 
act as MR molecular imaging agents. As the delivery of stabilised liposome 
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based nanoparticles to tumours has been visualised using MRI with a variety of 
nanoparticle formulations previously.133,134,159,171,313,326 Also, nanoparticle 
mediated delivery of therapeutic agents has also be shown previously,252,271 but 
to date the nanoparticle formulation described here appears to be the first that 
not only allows for the functional delivery of siRNA, such that a therapeutic 
effect is observed, but incorporates MRI and fluorescence labels for the 
simultaneous monitoring and corroboration of delivery. This, with potential 
ability to visualise early apoptotic cellular events, provides great encouragement 
for these two agents as therapeutic and prognostic MR contrast agents. 
 
7.1 Future Work 
The LEsiRNA nanoparticle system presented here has the potential for use in a 
wide range of cancers and many alternative siRNAs could also be encapsulated 
to knockdown other pathways involved in cancer. It would also be possible to 
knockdown more than one pathway at a time involved in cancer, by 
encapsulating multiple siRNAs targeting various pathways to increase the 
effectiveness of the therapy. 
 
Previously liposome based agents have been used to deliver cytotoxic 
therapies to tumours, such as doxorubicin.36,327-329 In addition to this it was 
shown that a reduction in Survivin level produced by Survivin siRNA delivery, 
causes the tumours to become more susceptible to doxorubicin. Therefore, co-
encapsulation of the two tumour therapies could lead to a much more 
pronounced therapeutic effect. 
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The tumour growth rate decreases produced by Survivin LEsiRNA 
nanoparticles described here are from a single injection. The use of multiple 
injections might lead to a reduction in size and potentially a complete regression 
of the tumour. To visualise this a longer time course than 72 hours would be 
required, which would also show any increased survival rate produced by the 
particles. 
 
To assess the siRNA delivery inside the tumour cells in vivo, it could be 
possible to use bioluminescence. If a cancer cell line was created, which 
expressed the luciferase gene, LEsiRNA nanoparticles encapsulating luciferase 
siRNA could be administered. This would allow for MR monitoring, as seen 
here, and also visualisation of the luciferase protein levels by bioluminescence 
measurements.  
 
The apoptotic targeted contrast agent tested here, may not be binding 
specifically to the early apoptotic marker, phosphatidylserine. As although 
previous research has shown that the Zn-DPA ‘arms’ bind specifically to 
phosphatidylserine308,309 and therefore early apoptosis, it could be possible that 
the compound is binding to other phosphate anions that are present at a later 
stage of apoptosis or even necrosis. To determine if this is the case a FITC 
label should be added to the contrast agent and then assessed by flow 
cytometry and compared to the gold-standard PI and annexin V-FITC assay. 
This should then confirm whether or not the contrast agent binds specifically to 
phosphatidylserine and therefore can be used as a marker of early apoptosis or 
if it binds to a wider range of phosphate anions.  
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A possible way to determine if it is specific binding and not just unbound 
contrast agent not being removed completely, would be to add additional 
washes in an attempt to completely remove the unbound contrast agent from 
the cell pellet. Another method to test this would be to increase the 
concentration of contrast agent in an attempt to saturate the phosphatidylserine 
binding. If it was indeed specifically binding to the phosphatidylserine then there 
would be a plateau in the drop of T1 values of the apoptotic cells, whereas if it 
was non-specific or non-bound the T1 values would continue to drop in a 
concentration dependent manner.  
 
To determine if the contrast agent can actually be used to detect early apoptotic 
events it would need to be tested in an in vivo tumour model that involves 
tumour therapy eliciting apoptosis. T1 mapping and T1 weighted imaging would 
be performed and the contrast agent administered to untreated and LEsiRNA 
treated animals to assess the difference in uptake of the agent between the two 
groups, with the hope that the drug treated group would have decreased T1 
values and an increase in signal intensity for the tumour.  
 
As mentioned previously it would be advantageous to measure the effect of the 
LEsiRNA nanoparticles over a longer time. This chronic model would also give 
a much better indication of the particles use as a clinical therapy. In addition to 
this, the apoptotic agent could be used to monitor the effects of the LEsiRNA 
nanoparticles at a cellular level, non-invasively. 
 
As the EPR effect is a trait of all tumours, the LEsiRNA nanoparticles could 
potentially be used to diagnose and treat metastatic cancers. This could be 
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tested in an in vivo model such as the MDA-MB-231 cell line, which is known to 
metastasise. If the therapy is successful in a metastatic model as well, the 
LEsiRNA nanoparticle system would appear to have massive potential as 
tumour therapy and could possibly be tested further in a clinical trial.   
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10 APPENDIX  
10.1 MRI History 
MRI stems from the phenomenon of nuclear magnetic resonance (NMR) 
discovered independently by Bloch and Purcell in 1946,330,331 for which they 
were awarded the Nobel Prize in Physics in 1952. The first images were 
demonstrated in 1973 by Lauterbur and Mansfield332,333 who subsequently won 
the Nobel Prize in Physiology or Medicine in 2003 for their work. Current MRI 
techniques are generally based on the work by Ernst and co-workers in 1975, 
where they proposed using phase and frequency encoding gradients and then 
to Fourier Transform the data to form an image.334 Ernst was awarded the 
Nobel Prize in Chemistry in 1991 for this work. Since then the MRI field has 
grown exponentially encompassing many aspects of medicine, physics, 
chemistry and psychology. 
 
10.2 Basic Principles of NMR 
10.2.1 Nuclear Spin 
MRI exploits one particular finding of quantum mechanics that some particles 
have an intrinsic property known as ‘spin’. Particles with an odd number of 
protons, neutrons, or both are said to spin, with spin levels coming in multiples 
of ½. In magnetic resonance any particle with spin can potentially be detected 
and a list of nuclei often studied are shown in Table 10.2.1. 
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Nucleus 
Spin 
Quantum 
Number 
Gyromagnetic 
Ratio γ 
(MHz/T) 
Natural 
Abundance 
(%) 
Biological 
Abundance 
by mass 
(%) 
Sensitivity 
1H     42.58 99.985 10 1.00 
13C     10.71 1.11 0.2 1.76x10
-4 
19F     40.08 100 <0.01 0.834 
23Na     11.27 100 0.1 9.27 x10
-4 
31P     17.25 100 1.2 6.65 x10
-4 
Table 10.2.1. Commonly observed elements in MR and their associated 
properties. 
 
 
The primary particle observed is the proton 1H. This is due in part to the fact 
that it is the most sensitive of MR observable elements and secondly to that it 
has a very high abundance in the human body, making it the ideal particle to 
use in biological studies.  
 
As 1H is positively charged and spinning, it creates a magnet field which is 
randomly orientated (Figure 10.2.1a), but when placed into an external static 
magnetic field (B0) the spins either line up parallel (low energy state) as seen in 
Figure 10.2.1b, or anti-parallel (high energy state) to B0 as shown in Figure 
10.2.1c. When the spins are aligned with B0 they precess around B0 at a rate 
determined by the Larmor equation:  
      
 
Where ω is the resonant frequency in megahertz (MHz), γ is the gyromagnetic 
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ratio in megahertz per Tesla (MHz/T) and B0 is the strength of the external 
magnetic field in Tesla (T).  
 
 
Figure 10.2.1. (a) Spins randomly orientated, (b) spins lining up parallel to an 
external magnetic field B0, (c) spins aligned anti-parallel to B0 and (d) a spin 
packet with the net magnetisation M0, aligned parallel to B0. 
 
 
10.2.2 Spin Packets 
At room temperature there is a small excess of spins aligned parallel with the 
field when compared to the anti-parallel spins. The individual spins can be 
added together for simplicity and are collectively known as a ‘spin packet’, 
which has a net magnetisation parallel to B0 as seen in Figure 10.2.1c. Although 
all the individual spins precess about B0, the net magnetisation (M0) does not 
precess, as all the individual spin phases cancel each other out. 
 
10.2.3 MR Signal Generation 
In NMR and MRI the external magnetic field is said to be on the z-axis in a co-
ordinate system and the net magnetisation (M0) is flipped from the z-axis into 
the xy plane. This is achieved by the application of another, smaller magnetic 
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field, B1, which is created by the application of an RF pulse from a transmit coil 
at the Larmor frequency perpendicular to B0, along the x-axis. The 
magnetisation is then said to be excited. As the magnetisation is precessing 
about both the B0 and B1 fields simultaneously it flips to the x-y plane as a 
spiral, when viewed in the laboratory frame of reference as seen in Figure 
10.2.2a. If it is viewed from the rotating frame of reference, one rotating at the 
resonant frequency ω, then the magnetisation smoothly tips down into the x-y 
plane as seen in Figure 10.2.2b.  
 
Magnetisation that is flipped 90o by an RF pulse is said to be a 90o pulse and 
one that flips the magnetisation into the –z-axis is said to be a 180o pulse. The 
flip angle, θ, is dependent on the strength and time that the RF pulse is applied 
for. 
 
 
Figure 10.2.2. (a) The magnetisation vector spirals down into the transverse 
plane upon application of an RF pulse whose magnetic field B1 is orientated 
along the x axis. (b) when viewed in a rotating frame of reference, rotating at ω 
around the z axis, the magnetisation vector appears to tip into the transverse 
plane. 
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Once the RF transmitter is turned off, RF energy is released at the resonant 
frequency (this is the NMR signal), the net magnetisation starts to recover along 
the z axis (T1 relaxation) and the spins in the xy plane start to dephase (T2/T2* 
relaxation). The amount of signal received is directly related to the above 
processes and also the spin density, which is the amount of spins in a given 
location. 
 
As the magnetisation is now precessing in phase along the x-axis it induces a 
large current in a receiver coil, often the same as the transmit coil, and this is 
the MR signal. As time progresses the magnetisation vector rotates 90o and is 
then aligned with the y-axis and no signal is recorded as the coil can only 
receive signal along the x-axis. After a further 90o rotation, a signal is received, 
however it is negative when compared to the original signal. This sinusoidal 
curve decays over time as the spins start to dephase due to spin-spin 
interactions and external magnet inhomogeneities, thus the signal received is 
slightly reduced and eventually spirals to the centre of the x-y plane. The signal 
that is observed by the receive coil is called a free induction decay (FID) and is 
shown in Figure 10.2.3. 
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Figure 10.2.3. A free induction decay (FID) showing both T2 and T2* envelopes. 
 
 
10.2.4 T1, T2 and T2* Relaxation Times 
At equilibrium, as stated earlier, the magnetisation is aligned parallel to B0 and 
this is called M0. At this point the z component of magnetisation, Mz, is equal to 
M0 and there is no Mxy magnetisation. If a 90
o RF pulse is used, all the 
magnetisation is flipped from the z axis into the x-y plane, so that Mz equals 
zero and once the pulse is switched off Mz starts to recover towards M0. T1 is 
the time taken for Mz to recover from 0 to 63.2% of the equilibrium 
magnetisation, M0 as seen in Figure 10.2.4a. The recovery of the magnetisation 
to M0 is described the equation: 
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It is also known as longitudinal relaxation as it is the recovery along the 
longitudinal (z) axis and also as spin-lattice relaxation as the energy released 
goes into the surrounding lattice.  
 
Immediately after the 90o pulse the magnetisation is all in the x-y plane and all 
in phase, meaning that they are all lined up in the same direction and spinning 
at the same frequency, ω. Due to the individual spins interacting with each 
other, the spins start to experience slightly different magnetic fields and this 
leads to them precessing at different rates, causing a cumulative loss in phase 
and therefore signal. These temporary and random interactions, are known as 
spin-spin interactions and are also known as transverse or T2 relaxation. This 
happens simultaneously as Mz recovers to M0, but also independently and T2 is 
the time taken for the signal to reach 36.8% of its original value as seen in 
Figure 10.2.4b. The transverse magnetisation, Mxy, decay rate is described by: 
 
               
 
T1 and T2 are inherent properties of tissue that are specific to a given tissue at a 
specific field strength. Due to magnetic fields not being completely 
homogeneous another term is introduced called T2*. The value T2* is always 
less than T2, as the inhomogeneities of the magnetic field increase the 
dephasing of Mxy, as seen in Figure 10.2.4b.  
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Figure 10.2.4. (a) The exponential recovery of Mz back to M0, showing the T1 as 
the time when 63.2% of the magnetisation has recovered. (b) The exponential 
decay of signal due to T2 (dashed line) and T2* (solid line), with the time for both 
when signal has decayed to 36.8% of its original value. 
 
 
10.3 Spatial Encoding 
To generate an image for MRI, the signal from the spins needs to be spatially 
encoded so that they can be spatially localised. This spatial localisation comes 
from the use of gradients that change the magnetic field in the z, x and y planes 
to establish a relationship with resonant frequency and position.  
 
10.3.1 Slice Selection 
The first step in spatial localisation is to only excite spins in a particular slice. To 
do this a magnetic gradient is applied linearly, which causes the field strength to 
vary linearly from the centre of the magnet. This leads to a gradient of resonant 
frequencies such that spins at one side precess quicker than ones at the other 
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side of the gradient, as described by the Larmor equation (ω   γB0). Therefore 
to selectively excite a particular slice, an RF pulse applied at the resonant 
frequency will only excite spins at that slice and spins either side of the slice will 
be at different resonances and hence not absorb the energy. If the gradient 
applied is along the z axis then the slice obtained will be an axial slice, if it is 
applied along the y axis then the slice will be coronal, if along the x axis then the 
slice will be sagittal and if a combination of two or all three are used then any 
oblique slice will result.  
 
The thickness of the slice excited depends on two factors – the bandwidth of the 
RF pulse used and the steepness of the applied gradient. The bandwidth 
describes the range of frequencies with an RF pulse and therefore a pulse with 
a large bandwidth would excite a larger range of spins and lead to a thicker 
slice, whilst changing the centre frequency of the pulse will change the position 
of the slice along the gradient. If an RF pulse with a specific bandwidth is used 
along with a shallow gradient, then the slice will be thick in comparison to that 
acquired with the same pulse applied with a steep gradient, as the range of 
frequencies excited will be less in the steeper gradient due to the Larmor 
equation as depicted in Figure 10.3.1. 
 
As the bandwidth of the RF pulse is a range of frequencies it takes time to 
excite the whole range and as soon as the spins are tipped into the xy plane 
they precess about B0 at their respective frequencies and start to dephase. To 
counteract this effect a gradient of the opposite polarity is applied to reverse the 
spins that were dephasing so that at the end of the reversed gradient all the 
spins are in phase with each other. 
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Figure 10.3.1. Application of a slice selection gradient, in this case along the z 
axis, causes spatial variation of resonant frequency in this direction. Application 
of an RF pulse then excites only a small proportion of the subject in a plane 
perpendicular to z. Varying the centre frequency of the RF changes the slice 
position while varying the bandwidth changes the slice thickness. Also changing 
the steepness of the gradient would effect slice thickness. 
 
 
10.3.2 Phase Encoding 
Once the spins have been excited using a slice select pulse they then need to 
be localised in the two remaining planes so that an image can be formed. 
Another gradient is applied, known as the phase encode gradient, in the y 
plane, that causes the spins at one side of the gradient to rotate quicker than at 
the other side in a linear fashion. The phase encode gradient is then switched 
off and the spins rotate at the same, original, frequency, but with different phase 
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depending on their position along the y axis. The magnitude of the phase 
encode gradient is changed for each excitation and each time an additional 
gradient is also applied, known as the frequency encoding gradient, to give 
complete spatial localisation. 
 
10.3.3 Frequency Encoding 
If a frequency gradient is then applied, in the x plane, then the spins will start to 
precess at different rates depending on their position along the gradient. This 
change in frequency can be measured and therefore their position on the x 
plane can be distinguished. 
 
10.3.4 k-space 
k-space is where the measured signal from the phase encoding and frequency 
encoding gradients is collected. When it is Fourier Transformed, by a 
mathematical operation, it forms the image of the object scanned (Figure 
10.3.2.). 
 
                         
Figure 10.3.2. The k-space image on the left forms the image on the right after 
Fourier Transformation 
Fourier 
Transform 
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10.4 Imaging Sequences 
The general aim of imaging is to differentiate various tissue types and their 
biological state. To do this sequences have been developed that take 
advantage of the fact that different tissues and biological pathologies have 
different T1, T2, T2* times and to a lesser extent different spin densities. The 
simplest method of data collection would be to record the FID, but the time 
taken to apply the magnetic gradients to impart spatial localisation is relatively 
long, which would mean a significant amount of signal would have decayed. 
Therefore the majority of the sequences utilise an echo and most sequences 
implemented are based on either gradient echo techniques or spin echo 
sequences.  
 
10.4.1 Gradient Echo Sequence 
In a gradient echo sequence an RF pulse is applied to the sample along with 
the slice selective gradient, so that a particular slice is excited. After the RF 
pulse has been applied the slice select gradient is reversed so that the spins 
come back into phase (RF and Gz lines in Figure 10.4.1.). A phase encoding 
gradient is then applied to give the spatial location in the y plane, (Gy line in 
Figure 10.4.1.). The frequency gradient, also known as the readout gradient, is 
then applied along the x axis. The gradient is first applied negative in sign which 
causes an initial dephasing of the spins, then it is reversed, so that it is now 
positive, which causes the spins to come back in to phase while the data are 
sampled (Gx line in Figure 10.4.1.). The point at which the signal intensity is 
maximum is called the echo (Signal line in Figure 10.4.1.) and the time taken 
from the RF pulse to the centre of the echo is known as the echo time (TE). 
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These steps are then repeated, but with different magnitudes for the phase 
encoding gradients varying from Gmax to Gmin, with the time between each RF 
pulse know as repetition time (TR). 
 
 
 
Figure 10.4.1. A gradient echo pulse sequence diagram. With Gz, Gy and Gx 
corresponding to the slice selection, phase encoding and frequency encoding 
gradients respectively. The RF pulse is applied in the presence of a slice select 
gradient on z, the magnitude of the phase encode gradient on y is changed with 
each excitation and an initial dephasing gradient on x, the frequency encoding 
gradient, is followed by reversal of the gradient and the echo is collected.   
 
 
 
 
RF
Gz
Gy
Gx
Signal
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10.4.2 Spin Echo Sequence 
In a spin echo sequence a 90o pulse is applied to flip the magnetisation into the 
xy plane (Figure 10.4.2a), along with a slice select gradient in the z axis, to 
excite a particular slice which is immediately followed by a refocusing lobe to re-
phase the spins (Figure 10.4.3. RF and Gz lines). A phase encoding gradient 
along the y axis is also applied, as in a gradient echo, which is stepped in 
magnitude for each excitation covering Gmax and Gmin (Figure 10.4.3. Gy line). 
However, in a spin echo sequence a 180o RF pulse is used to form the echo, 
instead of the frequency encoding gradient used in a gradient echo sequence. 
The 180o pulse is applied in combination with the slice select gradient at time 
TE/2 after the 90o pulse (Figure 10.4.3. RF and Gz). This causes the spins that 
have dephased and hence, caused a loss in coherence, to invert (Figure 
10.4.2c and d). As the spins are precessing at the same rate that they were, 
they will start to come back into phase with each other. After a further time of 
TE/2 after the 180o, the spins are all aligned in phase again forming the echo as 
seen in Figure 10.4.2f, and the signal is detected in the presence of the readout 
gradient.  
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Figure 10.4.2. Spin echo sequence. (a) shows the equilibrium magnetisation at 
M0 before the application of the 90
o RF pulse. The 90o causes the M0 to flip into 
the xy plane as shown in (b). After a time of TE/2 the spins have dephased (c), 
and a 180o RF pulse is applied to flip the spins (d), so that the spins are 
reversed (e) and they come back into phase to create the echo (f). 
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Figure 10.4.3. A spin echo pulse sequence diagram. With Gz, Gy and Gx 
corresponding to the slice selection, phase encoding and frequency encoding 
gradients respectively. The RF pulse is applied in the presence of a slice select 
gradient on z, the magnitude of the phase encode gradient on y is changed with 
each excitation and a dephasing gradient on x, the frequency encoding 
gradient. This is followed by a 180o RF pulse, in conjunction with the slice select 
gradient, which causes the spins to re-phase and generates the echo which is 
recorded in the presence of the frequency encoding gradient.  
   
 
10.4.3 Imaging Parameters 
In addition to the imaging parameters mentioned earlier, echo time (TE) and 
repetition time (TR), there are other parameters involved in sequences to 
RF
Gz
Gy
Gx
Signal
TE/2 TE/2
90o 180o
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change the image formed, depending on the application.  
 
Flip angle is the angle that the net magnetisation is moved away from B0 at, and 
the lower this is the quicker the gradients can be reversed to create the echo 
and hence the quicker the sequence can be completed. A low flip angle does, 
however, cause a loss in signal as less of the magnetisation is placed into the 
xy plane, so a balance is needed.  
 
The matrix size is the number of voxels collected in the frequency and phase 
encode directions and are typically multiples of 128. The field of view (FOV) is 
directly linked to the matrix size such that matrix size multiplied by the voxel 
size equals the FOV.  
 
The number of slices in a particular plane are collected by each slice being 
excited by the slice select gradient and the data being obtained by applying the 
phase and frequency encoding gradients.  
 
To increase the image quality averaging can be used, where the sequence is 
repeated and then the images are averaged together. This parameter works 
well as the background noise is random and therefore is not additive, whereas 
the signal is. Therefore signal averaging increases the signal to noise ratio 
(SNR) and this is increased by the square route of the number of averages, but 
the cost is that averaging also increases the imaging time taken to acquire the 
data.  
 
The combination of all these parameters and the choice of sequence allows for 
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a massive range of different contrast to be generated depending on the 
application. 
 
10.5 Measuring T1, T2 and T2* 
As was stated previously certain tissues have particular T1, T2 and T2* values, 
this can change due to pathology, therefore it could potentially be useful to 
know the values. This can then be used to decipher one tissue from another or 
from one pathology to another by using the appropriate sequence and 
parameters. 
 
10.5.1 T1 Measurement 
T1 can be measured by various different methods, the most accurate of all 
being the inversion recovery method. In this method the net magnetisation is 
flipped into the negative z axis using a 180o RF pulse. It then gradually recovers 
towards M0, and after a given time, known as the inversion time (TI), a 90
o pulse 
is applied. Then the rest of the sequence is a standard spin echo sequence. If 
TI is varied and the overall TR is long enough to allow full recovery of the 
magnetisation to M0, then T1 can be calculated by plotting the signal to the 
equation: 
 
                 
 
This method, however, is very time consuming, so another method known as 
the saturation recovery method is often used. In this method a standard spin 
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echo sequence is used, with as short a TE as possible and a varied TR and the 
signal is fitted to the equation: 
 
                 
 
10.5.2 T2 Measurement 
T2 can be measured by using a standard spin echo sequence, as this will rule 
out the effects of B0 inhomogeneities and therefore results in T2 measurements 
unaffected by any T2* decay. A long TR is used on the order of five times T1, to 
allow full recovery of the magnetisation and so that there are no influences from 
T1. TE is then varied and the signal plotted to the equation: 
 
                
 
10.5.3 T2* Measurement 
As just mentioned T2 can be measured using a spin echo sequence. Similarly 
T2* can be measured using a gradient echo sequence, again varying the TE 
and then fitting the signal to: 
 
                 
 
